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ABSTRACT

Skin tissue engineering has made tremendous progress in producing skin substitutes for clinical
grafting. Recently, three-dimensional (3D) bioprinting has been increasingly employed to
fabricate living skin constructs with 3D spatial precision and microenvironmental architecture.
However, this is hitting a bottleneck due to a paucity of functional materials and bioinks that
are both biocompatible, functional and printable. An array of biological properties is
demonstrated in the category of extracts broadly known as ulvans, including antibacterial, antiinflammatory and anti-coagulant activities. Ulvans are sulfated polysaccharides derived from
green algae, and structurally resemble mammalian connective glycosaminoglycans such as
dermatan sulfate and chondroitin sulfate. It is therefore a strong candidate for applications in
wound healing and tissue regeneration. However, the development of ulvans in biomedical
applications is limited due to high structural variability across species and a lack of consistent
and scalable sources. In addition, the modification and formulation of these molecules is still
in its infancy with regard to progressing to product development. The present work investigates
a rhamnose-rich ulvan polysaccharide, ulvan-84 (Ul84) obtained from a controlled source of a
cultivated, DNA-barcoded species of Australian Ulvacean macroalgae, to reveal the potentials
in skin tissue engineering and wound healing application.

Three Ul84 extracts including PhycoTrix, PhycoDerm, and PhycoDerm® PhycoTrix (PDPT)
have been studied. Firstly, the chemical composition, structure and molecular weight (MW) of
the three Ul84 extracts were characterized. Results showed that PhycoTrix contained 21.1% of
protein (3.2% nitrogen (N)), 52.7% of total carbohydrates, 11.7% of uronic acids, 14.6% of
sulfate (5.3% sulfur (S)) and 11.5% of ash. PhycoDerm contained 13.2% of protein (2.9% N),
48.0% of total carbohydrates, 15.9% of total uronic acid, 16.9% of sulfate (6.0% S) and 13.8%
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of ash. PDPT contained 3.1% protein (1.1% N), 12.9% ash and 6.1% S. Monosaccharide
analysis revealed that Ul84 was mainly composed of L-rhamnose, D-xylose, D-glucuronic acid,
L-iduronic acid, D-glucose and D-galactose. Gel permeation chromatography illustrated a
broad MW distribution for PhycoTrix (1,244 kDa) and PhycoDerm (1,002 kDa) with a
polydispersity index of ~1.6. Spectroscopic analysis confirmed characteristic peaks
corresponding to structures in Ul84. Ul84 also exhibited concentration-dependent aggregation
behaviour.

PhycoDerm was methacrylated to enable photo-crosslinking for hydrogel preparation to study
cell-material interaction using human dermal fibroblasts (HDFs). PhycoDerm methacrylate
(PDMA)-based hydrogels were prepared with tuneable mechanical properties and high water
contents. The hydrogels supported high cell viability and cell attachment, spreading and
proliferation of HDFs over 14 days, far more functional than comparable alginate gels.
Importantly, a PDMA-based bioink was developed for extrusion printing cell-free and cellladen 3D constructs both with high cell viability.

Ul84-based bioinks were optimized using PDPT for 3D bioprinting dermal-like structures.
Serial bioinks were developed using PDPT methacrylate (PDPT-MA) with/without gelatin
methacryloyl (GelMA). The inclusion of PDPT-MA facilitated the extrusion printing process
by reducing yield stress and improved mechanical strength. The 3D printed HDF-laden
structures supported cell proliferation and production of key extracellular matrix components
including collagen I, collagen III, elastin and fibronectin. Gene expression analysis revealed
that the inclusion of PDPT-MA significantly downregulated collagen III gene expression,
whereas it did not induce significant impacts on the gene expression of collagen I, elastin and
fibronectin. In vitro degradation demonstrated that PDPT-MA was able to protect GelMA from

II

degradation. Further, bilayer skin constructs were created by culturing HaCaT cells on the
surface of 3D printed dermal-like structures at the air-liquid interface. Histological studies
revealed skin-mimicking double-layered structures of the bilayer skin constructs.
Immunohistochemistry verified certain levels of stratification of the epidermal layer. Lastly,
PDPT-MA structures were assessed in vivo using a mouse full thickness wound model to
investigate the potential as temporary wound dressings. The pilot study demonstrated a nontoxic nature of Ul84 in vivo, and identified a major issue of poor scaffold adhesion to the wound
tissue.

In summary, the rhamnose-rich, cytocompatible heteropolysaccharide Ul84 supports cell
attachment, spreading and proliferation of human skin cells. Progress has been made in the
development of Ul84-based bioinks for skin bioprinting. These data provide basic yet
fundamental insights into the utilization of Ul84 as a promising biomaterial and ink ingredient
for skin tissue engineering and wound healing application.
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TEHSIS SCOPE AND OBJECTIVES

Thesis scope. The present project studied three polysaccharidic ulvan-84 (Ul84) extracts, i.e.,
PhycoTrix, PhycoDerm, and PhycoDerm® PhycoTrix (PDPT) provided by Venus Shell
Systems Pty. Ltd (VSS, Australia), towards the fabrication of its based structures for skin tissue
engineering and wound healing application. These extracts were received with different colours,
which may indicate incomplete depigmentation and possibly different purities. In addition,
very little information about their chemical compositions and structural properties were
available. This necessitated relevant studies to understand the raw materials in terms of the
chemical composition and structural characteristic before proceeding with structure fabrication
and biological work. The scope of this project covered three Ul84 extracts, and investigational
activities included chemical and structural characterization, chemical modification, hydrogel
preparation, 3D bioprinting, in vitro cell-related studies and in vivo assessment towards wound
healing.

Thesis objectives. The project aims to understand the chemical composition of the three Ul84
extracts, as well as cell-material interactions between Ul84 and human skin cells including
human dermal fibroblasts (HDFs) and HaCaT keratinocytes. It also aims to develop and
optimize Ul84-based bioink formulations for 3D bioprinting cell-laden structures for skin
bioengineering, and to evaluate Ul84-based structures in vivo towards wound healing
application. Specifically, the thesis has the following four interconnected objectives, each with
a primary goal to achieve.

The first objective is to perform chemical and structural characterization of the three Ul84
extracts. These extracts were characterized in terms of ash content, total neutral sugar content,
IV

total uronic acid content, sulfate content, protein content, elemental composition,
monosaccharide composition, molecular weight distribution, structural analysis and
aggregation behaviour. The results of this part guide material selection for subsequent
fabrication and cell-related studies.

The second objective is to develop Ul84-based hydrogels (2D structures) to study cell-material
interactions using HDFs and to justify its suitability as an ink ingredient. Before the purest
PDPT was received, PhycoDerm containing a lower protein content compared to PhycoTrix
was selected for the study. PhycoDerm was modified by methacrylation (PDMA) to enable
photocrosslinking for hydrogel formation. Following the seeding of HDFs onto freeze dried
PDMA hydrogels, cell-material interactions were studied by assessing cell viability, cell
proliferation and cell morphologies. The feasibility of 3D printing PDMA hydrogel with or
without cells was verified with an initial attempt to formulate Ul84-based bioinks. This part of
work demonstrated the cytocompatibility of Ul84 with a highlight in the proactive cell-material
interactions.

The third objective is to develop and optimize Ul84-based bioinks for 3D bioprinting dermallike structures and to construct dermal-epidermal bilayer skin structures. Studies in this section
were conducted with the purest PDPT. Since PDPT contained a much lower protein content
compared to PhycoDerm, the cytocompatibility of hydrogels based on PDPT methacrylate
(PDPT-MA) was first assessed against HDFs and HaCaT keratinocytes. To develop printable
bioinks, composite bioinks were developed by combining PDPT-MA with gelatin
methacryloyl (GelMA) and a rheological modifier of gelatin. By doing so, bioinks containing
serial PDPT-MA concentrations were formulated. The effects of inclusion of PDPT-MA on
printability and mechanical properties were evaluated. HDFs were embedded in these bioinks
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and cell-laden structures were bioprinted using the extrusion approach. The printed cellular
structures were characterized in terms of cellular behaviours including cell viability, cell
proliferation and gene expression and deposition of key extracellular matrix (ECM) proteins.
Subsequently, HaCaT cells were co-cultured with the matured 3D-printed cellular structures to
construct bilayer skin structures. The co-culture was exposed to air for up to 4 weeks to induce
epidermal differentiation. This was followed by structural characterization by histology and
molecular characterization of key protein markers in the epidermal structures by fluorescent
immunohistochemistry.

The fourth objective is to assess the potential of PDPT-MA-based acellular hydrogels/scaffolds
in treating full thickness wounds using a mouse excisional wound model. The forms of PDPTMA structures investigated included both an injectable solution allowing in situ
photocrosslinking and 3D printed, preformed macroporous scaffolds as dressing materials. In
parallel, 3D printed alginate scaffolds were used as a control. Due to time limitation, this
section only included the pilot animal study as to evaluate PDPT-MA structures in vivo and to
identify possible issues that need to pay extra attention to for a larger scale animal study to
follow. The animal work was conducted in collaboration with the Burn Injury Research Unit
at The University of Western Australia. Data were acquired and analyzed of wound closure
and basic histological studies including hematoxylin and eosin Y staining and Masson’s
trichrome staining.
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Chapter 1 General Introduction

Some parts of this chapter present work that has appeared in the published article “3D
Bioprinting Constructs to Facilitate Skin Regeneration” by Daikuara, L.Y., Chen, X., Yue, Z.,
Skropeta, D., Wood, F.M., Fear, M.W. and Wallace, G.G. (2021). Advanced Functional
Materials, 2105080.

1.1 Introduction
Skin is the protective and flexible covering of the human body, responsible for body sensation
and thermal regulation. As the frontier, skin is prone to physical, chemical and biological
injuries. Human skin features a multi-layered structure comprising epidermis, dermis and
hypodermis. In losses of epidermis only, skin is capable of regeneration to restore barrier
functions; whereas in losses of whole dermis, skin is unable to repair by itself to form a new
tissue. In this context, it is required to apply a skin graft or skin substitute to replace the lost
tissue. The need of transplantable skin grafts has been on the rise with increases in individuals
burdened with impaired wound healing. To meet the growing need of skin grafts, skin tissue
engineering has emerged to produce skin-mimicking tissues in vitro. Significant advances have
been made since 1980s, with various skin substitutes being successfully developed for clinical
use. Particularly, skin bioprinting has been gaining increasing attention since the first
demonstration by Lee et al. in 2009.1 However, challenges still remain in the replication of
cellular and tissue functions of the tissue-engineered skin substitutes. This chapter provides a
general review on skin architecture, wound healing, skin substitutes, skin bioprinting, skinspecific bioinks and challenges in skin bioprinting.
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1.2 Wound healing and skin grafts
1.2.1 Human skin: structure and function
1.2.1.1 Human skin anatomy
Skin is well known as the largest and outmost organ in the human body. It can be divided into
three anatomically different layers, including the superficial thin layer of epidermis, the middle
thick layer of dermis and the inner layer of hypodermis (Figure 1.1).2 Epidermis comprises
multilayers of epidermal cells (mainly keratinocytes and melanocytes) in tightly compact
arrangement. It forms the outer barrier of the body, being waterproof and physically,
chemically and biologically responsive to the external environment. Epidermis is generally 75150 µm in thickness with an average of ~0.1 mm for a total of 50-100 cell layers.3 Epidermis
is important in preventing body fluid loss and the invasion of hazardous substances from the
environment.2,4,5 Beneath the epidermis lies the dermis, as separated by the basement
membrane between them. Dermis is up to 4 mm in thickness with an average of ~2 mm. Dermis
is primarily inhabited by dermal fibroblasts interspersed in the network of extracellular matrix
(ECM) comprising multiple components. The major ECM components are collagens, elastin
and glycosaminoglycans (GAGs). ECM provides skin with mechanical strength and resilience.
Dermis is further distinguishable with two sublayers, including papillary dermis and reticular
dermis in the upper and lower section of dermis, respectively. The papillary dermis has thin
and weakly packed collagen fibres (mainly collagen III) while the reticular dermis contains
thick and highly ordered collagen fibres (mainly collagen I).6,7 Dermis also houses abundant
blood vessels for the provision of nutrients and oxygen, and nerve endings for body sensation.
Skin appendages include nails, hair and various glands. The subcutaneous hypodermis is a
layer interfacing underlying organs and tissues. It is predominantly composed of fat tissue and
responsible for thermal regulation and offers mechanical resistance against external force.8
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Figure 1. 1 Multilayered structure of the human skin showing various components.9

1.2.1.2 Skin cells
The predominant cells residing in human skin are epidermal keratinocytes and dermal
fibroblasts. Keratinocytes are the predominant component of the epidermis, and are terminally
differentiated in the direction towards skin surface with only cells in the suprabasal layer
retaining the self-renewal capacity during the lifetime. With the expression of different
differentiation proteins, keratinocytes form four or five distinctive cell layers including, from
bottom to top, stratum basale (SB), stratum spinosum (SS), stratum granulosum (SG), stratum
lucidum (only present in the epidermis from palms and soles) and stratum corneum (SC).3
Epidermal keratinocytes in SB remain proliferative. Dermal fibroblasts are the major cell type
occupying the dermis. They produce various ECM components and bioactive molecules
including growth factors and cytokines.10,11 For other cellular components, epidermis contains,
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in small amounts, melanocytes and Langerhans cells. Melanocytes are responsible for
producing melanin that endows skin with a specific tone.2 Immune cells are also present in the
dermis, being mast cells and macrophages.12 Further, skin is home to several types of stem
cells, which preserve the potential to self-rejuvenate and are able to differentiate to form other
types of skin cells. Stem cells mainly derive from hair follicles, sebaceous glands and epidermis.
They are important in promoting skin regeneration following the disruption of homeostatic
balance.13

1.2.1.3 Skin ECM
Skin contains two types of ECM, which are the interstitial dermal ECM and the pericellular
matrix of basement membrane (BM) separating dermis from epidermis.14 The interstitial
dermal ECM surrounds dermal cells to scaffold them physically. Dermal ECM molecules can
be divided into four distinct categories as per the characteristics of its multiple components.
These categories comprise the fibre-forming proteins (such as collagen I and collagen III ),
adhesive glycoproteins (such as fibronectin), GAGs and matricellular proteins15 (such as
thrombospondin-1) (Figure 1.2).2 Apart from physically scaffolding cells, dermal ECM exerts
considerable influences on cellular events in terms of cell proliferation, migration and
differentiation and cell functions. GAGs are hydrophilic acidic polysaccharides with different
patterns of sulfation. These molecules are able to contain a significant amount of water so as
to maintain a hydrated microenvironment for the interspersed dermal cells. There are six types
of GAGs in human skin, including heparin, heparan sulfate, chondroitin sulfate, dermatan
sulfate, hyaluronic acid (HA) and keratan sulfate (Table 1.1). HA is exceptional among them
without sulfation. GAGs play important roles in mediating cellular signalling and have
significant contributions to the wound healing process.
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The pericellular matrix of BM is considered as the matrix of epidermal cells. BM mainly
consists of laminins (e.g., laminin-332 and laminin-51116), collagen IV and collagen VII.17
Laminins are integrin-interacting glycoproteins mediating cell adhesion. There are many
isoforms of laminins, which are composed of heterotrimeric chains of α, β and γ. Laminins
form a polymeric network by non-covalent self-assembly of their monomer chains.18 Collagen
IV does not form fibrils but forms a covalently crosslinked network that contributes largely to
the mechanical stability of BM. Collagen VII is an anchoring fibril-forming collagen that binds
to collagen fibrils in the dermis.11 The thin sheet-like layer of BM bridges the gap between
dermis and epidermis and prevent them from dissociation to form an integral skin tissue.

Figure 1. 2 Illustration of major extracellular matrix components in the skin.19

Table 1. 1 Glycosaminoglycans in human skin extracellular matrix and the chemical structures
and components of respective main disaccharide repeating units
Glycosaminoglycan
(GAG)
Heparin

Main
disaccharide
Abbreviation
repeating unit
L-iduronic acid 2-sulfate
IdoA-2S(1→4)GlcNAc(1→4)
N-acetyl2&6S
glucosamine-2&6 sulfate
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Ref.
Gatti et al.,
197920

Heparan sulfate

Chondroitin sulfate

Dermatan sulfate

Hyaluronic acid

Keratan sulfate

β-D-glucuronic acid 2-sulfate
(1→4)
N-acetylglucosamine-2 sulfate
β-D-glucuronic
acid
β(1→3)
N-acetyl
galactosamine-4 sulfate
L-iduronic acid β-(1→4)/α
(1→3)
N-acetyl
galactosamine- 4 sulfate
β-D-glucuronic
acid
β(1→4)/(1→3) N-acetyl-Dglucosamine
→3)galactose-6 sulfate β(1→4)
N-acetyl-Dglucosamine-6 sulfate β(1→

GlcA-2S(1→4)GlcNAc-2S

Sarrazin et al.,
201121

GlcA-β-(1→3)GalNAc-4S

Sugahara et
al., 200322

IdoA-β-(1→4)/α(1→3)GalNAc-4S

Sasisekharan
et al., 200623

GlcA-β-(1→4)/
(1→3)GlcNAc

Itano et al.,
200224

→3)Gal-6S-β(1→4)GlcNAc-6S-β(1→

Funderburgh
et al., 200225

1.2.1.4 Skin appendages and others
Skin appendages include hair, nails, and various glands such as sebaceous glands and sweat
glands (Figure 1.1).2 They play vital roles in thermoregulation, body sensation, and special
protection.2,26 These accessory structures have embryological origins from the skin.27 On the
other hand, skin has abundant distributions of blood vessels, nerves and lymphatic vessels for
nutritional support, sensation and immune responses, respectively.

1.2.1.5 Skin functions
As the front line of human body, skin provides important barrier functions. Generally, skin has
the following basic functions including (1) prevention of invasion of foreign substances; (2)
prevention of body water loss; (3) body sensation; (4) thermoregulation; (5) mechanical
protection of underneath tissues and organs against external environments and (6) a specific
tone. Moreover, skin-residing immune cells such as Langerhans cells in the epidermis and
macrophages in the dermis put skin in a position of immune surveillance for both skin and the
body.12,28
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1.2.2 Wound healing process
Cutaneous wound occurs when skin integrity is damaged by physical, chemical and/or
biological causes.29 There are distinct types of wounds according to different classification
methods. According to the nature of wounds, there are acute wounds (burns and injuries) and
chronic wounds (pressure sores and traumatic ulcers amongst others). If different skin layers
are involved, there are superficial wounds, partial thickness wounds and full thickness
wounds.29 Cutaneous wound healing refers to the spontaneous cellular responses of the human
body to restore skin integrity and function. It is a highly orchestrated biological process
involving multiple cells and many bioactive molecules.9,30 The major cell types include
platelets (coagulation), phagocytic leucocytes (neutrophils and monocytes/macrophages),
fibroblasts (for ECM synthesis), endothelial cells (for vascularisation) and keratinocytes.31,32
Based on the distinct cellular events and the involvement of different cell types, the typical
wound healing process is normally sectioned into four overlapping phases, including
haemostasis (only for wound with haemorrhage), inflammation, proliferation and remodeling
(Figure 1.3).31,33-36

1.2.2.1 Inflammation
Upon an injury to the skin, the rupture of blood vessels triggers the recruitment of platelets
(thrombocytes) to the wounded site. Platelets can release many cytokines and growth factors
which promote the catalysis of fibrin formation from the fibrinogen precursor. Fibrin further
interweaves to form a hydrogel clot to trap blood cells to stop bleeding.35 Importantly, the fibrin
clot acts as a temporary matrix to support subsequent migration of neutrophils and monocytes
involved in the inflammatory stage into the wound bed.35,36 In response to chemoattractants
present in the fibrin clot, neutrophils infiltrate the wound area and remove the bacteria and
debris of necrotic tissue by phagocytosis.35 By chemotaxis, monocytes can also be recruited to
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the wound area, and be activated and transformed into macrophages.36 Macrophages are able
to secrete a number of growth factors, including, for example, platelet-derived growth factor
(PDGF), vascular endothelial growth factor (VEGF, a.k.a. vascular permeability factor),
transforming growth factor (TGF) α/β and insulin-like growth factor I.35 These macrophagederived growth factors are critical in the transition from inflammation to tissue repair.32

VEGF can also be released by epidermal cells during wound healing.37 Brown et al. found that
keratinocytes from both wound tissues and in vitro cultures were able to express VEGF, which
may account for angiogenesis and high permeability of blood vessels during wound healing.
The high permeability caused the extravasation of plasma proteins, leading to persistent
formation of fibrin gel.37 Keratinocyte-derived VEGF was also demonstrated to be an
chemoattractant for monocytes.38
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Figure 1. 3 Classic phases of the wound healing process.36

1.2.2.2 Granulation tissue formation
In the proliferation stage, the main activities include reepithelialization, angiogenesis and
granulation tissue formation.33 Reepithelialization is realized by the movement and relocation
of keratinocytes from the vicinity of the wound and from skin appendages33,35 along the surface
9

of the provisional fibrin matrix. The migration is a result of extensive enzymatic collapse of
the physical intercellular desmosomes between epidermal cells and of hemi-desmosomes
between epidermal cells and the basement membranes.33 On the other hand, epidermal cells
express integrin acceptors on their cell membranes,39 which enable them to bind to many
components of extracellular matrix (e.g., fibronectin) to facilitate their migration.33 Upon the
closure of the wound surface by migrating epidermal cells from the wound edges to the centre,
a protecting barrier is then regenerated to restore the fundamental function of the skin.33
Another important aspect of the proliferation stage is to recover the vascular access to the
wound for nutritive purposes to support the new granulation tissue.33 Angiogenesis is initiated
by endothelial cells in blood vessels interacting with growth factors like VEGF and PDGF via
receptor-ligand binding, which as a result activates the endothelial cells.33,35 The activated
endothelial cells are then enzymatically detached from the basal lamina by autocrine and able
to proliferate and further infiltrate the wounded area.35 The detachment and migration of
endothelial cells into the wound is termed “sprouting”.33,35 With the degradation of
extracellular matrix in the direction of vessel formation, many vessel sprouts interconnect to
form a vessel section which gradually matures to form blood vessels.35 In addition to
reepithelialization and angiogenesis, formation of granulation tissue occurs as well at this
stage.33,35,36 The migration and proliferation of fibroblasts from the neighbouring healthy skin
into the wound take place as a result of cellular responses to growth factors perfused in
surrounding tissue and proteins present in the temporary fibrin matrix.33,35,36 Meanwhile the
extensive synthesis of diverse ECM components by fibroblasts leads to the development of a
new matrix which replaces the provisional fibrin matrix.33,35
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1.2.2.3 Tissue remodeling
Upon the completion of matrix synthesis, some fibroblasts respond to TGF β and undergo
differentiation into contractile myofibroblasts which accelerate wound healing by contracting
the wound edges to close it.33,35 This simultaneously enters the last stage of wound healing,
tissue remodeling. Tissue remodeling often takes place about three weeks post wounding and
might persist for a long time.35,36 At this stage, formation of granulation tissue ceases as most
cells including endothelial cells, macrophages and myofibroblasts enter programmed death of
apoptosis.35,36 On the other hand, collagen is newly synthesized and deposited by fibroblasts in
an irregular way,40 in turn of which fibroblasts attach themselves to the newly synthesized
collagen.33,35 Collagen remodeling occurs based on continuous collagen synthesis and
catabolism, and finally collagen fibres align to form regularly oriented collagen bundles.29,33,35
In addition to collagen remodeling, wound contraction takes place upon fibroblasts taking on
a myofibroblast phenotype featured by highly expressed -smooth muscle actin.29,33 It is well
acknowledged that TGF β1 is responsible for the induction of differentiation of fibroblast into
myofibroblast.41

The field of wound healing has been evolving, and new insights have been gained regarding
more discrete functions of immune cells (e.g., neutrophil and macrophage), fibroblasts, and
stem cells (e.g., mesenchymal stem cells (MSCs), bone marrow-derived stem cells, adipose
tissue-derived MSCs, hair follicle-derived MSCs) during wound repair.42-44 Macrophage has
been demonstrated to take on M1 and M2 profiles with roles being pro-inflammatory and antiinflammatory, respectively during the inflammatory phase.42,45 Fibroblasts of varied lineages
have been found to influence dermal scarring.43,44 For example, a recent study has suggested
that the Engrailed-1 fibroblast lineage is able to mediate scar formation. Blocking the
activation of Engrailed-1 in fibroblasts leads to scar-free wound regeneration.44 With further
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development in cellular and molecular biology, the understanding of wound healing will
continue to advance.

1.2.3 Impaired wound healing
Provided the cellular event(s) during wound healing is prolonged or disrupted, the normal
healing process will be delayed.30 The most common disorders include persistent infection that
leads to biofilm formation and a prolonged inflammation phase46, and interferences in
molecular activities such as an abnormally high expression of matrix-degrading enzymes that
interfere with granulation tissue formation.47 Two major types of impaired wound healing are
chronic wounds and severe burns. They are often intractable, and remain nonhealing for months
and years.

1.2.3.1 Chronic wounds
Chronic nonhealing wounds comprise different types of ulcers, including amongst others
pressure ulcers and lower extremity ulcers (e.g., venous ulcers, arterial ulcers and diabetic foot
ulcers).48 These wounds are closely associated with clinical pathologies such as atherosclerotic
disease and diabetes.49 The underlying reasons of nonhealing chronic ulcers are the
compromised blood supply to the local skin tissue or disordered glucose levels. Studies have
found that the proteolytic enzymes, e.g., matrix metalloproteases (MMPs), in chronic ulcers
are expressed at abnormally high levels, compared to that in normal wounds.50 This disrupts
the normal healing process where some phases are prolonged or detained. The non-healing
status further fosters the development of bacterial colonization, leading to persistent
inflammation. Current therapeutic measures treating chronic wounds focus on pressure
redistribution, anti-infection and use of inhibitory agents (such as MMP inhibitors) loaded into
advanced wound dressings.49 Surgical interventions using bioengineered skin substitutes such
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as Apligraf®, a bilayered skin graft comprising allogeneic keratinocytes and fibroblasts, and
bovine collagen, have seen improved healing in chronic wounds (e.g., venous ulcers).51
However, these treatments are expensive52, and the high occurrence of chronic wounds in
today’s large aging population necessitates the development of cheaper yet effective solutions
to treat these wounds.48,49

1.2.3.2 Burns
Burns cause significant morbidity to the skin and the body. According to the depth of skin
affected, there are four degrees of burn wounds, which are first-degree burns involving only
the epidermis (superficial burns), second-degree burns affecting epidermis and portions of
dermis (partial thickness burns), third-degree burns affecting epidermis and the whole dermis
(full thickness burns), and fourth-degree burns with damage reaching beneath tissues and
organs.53 Due to the disruption of the barrier integrity, the risk of systemic infections in burn
patients is high, which account for most of the associated deaths. To improve patient survival,
a first and key step in treating burns is to cover the wound in a timely manner to isolate invading
microorganisms and to restore the barrier function. This can be achieved by the transplantation
of cultured epithelial autografts (CEAs) to promote re-epithelialization.54 Further improvement
has been made by shortening the lengthy time needed for the preparation of CEAs through
delivering keratinocyte cell suspension using a spray system.54-57 However, for full thickness
burns, the healing was less ideal due to the low take rates of CEAs and poor mechanical
resistance of the healed skin. These are majorly ascribed to the absence of an underlying dermal
component. In this respect, the current widely used measures in treating severe burns include
early excision to remove necrotic tissues and eschar, and subsequent application of skin
grafts.53,58 This approach lowers the risk of infection and promotes wound closure.
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Normally, therapeutic interventions are needed to facilitate and accelerate the healing process
of both chronic wounds and burns. Prompt wound closure is key to the prevention of bacterial
infection and loss of body fluids and electrolytes. With the high occurrence of nonhealing
wounds, the gap between the need and availability of transplantable skin grafts has been
continuously widened.

1.2.4 Wound dressings
Wound dressings are cell-free materials used to treat chronic ulcers for improved patient
wellbeing. Since chronic ulcers are a result of systemic conditions and compromised blood
supply in the lower extremities, external interferences are more desirable compared to
autologous skin transplantation using the patient’s own normal skin. Before safe and effective
artificial skin grafts become available and affordable, wound dressings remain the major
treatment to lower morbidity and relieve pain of patients in the long period of therapy.
Traditional wound dressings include bandages, cotton wool, lint, plasters, and gauzes. These
dressings were used extensively in the past, and are still in considerable use today due to easy
access and low costs. They are intended to cover and dry the wounds so as to protect the wounds
from bacterial infections.59 The introduction and use of antibiotics in the 19th century has aided
further control of bacterial infection, and has been a good complement to the use of traditional
wound dressings. In practice, dry wound dressings gradually become saturated with wound
exudates, and a frequent change of the wound dressings is needed. However, the removal
process easily causes trauma as wound dressings tend to adhere to and integrate into the wound
tissue.9

Modern wound dressings emerge with a substantial development thanks to the advancement in
materials science and fabrication technologies. One significant development is moist wound
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healing. Studies have demonstrated that the formation of a dry scab in human excisional
wounds led to retarded re-epithelialization, whereas a suitably moist environment promoted
the process.60 The important role of the moisture level in a wound initiates the use of
semiocclusive dressings to keep a wound moist.50 However, it is well acknowledged that the
presence of excessive wound fluids is detrimental to the healing process. In this context, a facile
strategy is to use highly absorbent wound dressings that reserve wound exudates whilst
maintain an intended moisture level.50 Typical such modern wound dressings include amongst
others hydrocolloid dressing, alginate dressing, hydrogel dressing and bioactive dressing.50,61,62
Through fabrication approaches, these dressings are processed into many forms such as porous
foams, films, sheets and hydrogels, all with a high ability to absorb wound fluids and to
maintain an appropriate moisture level.62 The use of bacteriostatic materials (e.g., chitosan) in
wound dressings further enhances the efficacy in promoting wound healing by reducing
infections.63 Modern dressings, when loaded with healing-promotion agents such as antibiotics
and bioactive molecules, also serve as drug delivery systems.50,62

Wound dressings have been used for thousands of years to facilitate wound healing, and have
advanced significantly from passive materials that are merely used to cover a wound, stop
bleeding, prevent bacterial invasion and absorb exudate, to active materials that enable a moist
wound environment for increased re-epithelialization rates, and more recently to active
materials that can deliver beneficial chemicals/drugs.50,64,65 However, for some hard-to-heal
wounds such as chronic ulcers and burns, even modern wound dressings can only serve as
expedient measures simply because they are incapable of steering cellular events toward tissue
regeneration and healing. These limitations necessitate a further more advanced level of
development of skin substitutes. The most distinguishing feature of skin substitutes from
modern wound dressings are their cellular reactivities.
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1.2.5 Skin substitutes
Impaired wound healing requires the application of a skin graft to promote skin repair and
regeneration. Traditional skin grafts including autografts, allografts and xenografts face
significant limitations regarding availability, safety and risks of introduced morbidity.66 These
issues are especially prominent when a large piece of autograft is needed. Skin substitutes are
transplantable artificial skin grafts obtained by skin tissue engineering. Apart from qualities of
safety and efficacy, an ideal skin substitute needs to exhibit; biodegradability, appropriate
porosity, matched mechanical properties, and be cost-effective. These features are important
to facilitate cell proliferation, migration and differentiation, and ultimately to achieve cell
functions.67 Numerous skin substitutes have been developed and clinically assessed, with some
of them being commercialized and approved for clinical applications.9,52,67-69

Basically, skin substitutes can be generalized into two forms, i.e., acellular and cellular skin
substitutes. According to the target wound type, skin substitutes can be categorized into three
classes, which are epidermal substitutes, dermal substitutes, and epidermal/dermal composite
substitutes (Table 1.2). Present commercially available skin substitutes are generally
comprised of allogenic skin cells and collagen or acellular dermis. For example, Integra®
dermal regeneration template, being the first bioengineered acellular dermal substitute in 1980s,
employed bovine tendon collagen and shark chondroitin sulfate as the matrix materials. A thin
silicone membrane possessing semipermeability was included to prevent loss of moisture from
the wound (Figure 1.4).70 Apligraf®, the first living human skin equivalent, is prepared using
allogenic fibroblasts and keratinocytes grown in a dermal matrix composed of bovine
collagen.69 These bioengineered skin substitutes have proven clinical efficacy in treating burns
and chronic ulcers. For example, allogenic cell sheets of keratinocytes showed clinical benefit
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of stimulating host epithelialization from the edges of the ulcer when treating venous leg
ulcers.71

However, these skin substitutes are not perfect in terms of promoting skin regeneration or
fulfilling full-ranged skin functions. Particularly, challenges remain in the regeneration of the
dermal vasculature and nerve endings, and skin apparatus such as hair follicles and various
secretive glands. A key factor behind this is that the reinvented dermal matrices are unable to
provide cell-instructive microenvironments, i.e., lacking either cell-adhesion structural motifs
or a suitable microstructure with a sufficient mechanical property, to facilitate cellular activities
toward tissue development. Whether or not cell-adhesion motifs are presented hinges on
material selection, while hierarchical microstructure is the concern of the scaffold fabrication
approach. On the other hand, collagen-/acellular dermis-based skin substitutes normally lack
immunologic defence and might be prone to bacterial colonization during application.70
Moreover, collagen-based skin substitutes are manufactured at a relatively high cost, limiting
their wide use. This biomedical scenario is driving further investigation in skin tissue
engineering with the goal being to find optimal solutions to enable massive production of
effective and safe skin substitutes at relatively low costs to meet the increasing need of
transplantable skin grafts.
Table 1. 2 Commercial skin substitutes
Skin substitutes
Epidermal substitutes
Cellular Cultured epithelial
(CEAs) (sheets)

Acellular

Brand

autografts EpiCel® (Genzyme
Biosurgery, Cambridge,
United States)
Autologous
subconfluent CellSpray® (Clinical
keratinocytes remaining actively Cell Culture, Perth,
proliferative
Australia)
Autologous
keratinocytes Myskin® (CellTran,
delivered on surface-modified United Kingdom)
silicone dressings
Freeze-dried lysates of expanded LyphoDermTM
allogeneic keratinocytes
(XCELLentis, Belgium)
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Target treatment
Deep dermal or full
thickness burns54
Acute partialthickness burns and
donor sites72
Burns and chronic
wounds73
Venous leg ulcers74

Dermal substitutes
Acellular A composite matrix comprised of
bovine tendon collagen and shark
cartilage chondroitin sulfate, with
a
superficially
coated
semipermeable silicone membrane
Decellularized cadaveric dermis

Integra® Dermal
Regeneration Template
(Integra LifeSciences
Corporation, United
States)
AllodermTM (LifeCell
Corporation,
Branchburg, United
States)
Bovine dermal collagen, bovine Matriderm (MedSkin
nuchal ligament elastin
Solutions Dr. Suwelack
AG, Germany)

Burn/scar
contracture75,76

Full thickness burns77

Full thickness skin
lesions in combination
with a split-thickness
skin graft78
®
A flexible monofilament nylon Biobrane-L
(Bertek Conventional wound
fabric (360 µm) bound to a thin Pharmaceuticals, United dressing79
layer of semi-permeable silicone States)
(6 µm); the nylon matrix being
chemically modified with porcine
collagen
Cellular Human foreskin fibroblasts grown Dermagraft® (-75 °C ±
Full thickness diabetic
within a bioabsorbable polymeric 10 °C) (Organogenesis
foot ulcers80
matrix made of polyglactin-910 or Inc., United States)
polyglycolic acid
Neonatal human (allogeneic) TranscyteTM (Advanced Burn wounds81
fibroblasts on nylon fibres of Tissue Sciences, La
Biobrane (nylon + silastic film), Jolla, Calif, United
then frozen
States)
Composite epidermal/dermal substitutes
Cellular The
dermal
compartment Apligraf®
(previously Venous leg ulcers and
composed of bovine type I known as GraftskinTM, diabetic foot ulcers83
collagen matrix populated with Organogenesis, United
allogeneic
fibroblasts;
the States )82
epidermal compartment composed
of top-seeded keratinocytes
A bovine collagen matrix seeded Orcel®
(Ortec Donor sites in burn
with allogeneic fibroblasts in the International,
United patients79
porous side and allogeneic States)
keratinocytes on the other side
with a confluent collagen gel
coating
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Figure 1. 4 Graphic presentation of Integra® Dermal Regeneration Template.70

1.3 Skin tissue engineering
Skin tissue engineering is a powerful tool to produce skin substitutes by integrating cells,
supporting materials and bioactive molecules. Skin tissue engineering has seen significant
progress over the last four decades. Key development primarily took place in the 1980s when
skin tissue engineering first gained its popularity (Table 1.3). While cells and signalling
molecules allow fewer options, supporting materials constituting the synthetic dermal matrices
allow enormously flexible options due to various material functionalization designs and
miscellaneous material combinations. Owing to the advancement of materials science, a wider
range of materials becomes selectable for matrix fabrication for skin tissue engineering. In
particular, materials that are delicately modified to conjugate cell-instructive motifs are highly
promising to deliver advanced skin substitutes with purposely tailored cell-material
interactions. A great deal of materials of synthetic and natural origins have been investigated
in order to evaluate their suitability as artificial matrices for skin tissue engineering,84,85 and
this work is still underway to explore optimal materials. On the other hand, increasing attention
has been paid to the engineering approach, which determines structural characteristics (scaffold
porosity and geometry85-87) of the fabricated structures.
Table 1. 3 Key development in skin tissue engineering
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Time line
1975
1979
1981
1981
1981

1995
2009

Event
Ref.
88
Establishment of in vitro culture of human epidermal keratinocytes
89
First development of cultured confluent epithelium sheets
90
First grafting of cultured epithelial autografts to treat burn patients
91
Development of living skin tissue composed of fibroblasts in collagen and
seeded keratinocytes on top
58
First introduction of acellular dermal substitute (Integra®) based on bovine
tendon collagen, shark cartilage chondroitin sulfate and a semipermeable
silicone membrane
Development of living bilayered skin graft (Apligraf®, Organogenesis Inc.) 82
using allogenic fibroblasts and keratinocytes and collagen
1
First 3D bioprinted skin construct

1.3.1 Conventional skin tissue engineering approaches
Over the past four decades, scaffold fabrication techniques have been extensively investigated
and established.31,92 Some well-established techniques are solvent casting in combination with
particulate leaching, lyophilization, electrospinning, electrocompaction and gas foaming
(Table 1.4). These techniques have been considerably utilized for fabricating porous scaffolds
as cell culture platforms.31,93 However, scaffolds fabricated with these conventional techniques
have suffered from several drawbacks such as lack of flexibility, limited porosity control, use
of toxic reagents and poor dispersion of seeded cells.31,92
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Table 1. 4 Conventional scaffold fabrication techniques
Fabrication
techniques
Solvent
casting/particulate
leaching

Description

Cell
encapsulation
After casting the dispersion of polymer and No
porogen (e.g., salt) in organic solvent (e.g.,
DMSO), the solvent is allowed to evaporate, and
the resulting polymer/salt matrix is immersed in
water to leach or dissolve away the soluble
porogen, producing porous structures.
Freeze drying
Following the freeze of an aqueous polymer No
(lyophilization)
solution that induces phase separation, ice is
removed by sublimation and leave a porous
polymer sponge.
Electrospinning
Through the application of a high voltage to a No
charged polymer solution inside a capillary
needle, a thin polymer solution jet is formed and
collected on substrates of opposite changes,
leading to the formation of nonwoven scaffolds
consisting of nano/micro-scale fibres.
Gas foaming
The polymer matrix is first impregnated with No
foaming agents (e.g., CO2, water) under high
pressure. When the pressure is brought to lower
levels, gas is removed due to a decreased
solubility, forming a porous polymer matrix.
Electrocompaction With an electrical field, protein molecules in a No
solution align electrochemically via isoelectric
focusing and form a highly oriented and
compacted bundle.
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Advantages

Limitation

Ref.

Tuneable pore size
and porosity

Lack of control of pore orientation
and interconnectivity; use of
cytotoxic organic solvents

92,94

Easy processing;
free of organic
solvents

Passive control of microstructure;
time/energy-consuming

92,94

High surface-tovolume ratio

Lack of control of pore size and
porosity; inability to fabricate
complex 3D structures

94,95

No organic
solvents involved

Lack of pore connectivity

96,97

improved
mechanical
properties

Produce more of a 2D structure;
Require covalent crosslinking for
structural stability in wet
conditions

98

1.3.2 Skin bioprinting approaches
Inspired by industrial textile fabrication technology, 3D bioprinting is emerging as an advanced,
powerful and versatile biofabrication platform for skin tissue engineering.9,92,99,100 3D
bioprinting, also known as bio-additive manufacturing, enables accurate and controlled
distribution of an ink-like mixture of scaffold-building materials, bioactive molecules and
tissue-specific cells in a predefined tissue-like architecture to provide patient-customised tissue
replacements in vitro via computer-aided design (CAD).100,101 3D bioprinting also promises
reproducibility and cost-effectiveness due to the automatic fabrication process.92,102 Generally,
there are two basic approaches in 3D bioprinting, namely the top-down approach and the
bottom-up approach (Figure 1.5).9,92,103 These approaches are distinguished between each
other by whether or not a preformed scaffold is involved.

Figure 1. 5 Graphic presentation of the top-down and bottom-up modality of 3D bioprinting
for skin bioengineering.104

The top-down approach, also known as scaffold-based approach, involves the use of a
prefabricated synthetic matrix to provide initial cellular support before the cells establish their
own ECM.9,103 The focus of this approach is to fabricate a cell-free scaffold. The preformed
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scaffolds should exhibit proper microstructures to facilitate the penetration and proliferation of
seeded cells, a suitable biodegradability rate, cell-interactive properties and tissue-matching
mechanical strength. More importantly, the scaffolds should not elicit any safety concerns in
terms of cellular rejection or disease transmission.105 Many types of scaffolds targeting skin
repair and regeneration have been fabricated both in laboratories and in industry for biomedical
uses. For example, Integra® dermal regeneration template, a commercially available dermal
substitute comprising a dermal component consisting of bovine tendon collagen and shark
cartilage chondroitin sulfate and an epidermal component consisting of a silicone membrane,
has been used in wound coverage and wound bed preparation, and demonstrated clinical
significance in the treatment of skin lesions like burns and chronic ulcers.106-108 The binary
collagen-GAG matrix provides a porous scaffold enabling cell infiltration while the thin layer
of semipermeable silicone membrane prevent wound desiccation and microbial invasion.
Preformed scaffolds are useful 2D models to study cell-material interactions.109 However, they
normally result in nonuniform and insufficient cellularization of infiltrating or seeded cells
within the scaffold. This is especially prominent for scaffolds preformed using conventional
scaffold fabrication techniques, such as lyophilization and electrospinning, that often lack
control over micro pore size and connectivity.100 Moreover, the increasing demand for cellbased transplantation has driven the research community to move forward with the bottom-up
approach, which allows the architectural assembly of cells and biomaterials to achieve desired
geometries and appropriate cell distributions.100

The bottom-up approach, without a preformed scaffold, relies on the capacity of cells to
(self)assemble to form cell aggregates or modular tissues and to produce their own ECM.9
Apart from techniques based on spontaneous self-assembly of cells and tissues, one emerging
fabrication technique for the bottom-up approach is additive manufacturing or 3D printing.105
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As a fabrication technique, 3D printing is also utilized by the top-down approach to produce
macroporous acellular 3D scaffolds. Importantly, 3D printing is widely employed to assemble
cellular components in a customized manner. 3D bioprinting enables suitable cellular
patterning specific to skin tissue with the assistance of CAD and material design. According to
the dispensing mode, three assembly modalities have been developed to realize 3D bioprinting,
which are; inkjet, extrusion and laser-assisted bioprinting (Figure 1.6).92,99 These bioprinting
modalities are distinguished by different driving forces, printing speeds, printing resolutions
and material/bioink characteristics (Table 1.5).101 Other emerging bioprinting strategies
include acoustic bioprinting, magnetic bioprinting, and stereolithography.110 Digital light
processing (DLP)-based bioprinting, a form of stereolithography, is a simple bioprinting
technique and has recently gained increasing attention for skin bioprinting (Figure 1.6D).99,111
Table 1. 5 Key parameters of commercially available 3D bioprinting techniques99-101,112
Bioprinting
Printing mode
Print speed
Resolution
Cell density
Cell viability
Viscosity of ink
Printed structure
Skin engineering
Cost

Inkjet bioprinting
Drop-by-drop
Fast (mm s-1)
50 µm
Low, < 106 cells mL-1
>85%
Low, 3.5-12 mPa s
Thin
Suitable
Low

Extrusion bioprinting
Line-by-line
Slow (10-50 µm s-1)
5 µm
High
95%
High, 30-6 ×107 mPa s
Thick and hierarchical
Suitable
Medium

Laser-assisted bioprinting
Dot-by-dot
Medium-fast (mm s-1)
< 500 nm
Medium, 108 cells mL-1
85%
Low, 1-300 mPa s
Thin
Suitable
High

1.3.2.1 Inkjet bioprinting
In inkjet bioprinting, the bioink composed of scaffold materials, cells and bioactive molecules
is jetted out of a printer head in a drop-by-drop manner onto a paper-like substrate.101 The
generation of bioink droplets is driven by a thermal or piezoelectric device (Figure 1.6A).100
The bioinks in this circumstance need to have low viscosity, and the deposited bioink needs to
be crosslinked immediately to permit the continuous addition of successive layers.
Solidification of the printed material is achievable via a physical and/or chemical crosslinking
mechanism, depending on the ink structures.100 This method offers a relatively high bioprinting
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speed, and is cytocompatible with living cells with high cell viability and at a low
manufacturing cost (Table 1.5).

Figure 1. 6 Schematic illustration of 3D bioprinting capabilities reported for skin bioprinting.
(A) Inkjet bioprinting: the ejection of bioink droplets is controlled by either a thermal or
piezoelectric actuator where pressure pulses are generated to regulate the valve-opening time.
(B) Laser-assisted bioprinting: a laser provides the driving force to propel the cell-laden bioink
onto a collector platform. (C) Extrusion bioprinting: driven by either pneumatic pressure, or an
advancing piston or screw, highly viscous bioinks are extruded in the form of continuous
filaments into direct contact with the substrate. (D) Digital light processing-based bioprinting:
the photosensitive polymer precursor in a container is cured layer-by-layer by projected and
patterned UV and/or visible light generated by a digital micromirror device.
Inkjet printing has been frequently adopted in the field of skin bioengineering. For example,
dermal equivalents were bioprinted via the inkjet bioprinting technique using alternating cell25

free layers of a commercially developed poly(ethylene glycol) (PEG)-based BioInk (regenHU
Ltd.) to confine cell layers of primary human dermal fibroblasts. A bilayered skin-mimicking
structure was then constructed by culturing seeded primary human epidermal keratinocytes on
top of the bioprinted dermal equivalent.113 This bilayered skin construct proved certain levels
of epidermal stratification. More recently, inkjet printing has been exclusively used to bioprint
skin epidermis due to the fact that skin epidermal layer barely involves any ECM. This
approach enables uniform distribution of epidermal cells versus conventional cell seeding. For
example, Kim and co-workers successfully constructed epidermis-like structures by dispensing
epidermal cells suspended in cell culture media using an inkjet printer.114-116 Inkjet bioprinting
has also been used to bioprint full thickness skin constructs. For instance, a bilayer pigmented
skin construct was 3D bioprinted by Ng et al. using the inkjet printing technique. The dermal
component comprised a bioprinted porous collagen matrix containing fibroblasts while the
epidermal layer consisted of bioprinted keratinocytes and melanocytes.117 The 3D bioprinted
skin construct showed superior characteristics with respect to epidermal stratification and
basement membrane formation compared to cast-made skin constructs (Figure 1.7). However,
the embedded cells in inkjet bioprinting may suffer damage due to thermal exposure and/or
mechanical stress during printing. Additionally, this method is unable to print viscous materials,
high cell densities or thick structures.100
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Figure 1. 7 3D bioprinted pigmented bilayer skin constructs showed uniform pigmentation in
comparison to cast skin constructs.
Collagen I was used as the matrix and bioink material for inkjet bioprinting. (a) The inkjet
bioprinting of pigmented skin used three types of cells including fibroblasts, keratinocytes and
melanocytes. (b) Optical appearances and histology analysis revealed more uniform production
of melanin granules in the bioprinted skin construct (top row) than in the cast one (bottom row).
(c) 3D bioprinted pigmented skin constructs (top row) showed successful expression of
collagen VII and keratin 1 indicting respectively potential basement membrane formation and
differentiation of epidermal keratinocytes; positive staining of HMB45 and keratin 6 were
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visualized in both the bioprinted and cast (bottom row) skin constructs. Adapted and
reproduced from reference [117].

1.3.2.2 Laser-assisted bioprinting
The advent of laser-assisted bioprinting (LaBP), where a laser provides the driving force to
propel the cell-laden bioink onto a collector platform, represents a substantial development
which allows force-free bioprinting (Figure 1.6B).9,100,101,112 This technology promises high
cell viability of the pre-embedded cells in materials and a relatively high printing resolution
(down to single cell printing). It has been successfully utilized for skin tissue engineering. For
instance, Koch et al. employed the LaBP technique to bioprint both murine 3T3 fibroblasts and
HaCaT keratinocytes to generate skin tissue using rat tail type I collagen as the matrix material
(Figure 1.8).118 After submerged culture for 10 days, the bioprinted cellular structure showed
a skin-like pattern. Later, the team assessed the bioprinted skin substitutes both in vivo on nude
mice with full thickness wounds and in vitro by culture at the air-liquid interface.119 Both in
vivo and in vitro skin constructs showed successful tissue maturation with multilayered and
stratified epidermis. However, the utilization of cell lines of diverse sources rather than primary
human cells represented a significant limitation. Disadvantages of LaBP include a narrow range
of printable materials, incapability of thick structure printing, a lengthy time frame and high
costs of the laser-printing system, considerably limiting the investigation and application of
this printing method.100,101
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Figure 1. 8 Skin bioprinting using the laser-assisted bioprinting technique.
(a) Schematic illustration of laser-assisted 3D bioprinting; (b) Demonstration of cell patterning
by laser-assisted bioprinting where fibroblasts (green) and keratinocytes (red) were printed to
form a grid structure. (c) Layer-by-layer printing of HaCaT cells expressing either red or green
fluorescent proteins; (d) Hematoxylin and eosin staining showed a bilayered structure of the
printed skin mimicking that of native skin. (e-h) Immunostaining confirmed the expression of
characteristic protein markers in the printed skin. Keratin 14 (K14) and Ki67 are markers
indicating cell proliferation while laminin is a marker indicating basement membrane
formation. a-b: scale bar = 500 μm. c-f: scale bar = 50 μm. Adapted and reproduced from
reference [118].

1.3.2.3 Extrusion bioprinting
Extrusion-based 3D bioprinting utilizes either pneumatic or mechanical (piston or screw)
pressure to drive a premixed cell-laden bioink in a syringe through an extrusion nozzle into
direct contact with the substrate (Figure 1.6C).110 It allows the bioprinting of materials with
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high viscosity.100 With the movement of the stage or the printer head, the bioink can be
deposited according to a predetermined architecture by CAD.9,92,100 This printing method
allows the bioprinting of a variety of materials and thick structures such as full thickness skin
constructs, greatly broadening the range of applications.100 Further, the extrusion printing
systems are well developed with multiple commercially available options that are user-friendly
and affordable for researchers and industries. These benefits allow investigation of many
materials for potentials in skin bioprinting. While there are several unfavourable aspects
including moderate printing speeds and resolutions, the overriding practical virtues of
extrusion-based 3D bioprinting embrace wider uses in the bioprinting of artificial skin (Table
1.5).101

Extrusion-based bioprinting has been increasingly utilized to engineer artificial living skin
tissues. For example, a research team in Spain performed extrusion-based skin bioprinting
using human patient-originated fibroblasts and keratinocytes and a bioink prepared from
human plasma containing fibrinogen.102 The bioprinted skin was characterized both in vitro
and in vivo, showing skin-mimicking structures and functions in terms of epidermal terminal
differentiation. It is noteworthy that this work used an extrusion syringe to deposit epidermal
keratinocytes suspended in cell culture media. Recently, Korean researchers conducted several
studies of skin bioprinting utilizing a hybrid 3D bioprinting system. They employed inkjet and
extrusion bioprinting for structuring the epidermal and dermal layer, respectively.114-116 For
instance, Kim et al. constructed a full thickness skin model with the dermal layer fabricated by
extrusion-based printing using a decellularized ECM bioink deriving from porcine skin,
followed by inkjet bioprinting of keratinocytes to form the epidermal layer. The bioprinted skin
showed marginal shrinkage during tissue maturation and improved cellular functions in terms
of epidermal stratification, new dermal ECM deposition, and barrier function. This bioprinted
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skin together with simultaneously bioprinted endothelial progenitor cells and adipose-derived
stem cells promoted in vivo wound healing.115 Pourchet et al. also performed extrusion based
skin bioprinting using a bioink made of gelatin, alginate and fibrinogen.120 The bioprinted skin
showed an anatomical structure mimicking that of human skin, as well as key characteristics
in terms of complete epidermal differentiation (Figure 1.9).
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Figure 1. 9 Skin bioprinting using the extrusion-based 3D bioprinting technique with a bioink
composed of fibrinogen, alginate and gelatin.
(a) A sketch depicting the conditions applied during the extrusion bioprinting process. (b) A
view of the extruded filament and the movement direction of the printing nozzle. (c) A complex
32

structure printed using the present printing method and bioink. (d) Hematoxylin and eosin
staining of the bioprinted skin showed a similar anatomical structure to the native human skin.
(e-f) Immunostaining showed the deposition of important extracellular matrix components of
collagen I, fibrillin, and elastin in the bioprinted skin. (g-h) Immunostaining demonstrated that
the bioprinted skin expressed laminin 332 and collagen VII, indicating the success of basement
membrane formation. (i-j) Immunostaining demonstrated that the bioprinted skin expressed
key epidermal differentiation protein markers of cytokeratin 10 (K10) and loricrin, indicating
successful epidermal stratification of the bioprinted skin. Adapted and reproduced from
reference [120].

While above three printing modalities are applicable for skin tissue engineering, extrusion
based bioprinting has been receiving growing interests due to a broader applicability and
moderate costs. In the body of work that this thesis represents, extrusion-based 3D bioprinting
was employed in the development of living skin constructs.

1.3.2.4 Other bioprinting capabilities for skin regeneration
DLP-based bioprinting has also been employed for skin bioprinting.111,121 As a type of
stereolithography, DLP-based bioprinting is a simple yet highly effective fabrication approach,
characterized by high accuracy, fine resolution and high printing speed.122 It enables the
solidification of photosensitive polymer solution in a reservoir plane-by-plane via the
projection of UV or visible light patterned by a digital micromirror device (Figure 1.6D).122,123
Kwak et al. fabricated a successfully stratified skin-like structure by DLP-based bioprinting.
NIH 3T3 fibroblast cells were distributed in a composite precursor solution comprising silk
fibroin and four-arm PEG. The mixture was subsequently cured by visible light in a layer-bylayer manner by controlling the movable stage. Results demonstrated high cell viability and
improved cell proliferation. Human keratinocytes seeded on top of the printed cellularized
hydrogel formed a thick keratin layer.121 Zhou et al. printed a functional living skin with
integrated vasculature by DLP-based bioprinting. In vitro characterizations showed that the
printed living skin with interconnected microchannels facilitated gas/nutrients exchange, and
thus supported better cell survival and proliferation, migration, and tissue ingrowth. In vivo
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studies in animal models revealed faster and better wound healing results with the deposition
of denser and well-organized collagen fibres similar to native skin and the regeneration of skin
appendages.111

Microfluidic bioprinting utilizes a microfluidic platform to load biopolymer solutions and cells
to form cell-populated mosaic hydrogel with spatiotemporal distribution of cells and
biomaterials.124,125 Leng et al. developed a skin printer based on the microfluidic approach to
print living cells into a sheet-like format. The skin substitute printed with human fibroblasts
incorporated into alginate hydrogel promoted wound healing and keratinization in a murine
wound model.125

1.3.3 Bioinks for skin bioprinting
Based on the constituents, there are generally two categories of bioinks, i.e., scaffold-free
bioinks such as cell spheroids and tissue strands, and scaffold-based bioinks.126 Here,
discussions are only made on scaffold-based bioinks as the goal of this project is to reinvent
ECM using polysaccharidic ulvan for scaffold-based skin bioprinting. The key element of
scaffold-based bioinks is the matrix material. Animal-sourced biomaterials derived from
connective tissues such as dermis and tendon are popular ink ingredients. These biomaterials
include proteins such as collagen I, elastin, gelatin and fibrinogen, and GAGs such as
chondroitin sulfate and hyaluronic acid. Decellularized dermal ECM is also explored as a
bioink for skin bioprinting.115 Plant-derived biomaterials, such as cellulose and pectin, have
also been investigated to develop bioinks for skin bioprinting.127 Marine-sourced biomaterials
including alginate, chitosan128, carrageenan and ulvan129 have recently drawn increasing
interests in bioink development for 3D printing living skin-like structures. Compared to
biomaterials privileged with innate biocompatibility, synthetic polymers are more
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advantageous with favourable mechanical characteristics. Common and frequently used
synthetic polymers in bioink development include; PEG130, Pluronic131, poly(vinyl pyrrolidone)
(PVP)117 and polycaprolactone (PCL)132.

Specific to skin bioprinting, a number of materials, especially gel-forming materials, have been
investigated for bioink development for direct cell embedding and printing. Table 1.6
summarizes skin bioprinting-specific bioinks developed in the last ten years. These bioinks
have different formulations and are characterized by different properties to accommodate
different printing modalities. Formulation of bioinks for inkjet printing is limited to a short list
of materials in order to meet the requirement of low viscosity. The most frequently used ink
ingredient for this printing modality is collagen I, followed by fibrinogen. Collagen I was also
the major material used to formulate bioinks for LaBP and extrusion based bioprinting. As
extrusion bioprinting caters well for the printing of highly viscous materials and high cell
densities, a more diverse range of materials have been used to develop extruding bioinks for
skin bioprinting. Materials for such bioink development include fibrinogen, gelatin, alginate,
chitosan, silk fibroin and dECM amongst others. These bioinks are generally cell-laden
hydrogels which feature a high water content, tunable mechanical strengths, and a porous
network that permits transport of nutrients and mobility of embedded cells.126 For instance,
Cubo et al. developed a bioink using human plasma fibrinogen, which was able to be
transformed into a fibrin gel matrix by the activities of thrombin.102 In many cases, extrudable
bioinks are formulated as composites containing several materials with each serving specific
functions. For example, Pourchet et al. has developed a composite bioink containing gelatin,
alginate and fibrinogen for extrusion-based skin bioprinting.120 Gelatin was used as a
rheological modifier to facilitate the printing process but was removable later after printing.
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Fibrinogen was used as a matrix component and provided cell adhesion sites. Alginate was
used to form a physical gel to provide structural support.
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Table 1. 6 Review of bioinks for dermal scaffold printing and skin bioprinting reported in the literature
Bioinks

Printing technology

Rat tail collagen I (2.05
mg mL-1)

Inkjet bioprinting

Rat tail collagen I (3.0
mg mL-1)

Inkjet bioprinting

PEG-based
BioInk
(regenHU Ltd.)

Inkjet bioprinting

D: collagen
E: 2.5% w/v PVP-based
bioink

Inkjet bioprinting

Bovine collagen, type I
(6 mg mL-1)

Inkjet bioprinting

Fibrinogen-collagen I

Inkjet bioprinting

Cells
-Primary adult human dermal fibroblasts
-Primary adult human epidermal
keratinocytes
-Neonatal human foreskin fibroblasts
(HFF-1, ATCC)
-Keratinocytes (HaCaT)
-Primary human dermal fibroblasts
(9.0×106 cells mL-1)
-Primary human epidermal keratinocytes
-Keratinocytes
-Melanocytes
-Fibroblasts (3 donors)
-Neonatal human dermal fibroblasts
-Neonatal
human
epidermal
keratinocytes
-Human epidermal melanocytes (HEMnDP, darkly pigmented neonatal)
-Amniotic fluid-derived stem cells
-Bone marrow-derived MSCs

Substrate
Petri
dish,
or
poly(dimethylsiloxane) moulds
with 3D surface contours
A printed collagen gel layer on
a poly-d-lysine-coated glassbottom petri dish

Animal model

Ref.

/

Lee et al., 20091

/

Lee and Singh et
al., 2014133

Polytetrafluoroethylene inserts
(0.4 μm pore)

/

Rimann et al.,
2016113

6-well culture inserts

/

Ng
et
2018117

al.,

Transwell membrane insert

/

Min
et
2018134

al.,

In situ printing

Immunedeficient mice

Skardal et al.,
2012135
Albanna et al.,
2018136

Bovine
plasma
fibrinogen and collagen
I;
Bovine
plasma
thrombin

Inkjet bioprinting

-Autologous dermal fibroblasts
-Autologous epidermal keratinocytes

In situ printing

Outbred athymic
nude
(Nu/nu)
mice;
specific
pathogen
free
Yorkshire pigs

Chitosan-PEG

Inkjet bioprinting

-Human neonatal foreskin fibroblasts
(seeded)

/

/

Hafezi et
2019137

al.,

Rat tail collagen I (3 mg
mL-1)

Laser-assisted bioprinting

-Murine NIH-3T3 fibroblasts
-HaCaT keratinocytes

MatridermTM

/

Koch et
2012118

al.,

Collagen

Laser-assisted bioprinting

Matriderm®

Human
plasma
containing fibrinogen

Extrusion bioprinting

-NIH-3T3 fibroblasts
-HaCaT keratinocytes
-Primary human fibroblasts
-Primary human keratinocytes
(Both cells are from skin biopsies.)

BALB/c-Nude
mice
Immunodeficient
athymic
nude
mice
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In vivo or in vitro on
polycarbonate transwell inserts
(1 μm pore)

Michael et al.,
2013119
Cubo et
2016102

al.,

Gelatin-chitosan
hydrogel
(negativepositive,
electrostatic
interaction)

Extrusion bioprinting

-Human neonatal foreskin fibroblasts
(seeded)

/

/

Ng
et
2016138

al.,

Alginate/gelatin

Extrusion bioprinting

-Human skin fibroblasts (seeded)

/

/

Shi
et
2017139

al.,

/

/

Pourchet et al.,
2017120

Petri dish

/

Kim et
2017114

al.,

/

Wistar rats

Intini et
2018140

al.,

Glass slides

SD rats

Shi
et
2018141

al.,

/

/

Admane et al.,
2019142

/

bALB/cA-nu/nu
mice

Kim et
2018115

-NIH 3T3 eGFP mouse fibroblasts
(ATCC)
-Normal human epidermal keratinocytes
(one-year old donor): seeded at 10000
cells cm-2
-Human primary dermal fibroblasts
-Human primary epidermal keratinocytes
-Human dermal fibroblasts
-Aneuploid
immortal
keratinocytes
(HaCaT cells)
(Seeded)
-Human melanocytes
-Human keratinocytes (HaCaT)
-Human dermal fibroblasts
-Human primary adult dermal fibroblasts
-Human adult keratinocytes
-Human neonatal dermal fibroblasts
(ATCC)
-Neonatal epidermal keratinocytes
-Adipose-derived MSCs from patient
-Endothelial progenitor cells from human
umbilical cord blood

Bovine gelatin (10%),
very
low
viscosity
alginate
(0.5%),
fibrinogen (2%) (w/v)

Extrusion bioprinting

Collagen type I (2% w/v)
with PCL mesh

D: Extrusion bioprinting
E: Inkjet bioprinting

Chitosan
(6%)/D-(+)
raffinose pentahydrate
(290 mM)

Extrusion bioprinting

GelMA/collagen,
tyrosinase-doped

Extrusion bioprinting

Silk fibroin, gelatin

Extrusion bioprinting

dECM (porcine skin)

D: Extrusion bioprinting
E: Inkjet bioprinting

Pectin
methacrylate
coupled with peptide
RGD (crosslinker: 5 mM
CaCl2)

Extrusion bioprinting

-Human neonatal dermal fibroblasts

/

/

Pereira et al.,
2018127

Human platelet lysate,
GelMA

Extrusion bioprinting

-Human dermal fibroblasts

/

/

Daikuara et al.,
2021143

D: skin-derived dECM,
fibrinogen
HD:
adipose-derived

D: Extrusion bioprinting
E: Inkjet bioprinting

-Human dermal fibroblasts
-Human epidermal keratinocytes
-Human umbilical vein endothelial cells

/

/

Kim et
2019116
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al.,

al.,

dECM,
bovine
fibrinogen
Vascular bioink: gelatin,
glycerol, thrombin

-Predifferentiated human preadipocytes
-Mature adipocytes

D: gelatin, fibrinogen,
collagen I, elastin
BM: laminin/entactin

D: Extrusion bioprinting
BM: Inkjet bioprinting
E: Inkjet bioprinting

-Neonatal human dermal fibroblasts
-Neonatal normal human epithelial
keratinocytes

Transwell insert membrane

/

Derr et
2019144

al.,

Alginate/honey

Extrusion bioprinting

-3T3 fibroblasts

/

/

Datta et
2018145

al.,

Decellularized porcine
dermis/alginate

Extrusion bioprinting

-Mouse embryonic fibroblast cell line
(NIH 3T3)

/

/

Lee
et
2020146

al.,

Decellularized
skin-derived
extracellular
matrix/bovine
fibrinogen

Extrusion bioprinting

-Primary human skin fibroblasts

/

/

Jorgensen et al.,
2020147

Transwell inserts of 3 µm pore
size

SCID/bg mice

Baltazar et al.,
2020148

/

/

In vitro and in vivo

Sprague Dawley
rats; pigs

human

plasma

D: rat tail type I
collagen
E: culture medium

Inkjet bioprinting

Silk fibroin/4-arm PEG

DLP-based 3D printing

GelMA/HA-NB/LAP

DLP-based 3D printing

-Human foreskin dermal fibroblasts
-Human foreskin epidermal
keratinocytes
-Human endothelial cells
-Human placental pericytes
-NIH 3T3 fibroblast
-Human keratinocytes
-Human skin fibroblasts
-human umbilical vein endothelial cells

Kwak et
2019121
Zhou et
2020111

al.,
al.,

Note: “D” represents dermal compartment; “E” represents epidermal compartment; “BM” represents basement membrane; “HD” represents
hypodermal compartment. PEG, poly(ethylene glycol); PVP, poly(vinyl pyrrolidone); PCL, polycaprolactone; GelMA, gelatin methacryloyl;
dECM, decellularized extracellular matrix; HA-NB, N-(2-aminoethyl)-4-(4-(hydroxymethyl)-2-methoxy-5-nitrosophenoxy) butanamide (NB)
linked hyaluronic acid; LAP, lithium phenyl-2,4,6-trimethylbenzoylphosphinate; DLP, digital light processing; MSCs, mesenchymal stem cells.
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In the following sections, some of the bioink-constituting materials that have already been
highlighted are discussed in terms of their skin printing-favourable properties, limitations and
considerations of their uses as ink ingredients.

Collagen I. Collagen type I is a principal ECM component in mammalian connective tissues
such as dermis, cornea and tendon. Collagen I accounts for about 70-80% of dermis dry
weight.149 As a fibre-forming protein, collagen I serves not only as a structural component but
also a signalling molecule mediating cell-material interactions through its cell-adhesion
peptides. Collagen type I is a frequently used scaffold material in skin bioengineering. For
bioink development, collagen I extracted from bovine134 and rat tail1,118 has been formulated
for skin bioprinting. Due to low viscosity and temperature-sensitive fibrillogenesis150, collagen
I based bioink formulations are often used in inkjet and laser-assisted bioprinting. The long
gelation dynamic of collagen I is another disadvantage that does not typically suit the printing
processes where a fast gelation/solidification is required to allow the dispensing of subsequent
layers. Further, the less desirable physicochemical properties, including poor mechanical
strength and fast degradation, have dampened its use as a single component bioink for skin
bioprinting. This drives the use of a secondary component(s) for structural reinforcement
and/or viscosity modification. For example, PCL mesh has been used to support printed
collagen bioinks for constructing the dermal compartment of a full thickness skin model.114 In
another work, Derr and co-workers developed a dermal bioink comprising collagen, gelatin,
fibrinogen and elastin. Gelatin facilitated the extrusion printing process by increasing the
bioink’s viscosity while fibrinogen was included to prevent matrix contraction by
strengthening the collagen gel.144
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Gelatin and gelatin methacryloyl (GelMA). Gelatin is a hydrolyzed product of collagen and
exhibits a thermoresponsive gelation behaviour. At physiological temperatures (35-37 °C),
gelatin solution is in a liquid form with random coil structures, whereas at cooler temperatures
(e.g., room temperature), it solidifies to form a gel with triple helix structures. This
characteristic makes gelatin a good candidate for extrusion-based 3D printing. Also, the
removable feature endows gelatin with a sacrificial property that can be harnessed for
facilitating printing of non-printable materials and for generating micro-channels on
demand.116,151 For example, vascular bioinks comprising printable and sacrificial gelatin was
developed to carry and deliver human umbilical vein endothelial cells to construct vascular
channels in a full thickness bioprinted skin construct.116 To prevent gelatin from being removed
at physiological temperatures, intermolecular chemical crosslinking was enabled via either
crosslinkers (e.g., genipin, glutaraldehyde) or introducing chemically coupled side chains in
the backbone of gelatin (e.g., GelMA). GelMA is methacryloyled gelatin that is
photocrosslinkable to remain as a structural component with adhesion peptides for cell
attachment. There have been a few gelatin/GelMA-based bioinks developed and studied for
skin bioprinting.120,128,139,142 For instance, Pourchet et al. prepared a gelatin-containing
composite bioink to enable printability by taking advantage of its gelation and removable
property.120 However, even though it has been shown to be a promising material for extrusion
bioprinting, gelatin/GelMA faces similar drawbacks to collagen as lacking mechanical strength
and being subject to fast degradation.152 A general strategy to overcome these drawbacks is to
make use of a secondary material without much elevation in the mechanical stiffness.

Fibrinogen. Fibrinogen is a precursor of fibrin. During bleeding upon cutaneous injuries,
fibrinogen is transformed into fibrin by the enzymatic activities of thrombin. Fibrin then forms
a hydrogel clot serving as a provisional matrix for fibroblast migration. As a natural part of the
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wound healing process, fibrinogen is a promising bioink ingredient for skin bioprinting. For
instance, Cubo and coworkers102 reported an extrusion bioink based on fibrinogen for the
fabrication of full-thickness skin grafts. The dermal equivalent was constructed by the
bioprinting of an in-situ mixed bioink comprising human dermal fibroblasts, human plasma
fibrinogen, and the crosslinker calcium chloride solution, with individual ingredient loaded in
three separate syringes before mixing. Post the printing, fibrin gel formation was induced at
37 °C for 30 min, followed by the extrusion of human keratinocytes in culture medium using
a fourth syringe. After overnight stabilization and grafting to mice, the printed skin showed bilayered structures and successful epidermal differentiation mimicking that of native skin.
Another study conducted by Pourchet et al.120 used fibrinogen in combination with
gelatin/alginate to construct a bilayered skin composite with structural and functional
properties resembling that of native skin. The major shortcoming of fibrinogen is rooted in its
fibrous characteristic that limits its printable working concentrations.126 Higher concentrations
easily cause nozzle clogging, whereas low concentrations would result in inadequate viscosity
and weak mechanical properties. In the circumstances, printability in terms of increasing
viscosity as well as structural support is pursued.126

dECM. Decellularized extracellular matrix (dECM) derived from either human dermis (such
as Alloderm®) or porcine/bovine dermis (such as EZ-Derm) has been developed as acellular
dermal substitutes for clinical use in wound treatment.153,154 By removing the
allogenic/xenogenic cells which represent major risks of immunogenicity, the dermis-specific
dECM maintained structural and biological properties and functionalities that replicate those
of in vivo skin ECM. This is a more promising bioink for skin bioprinting than any other
synthetic ECM-like bioinks. Kim et al. extracted dECM from porcine skin and characterized
the dECM bioink for skin bioprinting.115,116 The bioprinted full thickness skin constructs using
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the dECM bioink featured higher structural stability, and were more functional in promoting
dermal ECM deposition, epidermal differentiation and barrier functions over collagen-based
full thickness skin constructs. In skin bioengineering for real world applications, disadvantages
of dECM bioinks include the high manufacturing cost and risks of disease transmission. Strict
screening to ensure absence of pathological components is necessitated before dECM bioink
preparation.

Pectin. Pectin is a category of anionic polysaccharide derived from the cell wall of higher
plants (e.g., edible fruits).155 With a branched structure, the backbone of pectin is mainly
composed of galacturonic acid residues while the side chains often contain neutral sugars of
rhamnose, galactose and arabinose.156 The naturally originated pectin is biocompatible, and
exhibits attractive properties such as mucoadhesion157 and biodegradability158. Pectin is able to
form physical gels provided divalent cations such as Ca2+ are present.127 This ionic gelation
property renders it a promising candidate for bioink development. However, pectin lacks cell
adhesive motifs in its structure and mammalian adherent cells are unable to interact with it or
attach to it. Pereira et al. developed a single component bioink comprising
arginylglycylaspartic acid (RGD)-conjugated pectin for dermal bioprinting.127 The 3D printed
cell-laden structures with HDFs supported cell attachment, proliferation and ECM deposition.

Alginate. Brown seaweed-derived alginates are a type of anionic polysaccharide. The
constituting monosaccharides of alginates are mainly L-guluronate (G) and D-mannuronate
(M). G and M residues are arranged either in a tandem array, or in an alternating fashion, or
combinations of both.159 Alginates from different sources consist of different G and M blocks
in terms of length, residue organization and content. G blocks are responsible for the physical
gelation of alginates as induced by divalent cations of amongst others Ca2+. The length and
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content of G blocks have predominant impacts on the mechanical strengths of the resultant
hydrogels. Alginate hydrogels are highly biocompatible but bioinert materials due to the lack
of cell-instructive moieties. Chemical modifications are needed to conjugate cell-adhesion
motifs such as RGD peptide.160 Even though alginates have been intensively explored in the
field of skin tissue engineering for wound healing-related biomedical applications,159,161,162
only a few alginate based bioinks have been formulated for skin bioprinting purposes.120,139 In
these cases, alginates were used to provide structural support.

Chitosan. Chitosan is a type of cationic polysaccharide. Its natural form in nature is chitin, one
of the most abundant carbohydrate-based biomaterials which is obtained primarily from the
hard shell of marine crustaceans such as shrimps and crabs.63,163 Chitosan is a form of
deacetylated chitin, and able to solubilize in protonated aqueous solvents such as dilute acids.
The backbone of chitosan is featured by linearly organized monomers of glucosamine residues
and N-acetyl glucosamine moieties in 1, 4-glycosidic linkages (Figure 1.10). The glucosamine
content, indicative of the degree of deacetylation, is an important parameter closely associated
with the physicochemical and biological properties of chitosan.63 Chitosan exhibits an array of
attractive biological properties, including being antibacterial, anticoagulant (haemostatic), antifungal, antitumoral, and anticholesteremic. These structural and biological traits put chitosan
in a position with a heightened prospect of applications in skin tissue engineering and wound
healing.164 Owing to its haemostatic activity, chitosan has been widely utilized as a constitute
of wound dressings. However, chitosan does not contain cell-adhesive motifs and does not
support cellular activities without proper modifications. Recently, chitosan-based bioinks have
been reported for skin bioengineering.128,140 For example, hydrogel bioinks prepared with
polyelectrolyte of chitosan and gelatin were successfully employed for extrusion-based 3D

44

printing. The printed structures were pH-crosslinked and supported attachment and
proliferation of neonatal human foreskin fibroblasts.128

Figure 1. 10 Chemical structures of acetylated and deacetylated glucosamine residues in the
polymeric chitosan. The degree of deacetylation is indicated by “1-X”.165
PEG. Being a water-soluble polyether displaying biocompatibility, biodegradability and
nontoxicity, PEG has gained approval for biomedical uses by the United States Food and Drug
Administration.166 With various functional groups (e.g., hydroxyl, carboxyl) at the chain
termini, PEG is amenable to many types of chemical functionalization, leading to a high degree
of structural versatility. PEG lacks cell-responsive ligands, and due to this it is normally
functionalized with cell adhesive167 and/or enzyme-sensitive168 motifs to modulate cell
behaviours with respect to cell adhesion and migration amongst others. Owing to the low
immunogenicity, facile crosslinking approaches and controllable physicochemical properties
(mechanical strength and elasticity amongst others), PEG has been increasingly employed in
bioink development for 3D printing cellularized structures for tissue engineering
applications.130,169 For example, a composite bioink composed of four-arm PEG and silk fibroin
was used for DLP-based bioprinting of a dermal compartment encapsulating NIH 3T3
fibroblasts. With subsequent seeding of keratinocytes, bilayered skin constructs were
engineered showing successful tissue maturation and stratification with the generation of a
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thicker keratin layer.121 A commercial PEG-based bioink, marketed by regenHU Ltd, is
indicated for standardized inkjet bioprinting. This PEG-based bioink is claimed to have ECMlike properties, being cytocompatible, biodegradable, and easily crosslinkable with UV light.
The proof-of-concept printing of a skin model was demonstrated with primary dermal
fibroblasts being inkjet-printed and sandwiched between printed PEG-based bioink layers.
Following the seeding of keratinocytes, the skin model showed an epidermal-like structure.113

Ulvan. Ulvans are a category of water-soluble, gel-forming170,171 polysaccharides derived from
the cell wall of green algae.172,173 The chemical composition of ulvans is highly variable across
different sources.174 The main constituting monosaccharides include L-rhamnose, D-xylose,
D-glucuronic acid, L-iduronic acid, D-glucose and D-galactose (Table 1.7). Ulvans are
naturally sulfated at position C3 in L-rhamnose and/or at position C2 in D-xylose.173,174 The
sulfate groups and carboxylic groups endow ulvans with negative charges. The linear backbone
of ulvans is dominantly arranged in the fashion of disaccharide repeating units.172 The four
major disaccharide repeating units are comprised of sulfated L-rhamnose connected to Dglucuronic acid, L-iduronic acid, or D-xylose via 1, 4-glycosidic bonds.175 These structural
traits are shared by connective tissue GAGs such as dermatan sulfate and heparan sulfate as
found in human skin ECM.176 The unusual rhamnose moieties are unique across seaweed
polysaccharides,177 and are known to be able to bind to lectin sites on the surface of human
skin cells.178,179 Ulvans also exhibit diverse biological properties including, amongst others,
being antibacterial, anticoagulant and anti-inflammatory.180 These structural and biological
characteristics render ulvans a promising biomaterial for skin bioengineering and wound
healing application. Thus far, ulvans have been underexploited in this field, and only seen
limited research in bone regeneration181-184 and drug delivery185. While bioink development
using ulvans has been rare, the intrinsic low viscosity of ulvan solutions175 may represent a
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major disadvantage if boric acid-initiated gelation ought to be ruled out considering the
possible toxic effects. Further, ulvans need to be modified in order to form insoluble
structures.186
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Table 1. 7 Chemical heterogeneity of ulvan type polysaccharides across species and ecophysiology
Source
Ulva lactuca
Ulva lactuca
Ulva pertusa
Ulva conglobata
Entromorpha
prolifera
Ulva lactuca
Enteromorpha
compressa
Ulva spp.
Ulva rigida3
Ulva sp.
Ulva Armoricana
Ulva rotundata

Collection
time
/
Apr 1971
Aug 1971
Nov 1971
Feb 1972

Protein
(%)
4% N
8.70
33.75
21.16
30.13
/
/

Sulfate
(%)
13
/
/
/
/
22.9
23.2

Rha
(%)
31
28.0
6.08
1.47
1.96
40
38

Xyl
(%)
9.4
1.73
0.81
0.39
1.58
12
10

Glc
(%)
7.7
1.67
2.02
0.61
0.98
1.3
6.4

Gal
(%)
/
/
/
/
/
/
/

Man
(%)
/
/
/
/
/
/
/

Ara
(%)
/
/
/
/
/
/
/

IdoA
(%)
/
/
/
/
/
/
/

GlcA
(%)
19.2
11.68
5.73
2.45
15.74
19.0
6.5

MW

Ref.

/
/
/
/
/
91 kDa
360 kDa

Brading et al., 1954187

/

16.8

31

14

4.7

/

/

/

/

11.0

320 kDa

/

16.8

14.1

11.5

1.9

3.4

0.5

2.0

nd

19.0

/

/

27.8

10.9

14.4

4.2

4.0

1.1

3.2

nd

14.9

/

/
May 1993
/
/
2012
Spring

/
13.9
/

15.8
35.9
21.5
26.7

18.4
23.3
20.8
33.3

1.9
10.9
3.5
5.0

4.4
3.0
2.8
1.8

0.9
0.4
0.7
2.0

0.9
tr
/
/

/
nd
/
/

15.2
20.9
3.7
13.3

16.0
17.3

Lahaye et al., 1993170
Ray, 1995173
Lahaye, 1997191
Paradossi et al., 2002192

1

15.5

20.5

5.1

4.3

/

/

/

13.9

11.8

32.2
11

22.4

3.7
41

1.0

/
/
1.827.0

/
/
0.42.6

/
/

3.1

22.5

/

0.5-6.1

/
/
/
4×105Da
1.6×103
kDaa
790 kDa
57 kDab
126.9237.0 kDa
> 70 kDa

Tsubaki et al., 2014197
Tsubaki et al., 2016198

Mar 1976

Ulva. lactuca
1.3
Ulva sp.
/
<4
Chlorella
2.0/
ellipsoidea
11.8
Ulva
/
9.5
meridionalis
Ulva
/
2.3-5.9
meridionalis
Ulva ohnoi
Jun 2013
2.3-5.9
Monostroma
2011-2012
2.4
latissimum
Monostroma
Jan-Feb 2013 2.1-3.2
latissimum
a: equivalent pullulan; b: equivalent dextran.
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Abdel-Fattah et al.,
1973188

Yamamoto, 1980189

Lahaye et al., 1993190

Collén et al., 2011193
Costa et al., 2012194
Adrien et al., 2017195

1.9-6.1

0.211.6

/

58.897.6

10.0

16.4

9.8

49.5

19.2

1.1

/

13.1 (GlcA 4.0)

3.8-9.0 S

55-75

/

/

/

/

/

/

3.8-9.0 S

55-75

/

/

/

/

/

/

400 kDa,
800 kDa
2-3 kDa

16.3

72.2

20.9

3.1

1.1

0.1

/

4.9 (GlcA 2.6)

≥ 70 kDa

Tsubaki et al., 2014197

≤ 6.7%

~800 kDa

Tsubaki et al., 2016198

6.5-7.2

≤ 62.9
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Qi et al., 2017196

Tsubaki et al., 2016198

1.3.4 Challenges in skin bioprinting
Skin bioprinting promises high throughput manufacturing of skin substitutes with controllable
patterning of cells and materials in a predefined 3D architecture. However, to achieve
functional and transplantable skin structures for clinical application, challenges still remain in
several aspects.199,200

Firstly, it is a significant challenge to develop bioinks that not only meet the requirements of
characteristics such as safety, printability, biocompatibility and functionality amongst others
to favour skin tissue development but also meet the requirements for enabling scalable
manufacturing to reduce the costs.199,201 Even though great progress has been made over the
last decade in exploring bioink formulations using miscellaneous functional materials, there is
so far not a single bioink formulation exhibiting comparable features to natural ECM. This
reflects the extreme complexity of natural ECM, and indicates that there is a long way to go
before significant milestones are achieved and widespread therapeutic use is made possible.

Secondly, the paradoxes between physicochemical properties and cell behaviours remain to be
resolved. Mechanical strength that depends largely on polymer concentration and crosslinking
density is important for structural stability, whereas high concentration and crosslinking
density hampers microstructure control and accordingly cell behaviours. To address this issue,
delicate material designs are needed. For example, photocrosslinkable graphene oxide
methacrylate has been incorporated into GelMA hydrogels, and the dual-crosslinked structures
demonstrated more significant influence in structure toughness than in rigidity, more ordered
porosities and uncompromised cytocompatibility with fibroblasts.202 Lutolf et al. successfully
engineered the cell-invading properties of a PEG hydrogel via conjugating the MMP motifs,
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and human foreskin fibroblasts were shown to grow into the otherwise dense PEG network by
MMP substrate activities.168

Thirdly, skin bioprinting needs to conquer the lack of vascularization in the bioprinted full
thickness skin constructs. Currently, the mainstay of skin bioprinting uses a simplified model
where only two types of skin cells (dermal fibroblasts and epidermal keratinocytes) are
involved. The absence of vasculature in the bioengineered skin construct represents a critical
issue to its survival. Increasing attention has now been paid to the fabrication of vascularized
skin grafts to address this issue. For example, Baltazar et al. constructed vascularized skin
grafts by 3D bioprinting a dermal bioink comprising dermal fibroblasts, human endothelial
cells and pericytes interspersed in type I collagen solution.148 An epidermal compartment was
constructed by bioprinting keratinocyte cell suspension on top of the dermal compartment. In
vitro differentiation revealed that endothelial and pericytes self-assembled to produce vascularlike structures while keratinocytes formed a multilayered structure. After grafting in vivo, the
vascularized skin graft with or without pericytes was shown to integrate with the host tissue in
terms of the microcirculation system and was perfusable at week 4 post grafting. The
vascularized skin grafts in vivo also showed reduced structure contraction compared to the nonvascularized skin equivalents. In a manually fabricated skin construct, Yanez et al.203 printed
human microvascular endothelial cells in-between the epidermal and dermal layer to create a
skin graft with microvasculature. Treating full thickness wounds with this graft showed less
contraction compared to Apligraf® and similar skin structure to that of normal skin. More
advanced strategies of vascularization have been the use of a fugitive/sacrificial ink to create
the microchannels following the removal of sacrificial materials under mild conditions. Cells
for angiogenesis are often embedded in the fugitive inks, and when microchannels forms, cells
will line up along the inner wall of the microchannels and produce the blood vessel-like
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structures. The most common materials used in the fugitive inks include gelatin116 and Pluronic
F127204. For instance, Kim et al. developed vascularized full thickness skin equivalents by 3D
bioprinting a gelatin-based cell-laden vascular bioink to create perfusable microchannels in
bioprinted dermal and hypodermal tissues. When liquefied at 37 °C, vascular channels were
successfully created, and matured skin equivalents showed the presence of endothelial cells
expressing CD31 in the channel walls.116 Kolesky and co-workers have developed a method
by co-printing cells, ECM and vasculature in one set to produce heterogeneous 3D vascularized
structures.204 With the use of four printheads for different materials, each layer was dispensed
with a single bioink material and thus multiple layers of alternating materials resulted in a
complex structure. Fugitive Pluronic F127 based cell-laden bioink was subsequently liquefied
at 4 °C to create the vascular channels. This approach allows to print vascularized structures at
one-, two- and three-dimension with living cells perfused within the vascular networks. More
recently, skin vascularization was demonstrated using a DLP-based 3D printing technology.111
With the platform moved towards one direction, the cellularized bioink was cured in a layerby-layer fashion. Each layer was exposed to patterned UV light produced with a dynamic mask
generator. This enabled the production of a complex structure with microchannels allowing
movement and lining of human umbilical vein endothelial cells to form vasculature. In vivo
assessment of the vascularized structures promoted wound healing in both rat and pig models.

Lastly, the regeneration of skin appendages including skin-related glands, hair and skin tone,
and nerve system, is important to obtain skin equivalents with a full range of normal skin
functions.199 Even though the implementation of 3D bioprinting in skin appendage regeneration
is relatively underexplored at the moment, there have been a few studies relating to this
matter.205-208 For example, successful sweat gland regeneration has been demonstrated using
3D bioprinted epithelial progenitors in ECM mimics composed of gelatin and alginate.205
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Further, it was found that the microstructure defined by 3D bioprinting was able to guide sweat
gland morphogenesis.207 Compared to structures printed with a 400-µm tip, structures printed
with a 300-µm tip showed much more evident expression of markers for sweat gland tissue
differentiation. More recently, the role of mechanical properties of 3D structures bioprinted
with hydrogel inks was investigated in the differentiation of MSCs into sweat glands.208 The
bioink was composed of alginate and gelatin, and mechanical stiffness was manipulated by
varying polymer concentrations. Results demonstrated that genes associated with sweat gland
cell phenotype, function and development signalling pathway were up-regulated by printed
structures with higher stiffness. Stiffer structures were also noted to promote the activation of
Yes-associated protein in MSCs.

Despite successful but separate demonstrations in the bioprinting and regeneration of cutaneous
vasculature, skin pigmentation and skin appendages, the integration of all these features in one
skin construct has yet to be investigated.

The emerging concept of 4D bioprinting emphasizes the importance of temporal changes of
3D printed cellular structures as induced by external stimuli to responsive materials in the
printed structures or by tissue maturation such as matrix deposition.209 The strategies by
harnessing deformation characteristics of materials upon stimuli and/or self-assembly
capability of cells/tissues can be orchestrated to regenerate functional organs in skin bioprinting.

In summary, significant advances have been made in the technologies that can be utilized in
the fabrication of materials and structures for skin bioprinting. Experiences gained in the last
decade have been encouragingly instructive in terms of material(s) and cell(s) selection and cofabrication of skin appendages. Yet, skin bioprinting is facing several challenges in order to
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maximize its beneficial effects on the community with a great need in skin care products. One
significant challenge is to develop ECM-like bioinks that allow scalable processes and provide
appropriate microenvironments to favour cell functions toward skin tissue development. While
multiple materials are of particular interests for this application area, increasing efforts are
being made in sourcing new materials from the marine plants. Ulvans, a type of sulfated
polysaccharides from green algae, represents an economic and renewable biomass that may
hold promise for the application in skin bioprinting. The work of present thesis has investigated
a new material, ulvan from a controlled source of cultivated Australian macroalgae of Ulva
species, to uncover its possible roles in skin tissue engineering and wound healing application.
It may fill the blank in ulvan-based bioink development, and open the possibility of establishing
seaweed-based skin bioprinting platforms.
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Chapter 2 Characterization of Ul84 extracts from Venus Shell Systems
(VSS, Australia)

2.1 Introduction
Ulvans are naturally occurring sulfated polysaccharides obtained from the green algae cell
wall .1 These green algae belong mainly to the Ulva species and are frequently involved in
green tide formation with some opportunistic species growing rapidly and extensively in
eutrophic water bodies worldwide.2,3 While green tides present severe economic and
environmental issues, they represent a highly renewable and economic source of biomass for
interesting macromolecules such as ulvan polysaccharides.4 Ulvans are a major class of algaeoriginated polysaccharides, and comprise characteristically L-rhamnose, uronic acids, and
sulfate groups in the backbone.5 So far, ulvans are underutilized, and little added value is
claimed for this naturally sulfated polysaccharide.

Over the last 2-3 decades, research activities into ulvan type polysaccharides are increasing.
These focus on structural elucidation6-8 and chemical modification9-11 for possible biomedical
applications. However, utilization of ulvan type polysaccharides is still in the early stage. One
major reason for this is the high variation in the chemical structure.5 Ulvans from algal species
of different taxonomic entities and/or ecophysiology are reported to have different chemical
structures and compositions.12-16 Further, extraction methods and the introduction of scalable
processes contribute to the variation as well.15-18 Current knowledge of the chemical
constituents and structures of ulvans has been achieved primarily via structural analysis of
depolymerised ulvan by acid hydrolysis.6,17,19-21 However, strong acid treatment may alter or
damage the original structure of ulvans and some glycosidic linkages in ulvans are not
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necessarily subject to acid hydrolysis.5,22 An alternative approach is to make use of enzymes,
e.g., ulvan lyases, to depolymerise ulvans with specificity, and particularly to break the 1,4glycosidic bonds within the disaccharide units.6,23-25 This method is however limited by a short
availability of ulvan-degrading enzymes, even though a few ulvan lyases are being
identified.23,25-30 These undoubtedly hinder a better understanding of structure and function of
ulvans.

Ulvans feature a linear arrangement of monosaccharide units with a minor degree of
branching.1,5 Despite a large extent of structural heterogeneity, the general building blocks of
ulvans are disaccharide repeating units mainly comprised of sulfated L-rhamnose and uronic
acids.31 L-rhamnose-3-sulfate and the uronic acid of either D-glucuronic acid (GlcA) or Liduronic acid (IdoA) are linked via 1, 4-glycosidic bonds.31 This gives rise to two major types
of ulvanobiouronic 3-sulfate, i.e., type A (glucurorhamnose 3-sulfate, A3s) and type B
(iduronorhamnose 3-sulfate, B3s) (Figure 2.1; Table 2.1).1,5,32 Replacements of uronic acids in
A3s and B3s with D-xylose or D-xylose-2-sulfate have been reported as the minor disaccharide
repeating units of ulvans (Figure 2.1; Table 2.1).22,23 For sulfate modification, ulvan is
naturally sulfated at C3 in L-rhamnose and/or at C2 in D-xylose.5,19 These structural features
make ulvans an analogue to mammalian glycosaminoglycans such as dermatan sulfate and
hyaluronic acid.33
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Figure 2. 1 Chemical structures of major disaccharide repeating units of ulvan.

Table 2. 1 Proposed nomenclature, symbol, composition and glycosidic linkage of major
disaccharide units of ulvan type polysaccharides5,18,22,31,34
Proposed nomenclature and
symbol
Ulvanobiuronic acid Type A
(A3s)
Ulvanobiuronic acid Type B
(B3s)
Ulvanobiose U3s
Ulvanobiose U2’s3s

Disaccharide composition and linkage
→4) (β-D-glucuronic acid (1→4)-α-L-rhamnose-3-sulfate) (1→
→4) (α-L-iduronic acid (1→4)-α-L-rhamnose-3-sulfate) (1→
→4) (α- D-xylose (1→4)-α-L-rhamnose-3-sulfate) (1→
→4) (α- D-xylose-2’-sulfate (1→4)-α-L-rhamnose-3-sulfate) (1→

The disaccharide repeating units of ulvan contain both hydrophilic (-OH, -COOH and -SO3-)
and hydrophobic (-CH3) groups (Figure 2.1; Table 2.1). Ulvans therefore bear negative
charges and are able to absorb and retain water under physiological conditions. These structural
characteristics endow ulvan with unique properties in terms of solubility1, viscosity22 and
conformational behaviour35. Ulvans are shown to be water-soluble,1,33 and can be efficiently
extracted using aqueous solvents such as hot water.17,18,34,36 However, the aqueous solutions of
ulvans at high concentrations are cloudy and opaque as reported in the literature1 and observed
in our work. This is likely ascribed to the amphiphilic nature of ulvans such that water is not a
good solvent.34,35 Further, ulvan dispersions in water exhibit intrinsically low viscosity.34 This
is believed to stem from the reduced intermolecular interactions with ulvan chains potentially
developing a bead-like conformation in water.34 The ulvan from Ulva rotundata has been
shown to form bead-like ultrastructures in neutral and acidic conditions.34 The hydrophobic
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interactions through the methyl groups from L-rhamnose units may further propel ulvan
molecules to condense and form aggregates.34 This solution behaviour has also been implied
in the present study with an Australian macroalgae-specific ulvan extract. Importantly, this
aggregation phenomenon may influence the determination of the true molecular weight (MW)
of ulvans. MW can have significant impacts on the physicochemical and biological properties
of ulvans.22,37 Ulvans have been reported to have highly varied MW ranging from several kDa
to as high as 1600 kDa depending on extraction methods, as well as species and
growth/cultivation conditions.5,34 Ulvans also exhibit distinct biological properties including
amongst others antibacterial, anti-inflammatory and anticoagulant activities.1,38-43 These
properties may highlight the potential of ulvans in biomedical applications such as wound
healing.

Herein, a novel type of polysaccharidic ulvan, ulvan-84 (Ul84), was provided by an Australiabased company, Venus Shell Systems Pty Ltd (VSS). Ul84 was extracted from a DNAbarcoded algal species cultivated under controlled conditions, and was proposed for skin tissue
engineering and wound healing applications. We received three Ul84 extracts in total for this
project. The aim of this chapter is to characterize Ul84 extracts to gain a basic understanding
in terms of chemical composition, monosaccharide composition, MW distribution, structural
characteristics and aggregation behaviour. Our results confirmed that these Ul84 extracts
contained varying amounts of seaweed proteins, characteristic sugar units such as L-rhamnose
and uronic acids, and a moderate amount of sulfate groups.
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2.2 Materials and methods
2.2.1 Materials
Three Ul84 extracts were received from Venus Shell Systems Pty. Ltd. (VSS, Australia),
including (1) PhycoTrix, (2) PhycoDerm, and (3) PhycoDerm® PhycoTrix (PDPT) (Figure 2.2;
Table 2.2). These extracts were isolated from one Ulva species that was cultivated in artificial
ponds under controlled conditions. PhycoTrix is a crude Ul84 extract in the form of green fine
powder, and the other two extracts derived from PhycoTrix by precipitation with 50%
ammonium sulfate. PhycoDerm is in the form of brown crystal-like granulates while PDPT is
in the form of beige flakes with a MW of ~700 kDa. All three Ul84 extracts were dialyzed
against distilled water for 24 h to remove salts and impurities. The molecular weight cut-off
(MWCO) of the dialysis tube is 12-14 kDa. Final purified products were collected by
lyophilization, and were used in all experiments.

All three Ul84 extracts were characterized in terms of protein content, ash content, elemental
composition, aggregation behaviour and structural characteristics by 1H NMR and FTIR.
Further, PhycoTrix and PhycoDerm were exclusively characterized in terms of total neutral
sugar content, sulfate content, uronic acid content, monosaccharide composition and MW.
Table 2. 2 Product information of three Ul84 extracts from VSS
No.
1
2
3

Receiving/Start-to-use Date
1st Jul 2016
28th Apr 2017
9th Jul 2018

Product Name
PhycoTrix
PhycoDerm
PhycoDerm® PhycoTrix
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Colour
green
brown
beige

Batch No.
150803 NAC AT#1
/
18052

Figure 2. 2 Relationship of the three Ul84 extracts (top) and respective physical appearances
(bottom).
These extracts are obtained by deproteinization at different times with improved purities. The
deproteinization process also led to a concurrent depigmentation of the Ul84 extract.

L-iduronic acid (IdoA) was purchased from Synthose Inc. (Canada). N,N-dimethylformamide
(DMF), 96% ethanol, sodium hydroxide, potassium hydroxide, 32% hydrochloric acid, 98%
sulfuric acid, methanol, hexane and phenol were purchased from Chem-supply. All other
reagents were purchased from Sigma-Aldrich, including methacrylic anhydride (MA),
deuterium

oxide

(D2O),

sodium

nitrate,

sodium

azide,

Hexamethyldisilane

+

Τrimethylchlorosilane + Pyridine (HMDS + TMCS + Pyridine), 3:1:9 (Sylon™ HTP,
SUPELCO), acetyl chloride, L-rhamnose monohydrate, D-xylose, D-glucuronic acid, Dglucose, D-galactose, L-fucose, D-mannose, L-arabinose, D-sorbitol, 3-phenylphenol,
sulfamic acid, sodium tetraborate decahydrate, trichloroacetic acid, gelatin, potassium sulfate
and barium chloride dihydrate. All reagents were used as received unless otherwise indicated.
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2.2.2 Ash content
The ash content of the three Ul84 extracts was determined and the thermal decomposition
process was monitored by thermogravimetric analysis (TGA) using TG 209 F1 Libra
(NETZSCH, Germany). Prior to test, 5.0-15.0 mg of samples were vacuum dried overnight at
40 °C to remove residual water. The samples were then subject to thermal treatment under an
air atmosphere by heating from room temperature to 900 °C at a ramp rate of 10 °C min-1.18
Experiments were performed in triplicate.

2.2.3 Elemental analysis
The elemental composition of the three Ul84 extracts was analyzed using a CHNS/O Thermo
ScientificTM FlashSmartTM Elemental Analyzer (Thermo Fisher Scientific) with the MultiValve
Control (MVC) Module. The combustion temperature was set at 950 °C, and 2,5-bis (5-tertbutyl-benzoxazol-2-yl) thiophene (BBOT) was used as the standard. Prior to measurement, the
three Ul84 extracts were vacuum-dried overnight at 40 °C, powdered using a mortar and pestle,
and further dried under vacuum at 40 °C. Experiments were performed in triplicate.

2.2.4 Protein content
The protein content of the three Ul84 extracts was measured using a Micro BCATM protein
assay kit (Life Technologies). Here, to reduce the possible effects of polysaccharidebicinchoninic acid (BCA) reagent interactions, the method of standard addition was employed
by spiking ulvan solutions with various known concentrations of bovine serum albumin (BSA)
standard. Briefly, each of the three Ul84 extracts was dispersed in Milli-Q water at 1.0 mg mL1

. Aliquots of 100 µL of each Ul84 solutions were added to 1.5 mL Eppendorf tubes. The BSA

solution at 100 µg mL-1 of varied volumes (0, 50, 100, 150, 200, 250, 300, 400 and 500 µL)
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were added sequentially to each tube containing the Ul84 solution. The total volume in each
tube was 1.0 mL, topped up by adding Milli-Q water. 150 µL of spiked Ul84 solutions was
pipetted to a well in a 96 well plate in duplicates for BCA reactions by following the
manufacturer’s instructions. After incubation at 37 °C for 2 h, the absorbance was recorded at
562 nm using a microplate reader (POLARstar Omega, BMG LABTECH).

2.2.5 Total neutral sugar content
The total neutral sugar content of PhycoTrix and PhycoDerm was measured using the phenolsulfuric acid assay with L-rhamnose monohydrate as the standard.44 The assay is based on the
formation of soluble orange-yellow compounds of carbohydrates upon treatment with phenol
and concentrated sulfuric acid. The colouring compounds are condensed furan derivatives of
carbohydrates or phenolic compounds, which have characteristic absorption at 480 nm. Briefly,
1.0 mL of phenol solution (5% (w/v) in Milli-Q water) and 1.0 mL of each Ul84 solution (50
µg mL-1 in Milli-Q water) were pipetted to a glass vial. After swirling the vial gently to mix
well, 5.0 mL of concentrated sulfuric acid was added to the centre of the liquid mixture rather
than along the wall of the glass vial to achieve full colour reaction. The mixture was maintained
still on bench for 10 min to cool down naturally. It was then incubated at 30 °C in a water bath
for 20 min to allow thorough colour development. The absorbance readings at 480 nm were
recorded using a UV-1800 spectrophotometer (Shimadzu, Japan). The calibration curve was
obtained using the absorbance readings of L-rhamnose monohydrate tested in the range of 080 µg mL-1. Blanks were used by substituting distilled water for Ul84 solutions. Experiment
was carried out in triplicate. Net absorbance was used for quantification by subtracting the
absorbance readings of blanks from those of standards/Ul84 solutions.
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2.2.6 Total uronic acid content
The total uronic acid content of PhycoTrix and PhycoDerm was determined using the
sulfamate/m-hydroxydiphenyl assay with D-glucuronic acid serving as the standard.45 A pink
coloured product forms when uronic acid reacts with m-hydroxydiphenyl (a.k.a. 3phenylphenol) upon heating to about 100 °C in concentrated sulfuric acid. The resulting
derivative has a characteristic absorption at 525 nm. To reduce the browning colour from
heating neutral sugar with concentrated sulfuric acid, sulfamate solution was added.45 The
addition of sodium tetraborate decahydrate was to enhance the responsive signal of Dmannuronic acid and colour development by D-glucuronic acid to facilitate detection. Briefly,
0.4 mL of each Ul84 solution (1.0 mg mL-1 in Milli-Q water) was pipetted to a glass vial
containing 40 µL of sulfamate solution (4 M, pH 1.6) and mixed thoroughly. Sodium
tetraborate decahydrate was solubilized in concentrated H2SO4 at 120 mM, and 2.4 mL of asprepared mixture was added. After thorough mixing, the mixture was incubated in a boiling
water bath (~100 °C) for 20 min, followed by chilling on ice. Subsequently, 80 µL of mhydroxydiphenyl solution (0.15% (w/v), prepared in 0.5% (w/v) NaOH) was added. The
mixture was kept still on the bench for 10 min to allow full colour development. Absorbance
measurement at 525 nm was conducted using a UV-1800 spectrophotometer (Shimadzu, Japan).
Blanks were set by adding 80 µL of 0.5% NaOH where m-hydroxydiphenyl was omitted. The
absorbance readings of blanks need to be subtracted from those of individual Ul84
sample/standard. Experiment was carried out in triplicate. The calibration curve was made with
D-glucuronic acid tested in the range of 50-500 µg mL-1 following the same procedure.

2.2.7 Sulfate content
The sulfate content of PhycoTrix and PhycoDerm, following acid hydrolysis (1 M HCl, 110 °C,
8 h), was assessed using the barium sulfate turbidimetric method where potassium sulfate was
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applied as the standard.46 Briefly, the individual Ul84 extract was solubilized in 1 M HCl at
2.0 mg mL-1 in a test tube. The solutions were then maintained at 110 °C for 8 h to allow the
release of sulfate groups from Ul84 thoroughly. After cooling down, the hydrolysates were
centrifuged (8000 rpm, 20 min), and the supernatants were passed through a 0.22 µm
membrane. In a 200 µL aliquot of Ul84 hydrolysate, 3.8 mL of trichloroacetic acid (3% (w/v))
was added and mixed thoroughly. Subsequently, 1.0 mL of 1.0% BaCl2-0.5% gelatin solution
(w/v, centrifuged after preparation) was pipetted to the above mixture and further mixed. The
obtained mixture was allowed to stand on the bench for 20 min. Blanks and standards by
replacing Ul84 hydrolysates with 200 µL of 1 M HCl and potassium sulfate solution,
respectively underwent the exact same procedure. Absorbance at 360 nm was read against the
blanks using a UV-1800 spectrophotometer (Shimadzu, Japan). A calibration curve was
obtained with absorbance readings of potassium sulfate solutions, which were tested in a SO42concentration range of 0-120 µg mL-1 containing 0, 24, 48, 72, 96, and 120 µg of sulfate groups.
The SO42- content of Ul84 extracts was calculated by reference to the calibration curve.

2.2.8 Monosaccharide analysis
Monosaccharide composition of PhycoTrix and PhycoDerm was determined using a two step
method by acid methanolysis and trimethylsilyl (TMS) derivatization, and detected by Gas
Chromatography/Mass Spectrometry (GC/MS).47,48 Before methanolysis, samples were
thoroughly dried under vacuum at 40 °C to remove residual water. Briefly, 2 mL of 0.5 N
methanolic-HCl was pipetted to a micro-reaction vessel containing 5.0-10.0 mg of Ul84
extracts. The solution was incubated at 80 °C in an oil bath overnight. After cooling down to
room temperature, the sample was flushed with dry nitrogen to remove the methanolic-HCl.
Then 0.5 mL of methanol was added followed by drying with nitrogen. After repeating the
process for three times, the sample was solubilized in 200 μL of HMDS+TMCS+Pyridine

74

(3:1:9) reagent. Derivatization was undertaken at 80 °C for 60 min, followed by cooling down
to room temperature and drying under nitrogen. Finally, the derivatized sample was extracted
with 1 mL of hexane followed by centrifugation and filtration through a glass pipette packed
with a small piece of Kimwipes. The final sample volume was ~2.0 mL after rinsing the
Kimwipe-packed pipette with hexane. For monosaccharide standards (L-rhamnose
monohydrate, D-xylose, D-glucuronic acid, L-iduronic acid, D-galactose, D-glucose, Dmannose, L-fucose and L-arabinose), 2.0 mg of a monosaccharide standard, was used for acid
methanolysis and TMS derivatization using the same procedure as for Ul84.

For GC/MS analysis, 0.1-1.0 µL of the sample was injected to an Agilent 5975C/7890A system.
The GC column (HP-5MS) was 30 m × 250 µm × 0.25 µm. Helium was applied as the carrier
gas. Parameters of the oven setting were shown in Table 2.3.
Table 2. 3 Parameters of the oven setting for GC/MS
Initial temp
Ramp 1
Ramp 2

Rate
°C/min
/
5
3

Value
°C
100
120
230

Hold time
min
0
1
10

Run time
min
0
5
51.667

2.2.9 Molecular weight distribution
The molecular weight distribution of PhycoTrix and PhycoDerm was determined using a gel
permeation chromatography (GPC) system (Shimadzu, Japan) equipped with a combination of
three columns of Ultrahydrogel linear (8 × 300 mm), Ultrahydrogel 1000 (8 × 300 mm) and
Ultrahydrogel 500 (8 ×300 mm) (Waters, USA). Each Ul84 extract was dispersed in the mobile
phase of 50 mM NaNO3 containing 0.02% NaN3 in Milli-Q/methanol (85/15) at a concentration
of 4.0 mg mL-1. The obtained Ul84 dispersions were then filtered through a 0.45 µm membrane,
and 100 µL was injected into the GPC system. The mobile phase was eluted at a flow rate of
0.5 mL min-1. The oven of the GPC system was set at 40 C. Chromatograms were recorded
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using both a refractive index (RI) detector and an ultraviolet (UV) detector. Two detectors were
in tandem, with the UV detector located before the RI detector. The UV detector was set at 280
nm to monitor protein elution. Molecular weight was calculated using the calibration curve
established with dextran standards in the molecular weight range of 5-670 kDa.

2.2.10 1H nuclear magnetic resonance (1H NMR)
1

H NMR spectra of the three Ul84 extracts were obtained at 60 °C using a Bruker Avance III

400 MHz spectrometer (Bruker, Germany). Each Ul84 extract was dispersed in D2O at 3%
(w/v). Manual sampling was performed to ensure that correct temperature (60 °C) was achieved
for the test. Data were processed using the software Bruker Topspin 4.0.5.

2.2.11 Fourier transform infrared spectroscopy (FT-IR)
FT-IR spectra of the three Ul84 extracts were recorded using an IRPrestige-21 spectrometer
(Shimadzu, Japan) coupled with an attenuated total reflection (ATR) component. The
wavenumber was in the range of 4000-700 cm-1 at the resolution of 4 cm-1. Before FT-IR
analysis, the samples were dried overnight in a vacuum oven at 40 ºC to remove any residual
water.

2.2.12 Dynamic light scattering (DLS)
It was observed that all prepared Ul84 aqueous solutions in present work were turbid.
According to the literature as specified in the introduction (1.1), the polysaccharidic ulvan may
assume a bead-like conformation in water, and further condense to form microaggregates.
Dynamic light scattering (DLS) was performed to study the aggregation behaviour of the three
Ul84 extracts using a Zetasizer Nano-ZS (Malvern Instruments, UK). The particle size and
distribution of the three aqueous dispersions of Ul84 was determined. Individual Ul84 extract
was dispersed in Milli-Q water at 0.1 mg mL-1 and 1.0 mg mL-1, respectively. Prior to DLS
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measurement, all samples were filtered through 0.45 µm membrane to remove large particles
including dust. A glass cuvette of PCS1115 (9G) with square aperture was used for all
measurements. The experiment was carried out in triplicate.

2.3 Results and discussion
2.3.1 Chemical composition of Ul84 extracts
Table 2.4 summarizes chemical compositions of the three Ul84 extracts. It is clear that both
PhycoTrix and PhycoDerm contained a significant amount of protein, which were 21.1% and
13.2% (BSA equivalent), respectively. By contrast, PDPT contained much less protein (~3.1%).
Further elemental analysis of nitrogen supported these data (Table 2.4). For the purest Ul84
extract used here, PDPT still contained ~3.1% protein, which was higher than some ulvan
extracts reported in the literature.18,23 The presence of the hard-to-remove protein contaminants
in Ul84 extracts may indicate that there were close associations between the polysaccharidic
Ul84 and proteins in the algal cell wall. This is supported by other work.17,36 Ulvan extracts
from diverse sources have been reported to be easily co-extracted with proteins.5,18

Compared to PhycoTrix containing 52.7% of neutral sugar, 11.7% of uronic acid and 14.6%
of sulfate, PhycoDerm contained less neutral sugar (48.0%), more uronic acid (15.9%) and
more sulfate (16.9%) (Table 2.4). The differences in the total neutral sugar content and sulfate
content between PhycoTrix and PhycoDerm were supported by elemental analysis of carbon
and sulfur, respectively (Table 2.4). The ash content varied among the three Ul84 extracts,
with PhycoTrix, PhycoDerm and PDPT having 11.5 wt%, 13.8 wt% and 12.9 wt% of ash,
respectively (Table 2.4). The decomposition process (Figure 2.3) of the three Ul84 extracts
was monitored using TGA. Each underwent three phases of significant mass losses as the
temperature was increased to 900 ºC. Two critical temperatures were identified during the
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decomposition. One was ~220 ºC and the other was ~560 ºC for PhycoTrix and PhycoDerm
and ~710 ºC for PDPT. Below ~220 °C, there occurred an initial mass loss of ~15%. This was
possibly due to the escape of tightly bound water in the materials. After the temperature
exceeded ~220 °C and till ~560 ºC/~710 ºC, the materials underwent the second mass loss of
~50-60%. This indicated there was significant breakdown of the materials at this stage. When
temperature was higher than ~560 ºC (for PhycoTrix and PhycoDerm) and ~710 ºC (for PDPT),
the materials further decomposed and lost additional ~10-20% mass. The residual ash may
contain minerals and possibly some oxidized products. The difference in residual weights
(wt%) among three Ul84 extracts (Table 2.4) may be correlated with the counterion content in
association with varied sulfate contents.
Table 2. 4 Proximate chemical constituents of the three Ul84 extracts shown as wt% of dry
weight, and elemental analysis
Chemical constituents

PhycoTrix

PhycoDerm

PhycoDerm®
PhycoTrix
3.1 ±0.1
n/d
n/d
n/d
12.9 ±0.7

Protein (%)
21.1 ±0.4
13.2 ±0.2
Total neutral sugar (%)
52.7 ±1.0
48.0 ±2.4
Total uronic acid (%)
11.7 ±0.5
15.9 ±0.4
Sulfate (%)
14.6 ±0.4
16.9 ±0.4
Ash content (%)
11.5 ±0.6
13.8 ±0.3
Elemental analysis
C (%)
33.7 ±0.4 (32.6 ±0.2) 31.2 ±0.9 (31.1 ±0.2) 32.9 ±0.2
N (%)
3.2 ±0.1 (4.0 ±0.02)
2.9 ±0.1 (3.6 ±0.2)
1.1 ±0.03
S (%)
5.3 ±0.1 (4.8 ±0.03)
6.0 ±0.1 (5.6 ±0.04)
6.1 ±0.05
H (%)
6.3 ±0.2
5.9 ±0.3
6.3 ±0.3
Note: Data were presented as mean ±standard deviation (SD) of triple assays. Values represent weight
percent. n/d: not detected. C represents carbon; N represents nitrogen; S represents sulfur; H represents
hydrogen. Values in parentheses were obtained by the X-ray Fluorescence (XRF) Laboratory from
Mark Wainwright Analytical Centre at University of New South Wales using the LECO TruSpec CN
and S Module.
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Figure 2. 3 Representative curves of thermogravimetric analysis (TGA) of the three Ul84
extracts.
The curves illustrated the decomposition process of the three Ul84 extracts up to 900 °C under
air atmosphere, with ash contents expressed as residual weight (%). Arrows label critical
temperature points where significant mass loss was followed.

2.3.2 Monosaccharide composition
Monosaccharide analysis revealed that L-rhamnose, D-xylose, D-glucuronic acid, L-iduronic
acid, D-glucose and D-galactose were the main sugar units of both PhycoTrix and PhycoDerm
(Table 2.5; Figure 2.4). The monomer composition of PhycoTrix was 38.2 mol.% L-rhamnose,
14.2 mol.% D-xylose, 4.4 mol.% D-glucuronic acid, 5.3 mol.% L-iduronic acid, 4.1 mol.% Dgalactose, 15.2 mol.% D-glucose, and 17.7 mol.% others. By contrast, PhycoDerm contained
less neutral sugars (37.3 mol.% L-rhamnose, 12.6 mol.% D-xylose, 4.9 mol.% D-galactose and
5.8 mol.% D-glucose) and more uronic acids (9.5 mol.% D-glucuronic acid and 5.9 mol.% Liduronic acid) (Table 2.5). Small amounts of D-mannose and L-fucose were also detected,
whereas no L-arabinose was detected (Table 2.5). This constituent profile of Ul84 extracts is
consistent with the above colorimetric determinations, and shows consistency with those
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reported for ulvans from other sources.13,17,18,34,36 The higher D-glucose ratio in PhycoTrix may
indicate the co-extraction of other cell wall polysaccharides (e.g., cellulose).
Table 2. 5 Monosaccharide analysis of Ul84 extracts by GC/MS
Monosaccharide composition
L-rhamnose
D-xylose
D-glucuronic acid
L-iduronic acid
D-galactose
D-glucose
D-mannose
L-fucose
L-arabinose
Others

PhycoTrix/%
38.2
14.2
4.4
5.3
4.1
15.2
0.8
0.2
n/d
17.7

Note: Values represent mole percent; n/d, not detected.
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PhycoDerm/%
37.3
12.6
9.5
5.9
4.9
5.8
0.8
0.1
n/d
23.2

Figure 2. 4 Gas chromatography-mass spectrometry (GC-MS) chromatograms showing retention time (min) of trimethylsilylated methanolysates
of ulvan extracts.
Peak assignment for both PhycoTrix (A) and PhycoDerm (B): L-rhamnose (peak 1, 3, 4, 6, 7, 10), D-xylose (peak 2, 8, 9, 11, 13), D-glucuronic
acid (peak 12, 17, 22, 23), L-iduronic acid (peak 10, 13, 14, 15, 16, 19), D-glucose (peak 21, 22), D-galactose (peak 15, 17, 18, 20, 22), D-Mannose
(peak 14, 16, 20), L-fucose (peak 5, 9, 11), D-sorbitol (peak 12, 15, 24).
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The above data provided basic and important information regarding the chemical composition
of the three Ul84 extracts. This enables us to choose which Ul84 extract to use for the
subsequent fabrication and biological studies. Before the purest PDPT was delivered, major
work had been done on PhycoDerm. Therefore, the following chapters is based on PhycoDerm
(Chapter 3) and PDPT (Chapter 4 and 5), respectively.

In the past decades, ulvans have been widely investigated with respect to their chemical
compositions, and incongruent results have been reported.5,32,39,49 For instance, Costa et al.18
stated that the different extraction processes and characterization methods had influenced the
final data presentations of ulvan extracts from U. lactuca. Aguilar-Briseño et al.39 reported an
ulvan extract from Ulva clathrata with a different structural composition from using a different
methanolysis procedure. Our results were basically within the range reported for ulvan extracts
from other sources, viz. rhamnose 15.2 - 61.3 mol% (and 12.7 - 55.6 wt%), xylose 1.6 - 27.1
mol% (and 2.1 - 36.2 wt%), uronic acids 18.7% - 36.4 mol% (and 2.4 -35 wt%), glucose 0.05
– 19.0 mol% (and 0.5 – 26.2 wt%), galactose 0.5-2.2 mol% (and 0.5-5.1 wt%) and sulfate 8.732.2 wt%. These data were summarized from data collected with various green seaweed species
including Ulva rotundata,7,36,50 Ulva rigida,51 Ulva lactuca,17,18 U. fasciata,11,52 Ulva
clathrate,39 Enteromorpha prolifera,53 Ulva intestinalis,14,54 Ulva pertusa55 and Ulva
armoricana38,41 etc. The compositional profile of ulvan extracts has evolved over the last
decade since Lahaye and Robic5 reviewed that ulvans from varying sources are mainly
composed of 17-45% rhamnose, 2-12% xylose, 7-19% uronic acids, 0.5-6% glucose and 1623% sulfate. Apart from inherent batch-to-batch variations specific to natural products, the
variations in reported ulvan extracts generally stem from differences in species’ taxonomical
entities, extraction procedures and characterization methods. These factors, together with the
intermingled extract purity, make it difficult to do appropriate comparisons.
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2.3.3 Molecular weight
Molecular weight distribution of PhycoTrix and PhycoDerm was determined by GPC using a
RI and an UV detector (Figure 2.5). UV detection at 280 nm was to monitor the elution of
protein contaminants as confirmed by the Micro BCATM assay. PhycoTrix and PhycoDerm
showed similar trends with a broad distribution of molecular weight. Comparison of the GPC
chromatograms using RI detection with those obtained using UV detection suggested the
presence of approximately two populations, one was a higher molecular weight fraction with
absence of protein, and the other was a lower molecular weight fraction with protein
contaminants. For PhycoTrix, the weight average molecular weight (Mw) was ~1244 kDa for
the protein-free fraction, and ~5.6 kDa for the protein-associated fraction. For PhycoDerm, Mw
was ~1002 kDa for the protein-free fraction, and ~12.2 kDa for the protein-associated fraction.
Both protein-free fractions had a polydispersity index (PDI) of 1.6. However, due to the
tendency of ulvan to form aggregates34, it might be arbitrary to say these data represent the true
MW of ulvan. Nevertheless, these comparative data could provide an insight into
understanding the structure of these ulvan-rich extracts. Further, this result could provide some
guidance toward ulvan purification in terms of protein removal.

In the current method, the addition of organic solvent aimed to reduce the hydrophobic
interactions between ulvan molecules to prevent aggregation, a possible cause of variations in
ulvan MW.5,18,34 Between two extracts, it was also evident that PhycoTrix contained more
protein than PhycoDerm as indicated by the difference in UV absorption. This is consistent
with the above protein quantification results obtained by Micro BCATM protein assay.
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Figure 2. 5 GPC chromatograms of PhycoTrix and PhycoDerm obtained with a refractive
index detector and an UV detector at 280 nm.
Two detectors were in tandem, with the UV detector before the RI detector.

2.3.4 Structural characterizations of Ul84 extracts
Structural characterizations were conducted by 1H NMR and ATR-FTIR. 1H NMR spectra of
PhycoTrix and PhycoDerm showed uneven base lines at chemical shift between 1.8 ppm and
3.5 ppm, compared to that of PDPT (Figure 2.6). This suggests that impurities likely exist in
both PhycoTrix and PhycoDerm. Further, in 1H NMR spectra of all three extracts, it was
difficult to identify and assign individual peak to specific protons in the disaccharide repeating
units of Ul84. The only exception was the assignment of peaks at chemical shifts of 0.7-1.8
ppm to protons of methyl groups from L-rhamnose. The peaks with chemical shifts between
3.0-5.9 ppm were unidentifiable due to extensive signal overlap. These peaks were probably
attributed to the protons in the disaccharide units. The extensive signal overlap may arise from
a high degree of structural heterogeneity and the large molecular weight. The faint peaks with
chemical shifts between 7.0-9.0 ppm in the spectra of PhycoTrix and PhycoDerm were
probably attributed to protons of protein (amide) contaminants in these two extracts (Figure
2.6). There was no peak observed in the protein area in the spectrum of PDPT, indicating much
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less protein in this extract. This is consistent with protein quantification results. With
interferences from protein contaminants, plus the retarded molecular movement as a result of
large molecular weights, further structural interpretation of Ul84 extracts by 1H NMR is
restricted.

Figure 2. 6 Structural characterizations of three Ul84 extracts by 1H NMR.
(A) PhycoTrix; (B) PhycoDerm; (C) PhycoDerm® PhycoTrix. Spectra were recorded in D2O
at 60 ºC. Peaks at chemical shifts of 0.7 - 1.8 ppm (green shade) corresponded to protons of CH3 from L-rhamnose; Peaks at chemical shifts of 3.4 - 4.6 ppm and 4.8 - 5.9 ppm (purple
shade) corresponded to other protons of disaccharide repeating units of ulvan; Peaks at
chemical shifts of 7.0-9.0 ppm (yellow shade) corresponded to protons of proteins.

On the other hand, FT-IR spectra showed characteristic absorption bands corresponding to
uronic acids and sulfate esters in Ul84 (Figure 2.7). The absorption signals at ~1639 cm-1
85

(PhycoTrix and PhycoDerm) and at ~1620 cm-1 (PDPT) were likely results of the stretching
vibrations of the double bond of C=O from the carboxylic group of uronic acids in Ul84. The
characteristic absorption bands at ~1221 cm-1 (PhycoTrix) and at ~1219 cm-1 (PhycoDerm and
PDPT) corresponded to the S=O stretching vibrations while the bands at ~845 cm-1 (PhycoTrix),
~847 cm-1 (PhycoDerm) and ~841 cm-1 (PDPT) were results of the bending vibrations in the
axial position of C-O-S from sulfate esters.43,56

Figure 2. 7 Structural characterization of three Ul84 extracts by FT-IR.
2.3.5 Aggregation behaviour of Ul84
Ul84 aqueous solutions were turbid and formed precipitates from static settlement by gravity.
Dynamic light scattering (DLS) was hence performed to characterize the Ul84 dispersions
regarding the particle size and distribution. As shown in Figure 2.8, particle size distribution
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by intensity showed that aggregation peaks were present in all Ul84 dispersions at 1.0 mg mL1

, whereas were basically absent at a lower concentration of 0.1 mg mL-1. This suggested

aggregation was more prominent at a high concentration.

Figure 2. 8 Particle size distribution by intensity percent of Ul84 aqueous dispersions including
(A) PhycoTrix, (B) PhycoDerm and (C) PhycoDerm® PhycoTrix at different concentrations
determined by DLS.

Size distribution by volume of the same data by intensity was presented in Figure 2.9, and
reflected particle concentrations. At 1.0 mg mL-1, it was clear that PhycoTrix and PDPT
contained two major particle size populations whereas PhycoDerm contained only one. This
suggested a higher homogeneity of PhycoDerm dispersions than the others. At 0.1 mg mL-1,
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all three Ul84 dispersions showed one dominant particle size population, suggesting a
homogeneous dispersion for all Ul84 extracts at this concentration.

Figure 2. 9 Particle size distribution by volume percent of Ul84 aqueous dispersions including
(A) PhycoTrix, (B) PhycoDerm and (C) PhycoDerm® PhycoTrix at different concentrations
determined by DLS.

Z-average size describes the average intensity-weighted particle diameter, and reflects raw data
the most. Generally, particle sizes and PDI values of three Ul84 dispersions were larger at 1.0
mg mL-1 than at 0.1 mg mL-1 (Table 2.6). For example, particles formed by PhycoTrix had a
diameter of 313.0 ±3.7 nm at 1.0 mg mL-1 and of 75.49 ±2.38 nm at 0.1 mg mL-1. PhycoDerm
was shown to have similar Z-average size values at two concentrations, being 50.83 ±1.31 nm
at 1.0 mg mL-1 and 50.73 ± 1.23 nm at 0.1 mg mL-1 with however distinct PDI values.
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PhycoDerm® PhycoTrix formed larger particles of 337.3 ± 116.1 nm at 1.0 mg mL-1 whereas
formed smaller particles of 57.30 ± 2.43 nm at 0.1 mg mL-1. The big size variation at 1.0 mg
mL-1 may indicate significant aggregation at this concentration for PhycoDerm® PhycoTrix.
Table 2. 6 The Z-Average size and polydispersity index of Ul84 aqueous dispersions
Concentrations

Ul84

Z-average (d. nm)

Polydispersity index (PDI)

313.0 ±3.7

0.582 ±0.054

50.83 ±1.31

0.660 ±0.119

PhycoDerm PhycoTrix

337.3 ±116.1

0.622 ±0.111

PhycoTrix

75.49 ±2.38

0.424 ±0.035

50.73 ±1.23

0.411 ±0.010

57.30 ±2.43

0.420 ±0.035

PhycoTrix
-1

1.0 mg mL

PhycoDerm
®

0.1 mg mL-1

PhycoDerm
®

PhycoDerm PhycoTrix

Together, these data confirmed the aggregation behaviour of Ul84 extracts in aqueous solutions.
The aggregation phenomenon accounted for the turbidity of Ul84 solutions as observed in this
study, which was in accordance with relevant studies from the literature.34

2.4 Conclusions
In this study, three sequential Ul84 extracts isolated from a DNA-barcoded green algal sp.
(Chlorophyta) were characterized in terms of chemical composition, MW, structural
characteristics and aggregation behaviour. PhycoTrix, a crude Ul84 extract, contained 21.1%
of protein, 52.7% of total neutral sugar, 11.7% of total uronic acid, 14.6% of sulfate and 11.5%
of ash. PhycoDerm, deriving from PhycoTrix by further deproteinization, contained 13.2% of
protein, 48.0% of total neutral sugar, 15.9% of total uronic acid, 16.9% of sulfate and 13.8%
of ash. A further deproteinized extract, PhycoDerm® PhycoTrix, contained 3.1% protein and
12.9% ash, being the purest Ul84 extract in present studies. Monosaccharide analysis by
GC/MS showed that L-rhamnose, D-xylose, D-glucuronic acid, L-iduronic acid, D-glucose and
D-galactose were the major sugar units of Ul84. MW distribution determined by GPC
illustrated a broad distribution of molecular weight, with an Mw of ~1,244 kDa for PhycoTrix
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and of ~1,002 kDa for PhycoDerm as dextran equivalent, and a PDI of ~1.6 for both extracts.
Structural characterizations showed distinctive ulvan-related peaks and bands. Further, the
three Ul84 extracts were demonstrated to aggregate in aqueous solutions with concentrationdependent aggregation behaviours. These structural and molecular information lay foundations
for physicochemical and biological properties of Ul84 extracts.
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Chapter 3 Development of rhamnose-rich hydrogels based on PhycoDerm
toward wound healing application

This chapter presents work that has appeared in the published article “Development of
rhamnose-rich hydrogels based on sulfated xylorhamno-uronic acid toward wound healing
applications” by Chen, X., Yue, Z., Winberg, P.C., Dinoro, J.N., Hayes, P., Beirne, S. and
Wallace, G.G. (2019). Biomaterials science, 7(8), pp.3497-3509.

3.1 Introduction
Ulvacean macroalgae are infamously associated with green tide phenomena and have been
explored extensively as a potential renewable and economic biomass resource.1 A key area of
interest has been the utilization of the cell wall polysaccharides, which are broadly known as
ulvans. Ulvans are naturally sulfated and demonstrate a number of biological activities.2 In
particular ulvans exhibit a similarity to the glycosaminoglycan polysaccharides in mammalian
tissue; specifically dermatan sulfate and chondroitin sulfate.2,3 The fabrication of new
biomaterials that might take advantage of this similarity should enable applications in tissue
regeneration or wound healing. To date early research is promising yet underdeveloped.3,4 This
is largely due to high variability of the chemical structure and composition across species and
a lack of consistent and scalable sources.2,5 Further, fabrication into functional materials will
require a number of processes, including for example structural modification to enable stable
gel formation and transfer to scalable fabrication processes, and consistency of function
through all of the stages.
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Ulvan constitutes primarily monosaccharide units of rhamnose, xylose and uronic acids, and
sulfates. Structurally, ulvan is dominated by repeating disaccharide units, where uronic acid,
either D-glucuronic acid or L-iduronic acid, or D-xylose is linked to L-rhamnose-3-sulfate
through 1, 4- glycosidic bonds.2,5 Sulfate groups exist typically in the L-rhamnose units at the
position C3 or in the D-xylose units.5 In comparison with other algal polysaccharide categories
such as alginate6 and fucoidan7 from phaeophycean seaweeds, and carrageenan from
Rhodophycean red seaweed,8 ulvan is unique in its L-rhamnose-rich structure. Further there is
a high degree of variability in the molecular ratio of rhamnose in ulvans from different species.9
Studies have shown that L-rhamnose-binding lectins are present on the cell membranes of
human skin fibroblasts and keratinocytes whose cellular activities can be regulated by Lrhamnose-lectin interactions.10,11 Further, ulvan contains D-glucuronic acid and its epimer Liduronic acid units, resembling the mammalian glycosaminoglycans (GAGs) that are found in
human skin extracellular matrix (ECM), such as heparin, heparan sulfate, dermatan sulfate and
hyaluronic acid.2 These mammalian GAGs play vital roles in regulating cellular events
associated with wound healing.12 It is for these properties that ulvans are considered a potential
analogue to natural GAGs (Figure 3.1), that include binding, structural support and protection
of protein ligands such as collagen, growth factors and cytokines, with the benefits of increased
stability13 in a proteolytic environment like a wound and avoidance of animal sources in
medical devices. Lastly, ulvan exhibits diverse biological activities such as antibacterial,
antiviral, anti-inflammatory and anticoagulant activities.2 With this combination of features,
ulvan makes a strong candidate for the application in wound healing.
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Figure 3. 1 Ulvans share a high structural similarity to mammalian glycosaminoglycans found
in human skin, due to the presence of uronic acid units and sulfate groups.

Conditions of chronic wounds necessitate clinical intervention to accelerate wound healing
processes.14 To this end, skin grafts and bioengineered skin substitutes have been developed.
While traditional skin grafts have their inherent limitations,14 skin tissue engineering offers
wider options and have already delivered many skin substitutes for clinical use.15 However,
these skin products also face miscellaneous problems arising from the use of animal-derived
biomaterials, such as collagen and decellularized skin tissue etc. The potential safety concern
raised by these biomaterials is considered as the first issue coming before their mechanical
weakness and lack of long-term biostability.16,17 In this respect, algae-derived biomaterials,
such as alginate, have already been developed into wound healing products due to low
immunogenicity and versatile properties.6 However, alginate is primarily used in passive
wound dressings to absorb excessive exudates,18 due to its poor cell-matrix interactions.19
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This chapter focuses on the Ul84 extract PhycoDerm, which is also termed by the supplier as
xylorhamno-uronic acid (XRU). The objective of this work is to provide a foundation for our
ongoing research program to develop marine-based bioprinting platforms for wound healing
application. Specifically, we address the limitations in the modification and formulation of
XRU with regard to progressing to product development. XRU was modified by
methacrylation (XRU-MA or PDMA), and then photo-crosslinked to produce XRU hydrogels.
The hydrogels were assessed in terms of physicochemical properties and cytocompatibility
against a relevant cell model, human dermal fibroblasts (HDFs). To enable fabrication of 3D
XRU-based structures in a spatially controlled manner, an XRU-based bioink was developed
for 3D extrusion printing. Both 3D printed hydrogel scaffolds and cell-laden constructs were
developed with excellent cytocompatibility with HDFs. These results highlight the potential of
this sulfated, rhamnose-rich XRU extract as a promising biomaterial toward wound healing
applications.

3.2 Materials and methods
3.2.1 Materials
The sulfated, rhamnose-rich xylorhamno-uronic acid (XRU) extract (PhycoDerm™) with a
molecular weight of > 600 kDa was provided by Venus Shell Systems Pty. Ltd. (VSS,
Australia). The proximate composition and key characteristics are provided in Table 3.1. N,Ndimethylformamide (DMF), ethanol, sodium hydroxide and calcium chloride dihydrate were
purchased from Chem-Supply. Methacrylic anhydride, deuterium oxide (D2O), alginic acid
sodium salt (4-12 cP, 1 % in H2O, 25 °C), gelatin from porcine skin (gel strength 300, Type A)
and lithium phenyl-2, 4, 6-trimethylbenzoylphosphinate (LAP) were purchased from SigmaAldrich. All reagents were used as received.
Table 3. 1 The proximate composition and key characteristics of xylorhamno-uronic acid
(XRU) extract shown as wt. % of dry weight and elemental analysis
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Chemical components
Protein

XRU extract
13.2 ±0.2%

L-rhamnose

47.5 ±2.5%

Rhamnose:xylose

5-7

Total uronic acid
Sulfate
Elemental analysis

15.9 ±0.4%
16.9 ±0.4%

C

31.1 ±0.2%

N

3.6 ±0.2%

S

5.6 ±0.1%

3.2.2 Modification of the XRU extract with methacrylic anhydride
Methacrylation of the XRU extract was conducted using a method previously described1,20 with
some minor modification. Briefly, the XRU extract was dissolved in a binary solvent system
composed of Milli-Q water and DMF (50/50, v/v), followed by the addition of methacrylic
anhydride (MA, 5 molar equivalents of disaccharide repeating units of XRU). The reaction
mixture was stirred at room temperature, and the pH was maintained at 8.0-8.5 for the first 2 h
by the addition of 5 M NaOH. The reaction mixture was then stirred for another 22 h at room
temperature before being precipitated into ethanol. The precipitate was collected by
centrifugation, redissolved in deionized water, dialysed against deionized water for 48 h, and
then lyophilized. The methacrylated XRU extract (XRU-MA) was stored at -20 °C for further
analysis.

Structural characterization was performed by Fourier Transform Infrared Spectroscopy (FT-IR)
and 1H nuclear magnetic resonance (NMR). FT-IR spectra were recorded in the range of 4000700 cm-1 at a resolution of 4 cm-1 on an IRPrestige-21 spectrometer (Shimadzu, Japan) attached
with an attenuated total reflection (ATR) component. Prior to FT-IR analysis, the sample was
dried in a vacuum oven at 40 °C overnight. 1H NMR spectra were recorded in D2O at 60 °C
using a Bruker Avance III 400 MHz spectrometer (Bruker, Germany). The degree of
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substitution (DS), defined as the average number of introduced methacrylate group per XRU
disaccharide unit, was estimated approximately by 1H NMR by calculating the ratio of
integration areas of proton peaks from the methacrylate groups to that of the methyl groups of
the L-rhamnose in the polymer backbone.1,21

3.2.3 Preparation of molded XRU hydrogels
XRU-MA was dissolved in phosphate buffered saline (PBS) at various concentrations (5%,
7.5% or 10%, w/v). LAP was added to each solution at a final concentration of 0.06% (w/v).
Then, XRU hydrogels were prepared in an acrylic mold (8 mm diameter, 1.5 mm thickness)
via photo-crosslinking using a Lumen Dynamics OmniCure LX400+ (400 nm light source) at
various photo-exposure energies (792, 1524 or 2220 mJ). The hydrogel was washed with
deionized water for 48 h to remove any un-crosslinked polymer residue.

For in vitro cell culture, alginate hydrogels and collagen-coated XRU hydrogels were also
prepared for comparison. Alginate hydrogels (8 mm diameter, 1.5 mm thickness) were
prepared by crosslinking of an aqueous solution of alginic acid sodium salt (2% w/v) in calcium
chloride (2% w/v) for 10 min. For preparation of collagen-coated XRU hydrogels, the molded
XRU scaffolds were freeze-dried and saturated with a collagen solution (Type I, 0.5 mg mL-1
in PBS) at 37 ºC overnight. Then the coated hydrogels were washed with PBS to remove unbound collagen.

3.2.4 Physicochemical characterization of the molded XRU hydrogels
Mechanical properties. Mechanical test by micro-indentation was carried out using an EZ-S
mechanical tester (Shimadzu, Japan) in the compression mode with a 10 N load cell at a cross-
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head speed of 0.1 mm min-1. The Young’s modulus (E2) of the sample was calculated using
Equation (3.1).22

F = 8/3rE2d

(3.1)

where F is the force applied to the hydrogel sample, r is the radius (0.495 mm) of the indenter
tip, and d is the indentation depth. The data collected were linearly regressed by plotting the
applied force against the indentation depth. The gradient of the linear regression was then used
for the calculation.

Water uptake capacity. Samples of the molded XRU hydrogels were freeze-dried and their
dry weights (Wi) were recorded before being re-immersed in deionized water. At predetermined
intervals of 3, 8, 11 and 24 h, the swollen hydrogels were dabbed dry with Kimwipes to remove
surface water and the hydrated weights (Ws) were recorded at each time point. The equilibrium
water content and water uptake capacity were calculated using Equation (3.2) and (3.3),
respectively.

Water content (%) = (Ws – Wi)/Ws ×100
Water uptake capacity (%) = (Ws – Wi)/Wi ×100

(3.2)
(3.3)

Microstructure. The microstructure of the XRU hydrogels was characterized using a scanning
electron microscope (SEM, JEOL JSM-6490LV, Japan). The hydrogels were freeze-dried,
coated with platinum (15 nm) using a Dynavac sputter coater and observed under an
accelerating voltage of 15 kV.
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3.2.5 In vitro cell culture of HDFs on the molded XRU hydrogels
HDFs obtained from Cell Applications, Inc. (San Diego, CA, USA) were used at passages 1015 in the study. Cells were routinely maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM, Sigma-Aldrich) supplemented with 10% (v/v) fetal bovine serum (FBS, Invitrogen™)
and 1% (v/v) penicillin-streptomycin (10,000 U mL-1, Gibco™) in a 5% CO2 humidified
incubator at 37 °C. For in vitro cell culture, all the hydrogel scaffolds used in this study were
freeze-dried and UV sterilized.

Cytocompatibility of the XRU hydrogels was assessed by live/dead staining. Alginate
hydrogels were employed for comparison. Briefly, HDFs were seeded at a density of 0.5 ×106
cells per scaffold and incubated with 1 mL cell culture medium. At day 1 and 7 post cell seeding,
the cell-seeded hydrogels were incubated with calcein AM (5 µg mL-1) in the culture medium
for 25 min, and then propidium iodide (PI, 1 µg mL-1) in the culture medium for 5 min. The
hydrogels were washed with PBS and cell culture medium. Images of live (green) and dead
(red) cells were acquired using a confocal laser scanning microscope (CLSM, Leica TSC SP5
II).

Proliferation of HDFs cultured on the XRU hydrogels was evaluated using Quant-iT™
PicoGreen™ dsDNA assay (Thermo Fisher Scientific). The alginate hydrogels and collagencoated XRU hydrogels were used as negative and positive controls, respectively. For each type
of scaffolds, non-seeded hydrogels were used as blank controls. At predetermined time points,
cell-seeded hydrogels and cell-free hydrogels were collected, broken up using a spatula and
analyzed following the manufacturer’ protocol. The fluorescence reading was recorded using
a microplate reader (POLARstar Omega) at an excitation wavelength of 485 nm and an
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emission wavelength of 520 nm. Cell number in each scaffold was determined using a standard
calibration curve established with serial cell lysates of known cell numbers.

Cell morphology of the HDFs cultured on the XRU hydrogels was analyzed by F-actin staining.
The cells were fixed in 3.7% paraformaldehyde (PFA) for 10 min and permeabilized with 0.1%
Triton X-100 for 5 min at room temperature. Then the samples were stained with Alexa FluorTM
488 phalloidin (Invitrogen™, Life Technologies) in 1% BSA (1:40, v/v) for 50 min and
counterstained with 4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI, 1 µg mL-1 in PBS)
(Invitrogen™, Life Technology) for 10 min, then washed with PBS and imaged using CLSM.
HDF morphology was also examined by SEM. After fixation, the samples were dehydrated in
a graded ethanol series (30%, 50%, 70%, 90% and 100%) for 30 min at each concentration,
freeze-dried and coated with platinum for SEM observation.

3.2.6 Bioink formulation and rheology characterization
A composite bioink was formulated in PBS comprising 10% (w/v) XRU-MA, 5% (w/v) gelatin
and 1% (v/v) penicillin-streptomycin. LAP was then added to a final concentration of 0.06%
(w/v). The rheological properties of the bioink were characterized on an AR-G2 Rheometer
(TA Instruments) using a 15 mm plate geometry with a 2°cone, fitted with a Peltier temperature
controlled stage. The geometry gap between plates was set to 55 μm. Temperature sweep was
conducted from 40 °C to 8 °C at a ramp rate of 1.5 °C min-1, 1 Hz frequency and 1% strain.
The sample was loaded at 37 °C and equilibrated for 2 min prior to the temperature sweep
measurement. Viscometry was performed at 23 °C and 15 °C respectively with the shear rates
ranging from 0.1 to 1000 s-1. The sample was allowed to gel at room temperature (22-23 °C)
before loading onto the Peltier plate at 23 °C. A conditioning step with 5 min pre-shear at a
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shear rate of 5 s-1 and 5 min equilibrium both at 23 °C was applied before viscosity
measurement.

3.2.7 3D printing (cell-containing) XRU-based hydrogels
Cell-free XRU-MA constructs were firstly fabricated by extrusion printing in a layer-by-layer
fashion using a 3D Bioplotter (EnvisionTEC, Germany). The printer is housed within a
biosafety cabinet to ensure sterility. All printing was conducted at 23 °C with the substrate set
to 15 °C. The printing pressure and speed was 3.5 bar and 10 mm s-1, respectively. An extrusion
needle of 200 µm in diameter was used. A cuboid, 4-layered scaffold (10 × 10 mm) was
designed, exported as a Standard Tessellation Language (STL) file and sliced using the
Bioplotter RP® software. The infill of scaffolds was set to angles of 0°and 90°, with a print
height of 0.130 mm and line space of 1.0 mm in the Virtual Machines software (EnvisionTEC,
Germany). Once printed, the scaffolds were crosslinked with 400 nm light for 60 s (792 mJ).
The printed scaffolds were incubated in the culture medium of HDFs at 37 °C for more than
two days to remove the entrapped gelatin, freeze-dried and UV sterilized for 30 min on each
side. The 3D printed scaffolds were then seeded with HDFs, and live/dead staining and cell
proliferation assay were performed using the same procedure as detailed above.

For cell printing, HDFs were loaded to the bioink at a cell density of 1 ×106 mL-1, and the cellladen XRU-based constructs were printed using the same procedure as described above. Upon
printing, the 3D-printed cell-laden constructs were crosslinked with 400 nm light for 60 s (792
mJ), and incubated in the culture medium. Live/dead staining was performed at day 1 and day
7 post the printing.
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3.2.8 Statistical analysis
Data were presented as mean ± standard deviation (SD), where n ≥ 3. Statistical differences
were obtained using one-way or two-way analysis of variation (ANOVA) with Tukey’s
multiple comparisons post hoc test at a confidence interval of 95% (GraphPad Prism 9).

3.3 Results and discussion
3.3.1 Structural characterization of the modified XRU extract
The present study aims to provide a foundation for our ongoing research program to develop
marine-derived bioprinting platforms for wound healing application. XRU is readily soluble in
water, for which modification is required to render the structures stable in physiologically
relevant conditions. A photo-crosslinkable XRU was developed by reacting XRU with
methacrylic anhydride (Figure 3.2A). Here a binary solvent of Milli-Q water and DMF (50/50,
v/v) was employed, as it has been previously shown to improve the efficacy of methacrylation
as a result of improved solubility of methacrylic anhydride in the reaction system.20,23

The modified structure of XRU was verified by FT-IR (Figure 3.2B) and 1H NMR (Figure
3.2C). In the FT-IR spectra, the peak at ~1713 cm-1 for XRU-MA, not found in the spectrum
of the unmodified XRU extract, corresponded to the stretching vibration of C=O from the
conjugated ester linkage. In the 1H NMR spectra, methacrylation of the XRU extract was
demonstrated by the appearance of distinctive peaks in the double bond region (between 5.8
and 6.8 ppm) and a sharp peak that corresponded to the -CH3 of the methacrylate groups (2.3
ppm). The estimated degree of methacrylation was ~0.8-0.9 per XRU disaccharide unit.
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Figure 3. 2 Structural characterization of XRU and XRU-MA.
(A) Schematic representation of the XRU methacrylation; (B) FT-IR spectra confirmed the
successful modification by the additional peak at ~1713 cm-1 in XRU-MA; (C) 1H NMR spectra
obtained at 60 °C confirmed the successful conjugation of the methacrylate groups. The
proton(s) confined in boxes as shown in the formulae of XRU disaccharide repeating unit
(denoted by a, b, c and d, respectively) were marked in individual spectrum.
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3.3.2 Physicochemical properties of the molded XRU hydrogels
XRU hydrogels were prepared by photo-crosslinking and subjected to mechanical and wateruptake studies. The mechanical property of the XRU hydrogels prepared with various XRUMA concentrations (5%, 7.5%, or 10%, w/v) and photo-crosslinking energies (792-2220 mJ)
showed Young’s moduli ranging from ~18 kPa to ~309 kPa (Figure 3.3A). The Young’s
modulus increased with increasing the XRU-MA concentration and photo-crosslinking energy.
For example, the Young’s modulus of the XRU hydrogels crosslinked with a photo energy of
792 mJ increased from ~18 kPa to ~182 kPa when the polymer concentration increased from
5% to 10% (p < 0.0001, Figure 3.3A). Increasing the photo-exposure energy from 792 mJ to
2220 mJ resulted in a 2.5, 1.7 and 1.7-fold increase in the Young’s modulus of 5%, 7.5% and
10% XRU hydrogels, respectively. These correlations may result from an increase in
crosslinking density as a result of higher concentrations of macromer and/or photo energy. Our
results demonstrated that the Young’s modulus of an XRU hydrogel can be easily tailored by
manipulating polymer concentration and photo-crosslinking condition.

The water uptake capacity of a hydrogel is important for the targeted application in wound
healing as the moisture level in a wound area is critical for the healing process.24-26 The XRU
hydrogels demonstrated a high capacity to uptake and retain water, with ~30-80-fold increases
in weight within 24 h of hydration at room temperature (Figure 3.3B). These samples reached
their respective equilibrium water contents (> 96%) in less than 3 h (Figure 3.3C). Here, the
samples prepared from 5% XRU-MA and crosslinked with a photo energy of 792 mJ were not
included, as they were too fragile to maintain structural integrity during the course of study.
Amongst the three groups, increasing the polymer concentration resulted in a small but
significant reduction in the equilibrium water content. For instance, the equilibrium water
content of the XRU hydrogels exposed to 1524 mJ decreased from 98.8% to 96.8% when the
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polymer concentration increased from 5% to 10% (p < 0.0001, Figure 3.3C). Within each
group, the equilibrium water content decreased slightly with increasing the photo-crosslinking
energy. It should be noted that the water contents for 5%, 7.5% and 10% XRU hydrogels were
not significantly different when crosslinked with a photo energy of 1524 mJ and 2220 mJ,
respectively.

These data evidenced that the XRU hydrogels had versatile physicochemical properties, which
promised a wide spectrum of applications for the healing of different types of wound in the
body.27 Based on the results and reported Young’s modulus of human skin,28 the XRU
hydrogels with Young’ modulus of ~182 kPa (10% (w/v) XRU-MA, 792 mJ photo exposure,
denoted as XRU10 hereafter) were selected for the following in vitro study. The morphology of
this type of hydrogel, after being freeze-dried, was examined by SEM, which showed a highly
porous microstructure in the cross section (Figure 3.3D, E).
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Figure 3. 3 Physicochemical properties of the molded XRU hydrogels.
(A) XRU hydrogels showed tuneable mechanical properties with Young’s moduli in a range
of ~18-309 kPa by varying polymer concentration and photo exposure energy. Two-way
ANOVA with Tukey’s multiple comparisons post hoc test was performed for the statistical
analysis. * Indicates p < 0.05, ** indicates p < 0.01 and **** indicates p < 0.0001; (B) XRU
hydrogels had high water uptake capacity (~3000-8000%) after 24 h hydration and reached the
equilibrium water content within 3 h; (C) XRU hydrogels showed a high water content of >
96% after 24 h hydration. Two-way ANOVA with Tukey’s multiple comparisons post hoc test
was performed for the statistical analysis. * Indicates p < 0.05, ** indicates p < 0.01, ***
indicates p < 0.001 and **** indicates p < 0.0001; (D, E) Representative images showing the
microstructure of the cross section of the XRU10 hydrogels (10% (w/v) XRU-MA, 792 mJ). E
is the higher magnification of the confined area in D.
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3.3.3 In vitro evaluation of cell-material interactions on the molded XRU10 hydrogels
The XRU10 hydrogels were assessed for cytocompatibility against HDFs, one of the dominant
resident cell types in skin tissue. HDFs cultured on the XRU10 hydrogels demonstrated high
cell viability (Figure 3.4A, B). Also, the XRU10 hydrogels supported cell proliferation of HDFs
as demonstrated by a more densely populated cell colony at day 7 compared to day 1. This
result proved the innate cytocompatibility of the XRU10 hydrogels. By contrast, cells barely
attached to the alginate hydrogel, and little cell growth was observed over 7 days (Figure 3.4C,
D).

Cell proliferation was further quantified by PicoGreen assay. Over 2 weeks’ culture, HDFs
grown on the XRU10 hydrogels showed a 6.3-fold increase in cell number by day 14 (Figure
3.4E). By contrast, alginate hydrogel showed a much smaller number of attached cells at day
1 compared to that of the XRU10 hydrogel, and the cell number decreased over the culture time.
The poor cell attachment and proliferation of HDFs observed on the alginate hydrogels is due
to a lack of essential cell-matrix interactions.19,29,30 The higher cell proliferation rate observed
for the XRU10 hydrogels suggested that these hydrogels may interact actively with HDFs
whereby cell attachment and subsequent cell proliferation took places. In this context, the
reason for improved cell attachment remains to be elucidated, but might be due to the following
two factors. Firstly, the sugar components in XRU, such as L-rhamnose, may facilitate cell
attachment by interacting with HDFs through the cell membrane lectin sites.11 For instance,
Andres et al.31 reported that a rhamnose-rich polysaccharide RROP-1 was able to promote cell
proliferation likely by interacting with the lectin sites present on human skin fibroblasts through
the L-rhamnose moieties. Secondly, the protein component(s) present in the XRU extract may
also facilitate cell attachment by providing the cell binding ligands. From this point of view, it
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is of critical importance to study a protein-free XRU fraction for a better understanding of the
interactions between HDFs and XRU.
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Figure 3. 4 HDFs cultured on XRU10 hydrogels (10% XRU-MA, 792 mJ) after (A) 1 and (B)
7 days, and on alginate hydrogels after (C) 1 and (D) 7 days.
Calcein AM/PI were used to stain live (green) and dead (red) cells, respectively. (E) Cell
proliferation of HDFs on varying hydrogels including alginate, XRU10, and collagen-coated
XRU10 (Col-XRU10) hydrogels by PicoGreen assay. Two-way ANOVA with Tukey’s multiple
comparisons post hoc test was performed for the statistical analysis. * Indicates p < 0.05, **
indicates p < 0.01, *** indicates p < 0.001 and **** indicates p < 0.0001.

Collagen coating has been widely employed in tissue engineering to improve the initial cell
attachment to synthetic matrices.32 In this study, collagen was coated onto the XRU10 hydrogel
by simply soaking up collagen solution followed by fibrillogenesis at 37 °C. Compared to the
pure XRU10 hydrogels, collagen coating improved cell attachment as demonstrated by a higher
cell number at day 1. Collagen coating further promoted cell proliferation with a 7.5-fold
increase in cell number at day 14 compared to day 1 (Figure 3.4E). As a native ECM
component, collagen is known to carry cell adhesion peptides for cell recognition.33,34 The
enhanced cell attachment and proliferation could be a result of improved cell-matrix
interactions, thus pointing out a promising approach for further modification of XRU to
improve its biological functions in wound healing applications. Importantly, the XRU scaffold
offers an opportunity for the development on non-contracting collagen based scaffolds.
Collagen hydrogels have been intensively explored in skin tissue engineering and skin repair.17
However, the force generated by the cultured cells causes severe contraction of the collagen
gel, which would affect the normal healing process, due to insufficient wound covering after
transplantation of the collagen-based structures.35 In this study, the cell-seeded collagen-coated
XRU10 hydrogels did not show any notable dimension change within the period of study, and
this lack of significant contraction was attributable to the ulvan structure.

The organization and distribution of cytoskeletal actin filaments and cellular morphology of
HDFs cultured on the XRU10 hydrogels were examined by F-actin staining and SEM,
respectively (Figure 3.5). Fluorescent images revealed that HDFs had densely packed network
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of actin cytoskeleton yet with one or two cytoskeletal extensions at day 1, whereas actin
filaments were re-organized and distributed throughout the cellular body that possessed
multiple cytoskeletal extensions at day 7 with well visible bundles of actin filaments (Figure
3.5A-F). This indicated that HDFs attached and spread well on the XRU10 hydrogel. F-actin
staining exhibiting the cytoskeleton also revealed the cellular morphologies of HDFs. Overall,
HDFs took on mainly rounded shapes at day 1 and then the typical elongated and spreading
morphologies at day 7. Cell morphology of HDFs visualized by SEM showed rounded cell
shapes at day 1 and well spread and flattened morphologies at day 7, supporting the F-actin
staining results (Figure 3.5G-J). These cell behaviours demonstrated that HDFs attached well
on the XRU10 hydrogel and achieved full spreading with extended culture time. This may
provide a foundation for the observed high cell proliferation rate of HDFs cultured on the
XRU10 hydrogels, and substantiated the potential of the XRU-based hydrogel for promoting
cell attachment and spreading of HDFs.
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Figure 3. 5 Cell morphology of HDFs cultured on the XRU10 hydrogels (10% XRU-MA, 792
mJ) at day 1 (A-C, G-H) and day 7 (D-F, I-J) characterized by F-actin staining (A-F) and SEM
(G-J), respectively.
A & D: nuclei (blue); B & E: F-actin (green); C: merged image of A and B; F: merged image
of D and E. H and J is the higher magnification of the confined area in G and I, respectively.
Cells were highlighted by the yellow arrows in G-J.

3.3.4 Fabrication of (cell-containing) XRU-based constructs by extrusion printing
For 3D printing XRU10 hydrogels, a composite ink comprising 10% (w/v) XRU-MA and 5%
(w/v) gelatin was prepared. The XRU-MA solution on its own behaved like a runny liquid, so
gelatin was added to improve its printability. Gelatin has often been used in bioink formulation
for 3D printing, and this is attributable to its thermo-responsive gelation behaviour.36 The
thermo-gelling property of gelatin provides a means to engineer the viscoelastic properties and
hence the printability of its containing inks. Further, gelatin has also been used as a sacrificial
material in 3D printing as it can be readily removed post-printing.36,37 Figure 3.6A shows the
temperature sweep of the storage moduli (G’) and loss moduli (G’’) of the composite ink. Both
G’ and G’’ increased with reducing temperature and crossed at ~23 °C as a result of temperature
(T) induced sol-gel transition. When T > 23 °C, G’ was less than G’’, indicating the presence
of a viscous liquid. When T ≤ 23 °C, G’ was greater than G’’, indicating the presence of a
viscoelastic solid. In this study, 23 °C was selected for extrusion printing as the ink behaved
like a soft gel, which allowed it to be extruded as a consistent fibre. The ink was extruded onto
a colder substrate at 15 °C to help retain the printed structure. G’ at 15 °C was ~350 Pa, whereby
the ink behaved more solid-like and was capable of retaining shape before photo-crosslinking.38
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Figure 3. 6 Rheological behaviour of the XRU-MA/gelatin bioink demonstrated thermoresponsive phase change behaviour (A) and shear-thinning property measured at 23 °C and
15 °C, respectively (B).

One key property that an ink should have for extrusion printing is shear-thinning. This was
assessed here by performing the shear rate sweeps at 23 °C and a lower temperature of 15 °C,
respectively (Figure 3.6B). Figure 3.6B shows that the ink exhibited a non-Newtonian, shear115

thinning behaviour as the polymer network aligned with a high shear stress present. The shearthinning behaviour can be described by the power-law model (the Ostwald-de Waele Model)
as shown in Equation (4).39 The flow behaviour index, n, was determined to be 0.328 and 0.176
for the ink at 23 °C and 15 °C respectively, by fitting the viscosity-shear rate curve with the
power-law model.

𝜂 = 𝐾𝛾̇n-1

(3.4)

where 𝜂 is viscosity (Pa s), 𝛾̇ is shear rate (s-1), and K is the flow consistency index (viscosity
at a shear rate of 1 s-1).

When a non-Newtonian power-law fluid flows in a cylinder tube such as an extrusion needle,
according to the law of the wall, the fluidic portion near the wall of the tube moves the slowest
and is subjected to the highest shear rate, when compared to the faster moving portion in the
middle of the tube.39 To estimate the maximum shear rate that the ink experienced during
extrusion printing, i.e. the shear rate at the needle wall, the Rabinowitsch-Mooney equation
was utilized as shown below.40

𝛾̇ = (3n+1)Q/(nπr3)

(3.5)

where n is the flow behaviour index, Q is the volumetric flow rate (mm³s-1) and r is the radius
of the extrusion needle (mm). For extrusion at 23 °C, with a 200 µm needle diameter and an
extrusion rate of 10 mm s-1 (Q = π · (0.1 mm)²·10 mm s-1 ≈ 0.314 mm³ s-1), the maximum
shear rate during extrusion printing was estimated to be 604.9 s-1, which correlated to a
viscosity of ~0.7 Pa s. Immediately after the extrusion, the bioink experienced negligible shear
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rates (≤ 0.1 s-1), and came into contact with the cold substrate at 15 °C. Assuming a shear rate
of 0.1 s−1, the corresponding viscosity of the ink was ~1070.7 Pa s when touching the 15 °C
substrate, which was significantly higher than the one during the extrusion printing. The low
viscosity during extrusion (~0.7 Pa s) enabled the smooth and continuous flow of the ink
through the needle, while the high viscosity (~1070.7 Pa s) allowed it to maintain its shape
after the extrusion.41 These data were in good agreement with those reported in the literature.
Generally, the empirical ink viscosities for extrusion printing have been reported to range from
0.3 to 30 Pa s at the high shear rates (102-103 s-1) during extrusion, and range from 102 to 103
Pa s at the low shear rates of ≤ 0.1 s-1.38,40-43

The XRU-based ink was tested firstly for 3D printing cell-free macroporous scaffolds. The 3D
printed structures were stabilised by photo-crosslinking upon printing, and then incubated in
the culture medium at 37 °C to remove the entrapped gelatin. As shown in Figure 3.7A, the
3D-printed XRU scaffolds have an average strut width of 180 ±24 µm and pore size of 1022.0
±51.6 µm. As with the molded XRU hydrogels, the 3D printed XRU scaffolds supported HDF
attachment with high cell viability (Figure 3.7B, C) and proliferation over a period of 2 weeks
(Figure 3.7D). This is quantitatively demonstrated by a PicoGreen assay that showed a 10.1fold increase in the cell number by day 14 (Figure 3.7D). The bioink was also assessed for 3D
printing cell-laden structures. The 3D-printed HDFs-embedded constructs showed high cell
viability over a period of 7 days (Figure 3.7E, F). However, the encapsulated cells exhibited
rounded morphologies even at day 7 with minimal cell growth. This is probably due to the
formation of a densely packed polymer network which may impede to some extent cell-matrix
interactions and cell metabolic activities. Our work demonstrates a highly cytocompatible
nature of 3D printed XRU-based hydrogels as structural support. Optimization of the XRU ink
formulation for direct cell printing is currently being undertaken in parallel with more in-depth
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biological characterizations, to understand the effects of scaffold structure on the functions of
the encapsulated HDFs at the molecular level.
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Figure 3. 7 Fabrication of (cell-containing) XRU-based constructs by extrusion printing.
(A) A representative image of the 3D-printed XRU-based structures; (B, C) Representative
live/dead staining images of human dermal fibroblasts (HDFs) cultured in the 3D-printed
scaffolds at day 1 and day 7, respectively; (D) Cell proliferation of HDFs cultured in the
prefabricated XRU hydrogels by PicoGreen assay. One-way ANOVA with Tukey’s multiple
comparisons post hoc test was performed for the statistical analysis. **** Indicates p < 0.0001;
(E, F) Representative live/dead staining images of the 3D printed HDFs in the XRU hydrogels
after day 1 (E) and day 7 (F) in culture. Inset image shows magnified live/dead staining from
the same image. Living cells were stained green and dead cells red.

The cell work presented here using HDF represents a first biologically relevant step to test the
biocompatibility and safety of the biomaterial in wound healing. Future studies should focus
on in vitro characterizations to understand the role of ink formulation in dermal ECM secretion,
and subsequent optimization of 3D printing to produce skin like structures that imitate the
cellular organization and functions of native skin. In vivo characterizations are equally
important to assess tissue compatibility of the material firstly and then wound healing capacity
of 3D printed cellular constructs.

3.4 Conclusions
In this study we present the functionalization of a rhamnose-rich xylorhamno-uronic acid
(XRU) extract in the context of wound healing. The XRU extract was methacrylated and XRUbased hydrogels were prepared via photo-crosslinking of the incorporated methacrylate groups.
XRU-based hydrogels demonstrated high water uptake capacity and tuneable mechanical
properties. The gels were found to be highly cytocompatible with high cell viability and
supported cell attachment and cell proliferation when tested with HDFs. An XRU-based bioink
has been formulated for enabling controlled fabrication of 3D XRU structures via extrusion
printing both with and without cells. The 3D printed hydrogel scaffolds displayed high
cytocompatibility with HDFs. These results highlight the potential of this sulfated, rhamnoserich XRU extract as a promising biomaterial for dermal matrix, which provides a foundation
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for our ongoing research to develop marine-based bioprinting platforms for skin repair and
regeneration.
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Chapter 4 Bioink development and skin bioprinting based on PhycoDerm®
PhycoTrix

Some parts of this chapter present work that has appeared in the published article “3D bioprinting
dermal-like structures using species-specific ulvan” by Chen, X., Yue, Z., Winberg, P.C., Lou Y.,
Beirne, S. and Wallace, G.G. (2021). Biomaterials science, 9(7), pp.2424-2438.

4.1 Introduction
Cutaneous wound healing has commonly seen disruptions in severe burns and chronic wounds where
the wound healing process is impaired by massive fluid loss and/or persistent bacterial invasion. 1,2
This leads to a prolonged inflammation phase and ultimately non-healing wounds.3 Achieving rapid
wound closure is pivotal to reducing such complications.4 Surgical intervention is required by
application of a skin graft to cover the wound as an initial step. Traditional skin grafts including
autografts, allografts and xenografts have been used in the past. Shortage of supply of autografts or
immune rejections for allo/xenografts are significant limitations.4

Tissue-engineered skin graft alternatives, including epidermal substitutes, dermal substitutes and
epidermal/dermal substitutes, are commercially available and have proven to be clinically effective.5
The use of epidermal substitutes, known as cultured epithelial autografts (CEAs), has been a gold
standard for treating burns to close the wound permanently. However, treating full-thickness burns
with epidermal substitutes only leads to suboptimal healing outcomes, including high sensitivity to
mechanical stress and low take rates of the epidermal grafts due to the absence of an underlying
dermal layer.6 As a major part of human skin, dermis is responsible for a number of skin functions
including mechanical resistance and skin elasticity, and facilitates the epidermal grafting by provision
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of nutrients and enhanced cell-cell crosstalk.7 Therefore, dermal substitutes are an important
component when treating full-thickness wounds.

Commercially available dermal substitutes are unable to meet the growing need of the large
population burdened with chronic wounds or deep burns.8 They are primarily confined to the use of
collagen or acellular dermis as the matrix materials.5 These materials lack controllable sources for
scalability, thus impeding the mass production of dermal substitutes. This adds up to the already
staggering costs for wound care.9 The development of functional and cost-effective alternatives to
collagen-based dermal substitutes is still in need. For this purpose, challenges remain mainly in two
aspects. Firstly, the fabrication strategy is important for structuring the bioengineered dermal and full
thickness skin substitutes, and for reducing the manufacturing costs. This has advanced from the
primitive mixing of materials to the state-of-the-art three-dimensional (3D) bioprinting.10 3D
bioprinting enables the assembly of biomaterials and cells in a spatially controlled manner with the
assistance of computer-aided design. Among the current printing modalities, extrusion-based
bioprinting has gained increasing popularity for a wide range of applications.11 It allows printing of
bioinks of medium-high viscosity and high cell density, being amenable to fabrication of structures
with appropriate dimensions.12 Secondly, the selection of bioinks is important for supporting the skin
cells both mechanically and biologically. The majority of existing bioinks for dermal bioprinting has
been developed using collagen13, fibrinogen14, decellularized dermal extracellular matrix (ECM)15,
gelatin16, gelatin methacryloyl (GelMA)17, alginate16 and chitosan18. There are still limitations
however in terms of the tunability of these bioinks to address mechanical properties19, cell and tissue
specific interactions20, as well as compatibility. For example, a blend of GelMA with collagen was
demonstrated to improve the cell adhesion and viability, but also increased the mechanical
contractability of the newly developed tissue, compared to GelMA alone.21 These may or may not be
desirable traits depending on the application. Plant/marine-based biomaterials from renewable
sources such as cellulose, alginate and chitosan22 are promising candidates regarding safety and large124

scale production. However, these materials lack signalling motifs in their structures and are
biologically incapable of regulating cellular events.

In this study, we explore the purest Ul84 extract, PhycoDerm® PhycoTrix (PDPT) with a high
molecular weight of ~700 kDa, for bioink development and skin bioprinting. Due to unique features
including natural sulfation, richness of cell membrane lectin-recognizing rhamnose units (~50%), and
the

iduronic

and

glucuronic

acid

moieties,

Ul84

structurally

resembles

mammalian

glycosaminoglycans (GAGs) such as dermatan sulfate and heparan sulfate. As a major class of ECM
molecules, GAGs are involved in all phases of the wound healing process with significant roles in
maintaining hemostasis, regulating inflammation and neutrophil phagocytosis, supporting fibroblast
migration and proliferation and binding chemokines around endothelial cells to promote
angiogenesis.23 The resemblance to GAGs indicates that not only are cell compatibility and a hydrated
microenvironment for physically supporting cells achieved, but also that molecular motif signalling
and function may support tissue development. Further, GAGs have long been used in combination
with collagen for developing artificial skin with benefits of controlled biodegradation, improved
matrix mechanics, and a more porous microstructure.4,24 Many have also reported the use of marinebased polymers such as alginate and chitosan as the GAG replacements.25 The unique similarity of
Ul84 to native ECM molecules indispensably involved in the wound healing process suggests that
there may be heightened compatibility and functionality as a bioink ingredient.

Studies in Chapter 3 have demonstrated that PhycoDerm-based hydrogels had tunable mechanical
properties and supported attachment and proliferation of human dermal fibroblasts (HDFs).26 The
present work seeks to further unlock the potential of Ul84 towards wound healing application by
developing Ul84-based bioinks for 3D bioprinting dermal-like structures and developing bilayer skin
constructs. In Chapter 2, PDPT was measured to contain a much less protein content ((3.1 ±0.1)%)
than PhycoDerm ((13.2 ±0.2)%). Considering protein might be critical in mediating the cell-material
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interactions as demonstrated between XRU-MA (i.e., PDMA) and HDFs in Chapter 3, the
cytocompatibility of PDPT against both HDFs and HaCaT cells was evaluated in this chapter. PDPT
was modified by methacrylation (PDPT-MA) for 2D hydrogel preparation and ink formulation. The
PDPT-based bioinks were formulated as a combination of PDPT-MA, GelMA and gelatin at various
ratios. These bioinks were investigated in terms of printability and mechanical properties. Dermallike structures were 3D printed with HDFs encapsulated in these bioinks. The effects of ink
composition on cell growth, ECM gene expression and de novo ECM deposition were assessed.
Bilayer skin constructs were developed by culturing HaCaT cells on top of HDFs-populated dermallike structures. HaCaT cells were allowed to differentiate at the air-liquid interface for up to 4 weeks.
Histology and immunohistochemistry studies revealed that the skin constructs had skin-like bilayer
structures with certain characteristics associated with epidermal structuring and regeneration.

4.2 Materials and methods
4.2.1 Material preparation
All chemical reagents were purchased from Sigma-Aldrich unless stated otherwise. The ink
constituents were synthesized as follows under sterile conditions.

PDPT methacrylate (PDPT-MA) The dialyzed PDPT (Venus Shell Systems Pty. Ltd., Australia)
with a protein content of ~3.1% (w/w) was methacrylated to enable photo-crosslinking using an
optimized method described elsewhere.26 Briefly, 5% PDPT in MilliQ/dimethylformamide (DMF)
(1:1) was reacted with methacrylic anhydride (MA, 5 molar equivalents of Ul84 dimer unit) at room
temperature for 24 h. The solution pH was maintained at 8.0-8.5 for the first 2 h. PDPT-MA was
precipitated in ethanol, centrifuged and redissolved in reverse osmosis (RO) water. It was further
purified by dialysis against RO water (cellulose membrane, MWCO 12-14 kDa) at room temperature
for 48 h, lyophilized (Martin Christ, ALPHA 2-4 LD plus) and stored at -20 °C until further use.
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Gelatin methacryloyl (GelMA) Gelatin (gel strength 300, Type A) was methacryloyled as described
previously27 with minor modification. Briefly, 10% (w/v) gelatin in PBS was sterilized by chloroform
treatment at 4 °C for 16 h. The gelatin solution was then reacted with MA at 50 °C for 3 h. The
reaction solution was centrifuged, and the supernatant was neutralized with 5 M NaOH, purified by
dialysis at 40 °C for 72 h and then freeze dried.

Both PDPT-MA and GelMA were characterized by 1H nuclear magnetic resonance (NMR) with a
Bruker Avance III 400 spectrometer (Bruker, Germany). The degrees of substitution (DS) were
estimated using the 1H NMR spectra. For PDPT-MA, DS was determined by calculating the ratio of
integration areas of the peaks of the introduced methacrylate protons to that of L-rhamnose methyl
protons. To determine DS for GelMA, the integration area of the peak of methylene protons (ε-CH2)
from lysine residues, in both gelatin and GelMA spectra, was first normalized by that of phenyl
protons from respective phenylalanine residues. DS was calculated as the percentage of the lost signal
of methylene protons from lysine residues in the GelMA spectrum.

GelMA labelled with Rhodamine B (GelMA-R) 1.0 g of GelMA was solubilized in 100 mL of 0.1
M sodium bicarbonate (pH 9.0) at 37 °C overnight. 10.0 mg rhodamine B isothiocyanate was
solubilized in 1.0 mL dimethyl sulfoxide (DMSO) and added to the GelMA solution. The reaction
was maintained at room temperature and in dark overnight. The product was purified by dialysis
thoroughly against RO water for more than a week, protected from light, and then freeze dried.

PDPT-MA labelled with fluoresceinamine (PDPTMA-F) 1.140 g of PDPT-MA was dissolved in
22.8 mL of 0.1 M 4-Morpholineethanesulfonic acid (MES) hydrate (pH 6.0) at room temperature. 1.4
mL DMSO containing 0.114 g of N-hydroxysuccinimide (NHS) and 0.342 g of N-(3dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) was then added. The activation
was maintained for 15 min under continuous stirring, followed by the addition of 500 µL DMSO
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containing 11.4 mg of fluoresceinamine, isomer I. The reaction was maintained in dark for 24 h. The
product was purified by dialysis thoroughly against RO water for more than a week, protected from
light, and then freeze dried.

4.2.2 Preparation of PDPT-MA hydrogels
10% (w/v) PDPT-MA solution was prepared in PBS containing 1% (v/v) penicillin/streptomycin
(10,000 U mL-1, Gibco). Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) was added at a
concentration of 0.06% (w/v). PDPT-MA hydrogels were prepared via photo-crosslinking of 10%
(w/v) PDPT-MA solution injected in a disc mould (8 mm i.d. ×1.5 mm thickness). Crosslinking was
performed by exposure to visible light for 60 s (400 nm, 792 mJ). After thorough wash in water,
PDPT-MA hydrogels were freeze-dried and UV-sterilized before use.

4.2.3 Bioink formulation
Composite bioinks were formulated in PBS containing 1% (v/v) penicillin-streptomycin (10,000 U
mL-1, Gibco) at 37 °C. Ink constituents included PDPT-MA, GelMA and gelatin (Type A, gel strength
300) (Table 4.1). For each formulation, the concentration of gelatin was constant at 3.6% (w/v), and
the total solid content of PDPT-MA and GelMA was kept constant at 6% (w/v), with the concentration
of PDPT-MA varying from 0 to 6% (w/v). LAP was included at a concentration of 0.03% (w/v).
Fluorescent bioinks were formulated by replacing the GelMA in Table 4.1 with 19 portions of pristine
GelMA and 1 portion of GelMA-R, and replacing PDPT-MA with 19 portions of pristine PDPT-MA
and 1 portion of PDPTMA-F. 9.6% (w/v) PDPT-MA (free of gelatin, U9.6) was also prepared for
comparison.
Table 4. 1 PDPT-MA-based bioink formulations
Bioink
U0
U2
U4
U6

PDPT-MA (w/v %)
0
2
4
6

GelMA (w/v %)
6
4
2
0
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gelatin (w/v %)
3.6
3.6
3.6
3.6

4.2.4 Rheological characterization
Rheological tests were performed on a TA-G2 Rheometer (New Castle, DE) coupled with a
temperature-controlling Peltier plate. A plate geometry (15 mm in diameter) with a 2°cone was used
throughout the experiment. The geometry gap distance was set as 55 µm. The sol-gel transition
temperature was determined by oscillatory temperature sweeps from 40 °C to 8 °C at a ramp rate of
1.5 °C min-1, 1 Hz and 1% strain. Each sample was loaded at 37 °C, followed by equilibrium at this
temperature for 2 min. The flow profile was assessed by measuring the viscosity as a function of
shear rates (0.1-1000 s-1). Yield stress was determined by oscillatory stress sweep from 1 to 10000
Pa. The bioinks were also subjected to the step strain study to evaluate the shear-recovery properties.
Following stabilization at the low strain (1%) for 2 min, the inks were subject to 3 cycles of alternating
high (1000%) and low (1%) strains. In each cycle, the sample was maintained at the high strain for 3
min and the low strain for 2 min. For viscosity, yield stress and step strain measurements, 2.0 mL
bioinks liquefied at 37 °C were allowed to quickly gel in ice for 5 min followed by warming up at
room temperature before loading. The temperatures for sample loading and testing were set at 27 °C,
25 °C, 25 °C and 22 °C for U0, U2, U4 and U6, respectively. Prior to measurement, a 5 min pre-shear
at a shear rate of 5 s-1 was performed followed by 2 min equilibration. All tests were performed in
triplicate.

4.2.5 Semi-quantification of printability
The printability of bioinks was further characterized using a method reported by Ouyang et al.28,
which assesses the pore rectangularity of the 3D printed lattice structures. 4-Layer lattice structures
were 3D bioprinted with these bioinks. The bioprinting conditions were specified in a later section
regarding cell printing (4.2.8). The printability (Pr.) was calculated using Equation (4.1) and (4.2) as
below:

C = 4 πA/L2

(4.1)
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Pr. = (π/4) ·(1/C) = L2/16A

(4.2)

Where C, L and A represent the circularity, the perimeter and the area of a pore, respectively. When
Pr. = 1.0, good square-shaped pores are produced, indicating ideal ink gelation and good printability.
Whereas, Pr. < 1.0 and Pr. > 1.0 indicate poor printability of the bioink due to suboptimal gelation.
Measurements of the pore area and perimeter were performed using ImageJ 1.48v.

4.2.6 Mechanical properties
Hydrogel samples based on PDPT-MA bioinks were prepared in disc form (8 mm diameter, 1.5 mm
thickness) by casting. The samples were photo-crosslinked by exposure to visible light (400 nm,
LX400+) for 60 s (792 mJ). Then the samples were washed in cell culture medium at 37 °C for 3 days
to ensure adequate removal of free polymers and gelatin. The samples were subjected to mechanical
measurement using a Dynamic Mechanical Analyser (DMA, Q800, TA Instruments). A stress-strain
curve was obtained at 37 °C for each hydrogel sample under the compression mode. The sample was
compressed up to 0.300 N at a ramp force of 0.100 N min-1 and with a preload force of 0.0010 N.

4.2.7 Cell culture and in vitro cytocompatibility assessment of PDPT-MA hydrogels
Human dermal fibroblasts (HDFs) (Cell Applications, Inc., USA) and HaCaT cells (immortalized
human keratinocytes with genetic alterations; cell stocks from the laboratory) were routinely cultured
in Dulbecco's Modified Eagle Medium (DMEM, Sigma-Aldrich) supplemented with 10% (v/v) fetal
bovine serum (FBS, Invitrogen), 100 units mL-1 of penicillin and 100 µg mL-1 of streptomycin
(denoted as cell culture medium hereafter) at 37 °C in a 5% CO2 humidified incubator. Cell culture
medium was refreshed every 2-3 days. HDFs between passage 6 and 10 were used in the study, with
passage 6-7 used for gene expression analysis. HaCaT cells at passage 8 and 9 were used.
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HDFs were seeded onto lyophilized PDPT-MA hydrogels at a seeding density of 0.5 × 106 per 100
µL for each hydrogel scaffold. After 2 h cellular attachment, each cell-seeded hydrogel was incubated
in 1 mL cell culture medium and cultured at 37 °C in a 5% CO2 incubator. At day 1 and day 7 post
seeding, live/dead staining was performed using the method as described in Chapter 3. Briefly, cellseeded samples were incubated with calcein AM (5 µg mL-1) for 25 min, and then in propidium iodide
(1 µg mL-1) for 5 min. Live/dead images were taken using a confocal laser scanning microscope
(CLSM, Leica TCS SP5, Germany).

Prior to seeding HaCaT cells, lyophilized PDPT-MA hydrogels were rehydrated in cell culture
medium for 30 min. HaCaT cells were then seeded on top of the hydrated hydrogels at a cell density
of 5 × 104 per cm2. After 2 h cellular attachment, HaCaT-seeded hydrogels were cultured in
submerged condition in 1 mL cell culture medium for up to 11 days. At day 1, 7 and 11, live/dead
staining was performed as above described.

4.2.8 Cell printing and post-printing cellular growth
Cell-laden structures were 3D bioprinted in the form of layered lattice (10 × 10 mm) using a 3D
Bioplotter (EnvisionTEC, Germany). Before printing, HDFs were trypsinized and re-suspended in
2.0 mL bioink at a density of 1.0 × 106 mL-1. The printing parameters were optimized as shown in
Table 4.2. 27G cylindrical needles (length = 12.7 mm, inner diameter = 0.20 mm) were used for all
printing. For each construct, four layers of cell-laden bioink were dispensed onto a sterile substrate
at room temperature, but at 15 °C for U6 as this presented better retention of the printed structure
shape fidelity. The layers of the lattice were patterned at an alternating angle of 0°and 90°. The
printing height per layer and line space between the extruded filaments were set at 130 µm and 1.0
mm, respectively. Post-printing stabilization was performed via photo-crosslinking for 60 s (400 nm,
13.2 mW, Omnicure LX400+). Structures printed with individual cell-free bioink were used as blank
controls. The printed structures were incubated at 37 °C in a humidified atmosphere with 5% CO2 for
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2 weeks. For the gene expression study, HDFs cultured in a 12-well plate at 0.04 × 106 cm-2 to a full
confluence were used as the two-dimensional (2D) control.

At day 1, 7 and 14 post cell printing, cell viability was assessed by live/dead staining as described
above.26 Total metabolic activities reflecting cell proliferation rates were evaluated using
PrestoBlue™ cell viability reagent (Life technologies) at day 1, 4, 7 and 14 by following the
manufacturer’s protocol. Briefly, at predetermined time points, each sample was transferred to a new
well and incubated with 1 mL of PrestoBlue™ reagent (1 ×, diluted in cell culture medium) for 1 h
at 37 °C with 5% CO2. The fluorescence of each sample was recorded on a microplate reader
(POLARstar Omega) with an excitation and emission wavelength of 544 nm and 590/10 nm,
respectively. Data were collected for triplicate samples (both cell-laden and cell-free). Relative
fluorescence units (RFUs) were obtained by subtracting the average reading of cell-free samples from
that of cell-laden samples. Fold changes were then calculated via dividing RFUs of day 1, 4, 7 and
14 by that of day 1, and were plotted against culture time.
Table 4. 2 3D bioprinting parameters
Bioink
U0
U2
U4
U6

Printing Temperature/Substrate
Temperature
~27 °C/Room Temperature
~25 °C/Room Temperature
~25 °C/Room Temperature
~22 °C/~15 °C

Printing
pressure
3.5 bar
3.5 bar
3.5 bar
3.0 bar

Printing
speed

Crosslinking condition

8.0 mm s-1

60 s, 13.2 mW (approx.
792 mJ, 400 nm)

3D bioprinting was also performed with fluorescent bioinks containing HDFs. At day 1 and day 14
post printing, the cellular samples were washed with PBS, fixed in 3.7% PFA and cryo-protected in
30% sucrose overnight. The samples were then embedded in OCT compound mounting medium
(Thermo Fisher Scientific) and snap frozen in 2-methylbutane in liquid nitrogen. The OCT blocks
were cryosectioned at 7 µm using a cryostat (CM1950, Leica), and sections were collected on
adhesion slides (POLYSINE, Thermo Scientific) and stored at -80 °C before analysis. After
equilibrating at room temperature, sectioned samples were washed with PBS before mounting with
ProLongTM Gold Antifade Mountant (Life Technologies) for imaging using CLSM. Porosity of
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sectioned matrix was roughly estimated using ImageJ 1.48v.

4.2.9 Quantitative gene expression analysis by qPCR
Gene expression analysis for the targeted genes including COL1A1, COL3A1, ELN and FN1 was
conducted by real-time quantitative polymerase chain reaction (RT-qPCR) using a two-step method.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was selected as the reference gene for
normalization. TaqMan gene expression assays (Life technologies) were used as listed in Table 4.3.
At day 14 post printing, 3D printed cellular structures were washed with PBS and homogenized in
TRIzol reagent (Life Technologies) using a Bullet Blender tissue homogenizer (Next Advance, USA).
2D cultured HDFs were lysed with 100 µL cm-2 TRIzol reagent. Total RNA was isolated from the
TRIzol hydrolysates using the Direct-zol RNA kit (Zymo Research, USA) by following the supplier’s
instructions. The concentration and purity of extracted RNA was examined using a NanoDrop 2000c
Spectrophotometer (Thermo Scientific).

Complementary DNA (cDNA) was synthesized using a High-Capacity cDNA Reverse Transcription
Kit (Life Technologies) by following the manufacturer’s protocol. A 20.0 µL reaction was prepared
for each synthesis with approx. 200.0 ng total RNA as the template. For no-reverse-transcriptase (RT) control, RNA of the same amount was diluted to 20.0 µL with RNase-free water and run in
parallel for each RNA sample. Synthesized cDNA was stored at -30 ºC before qPCR.
Table 4. 3 Information of TaqMan assays
Gene
symbol

Assay ID

GAPDH

Hs02786624_g1

COL1A1
COL3A1
FN1
ELN

Hs00164004_m1
Hs00943809_m1
Hs00365052_m1
Hs00355783_m1

Assay Design
Both primers and probe
map within a single exon
Probe spans exons
Probe spans exons
Probe spans exons
Probe spans exons

Target

Amplicon
length

Dye

Human

157

FAM-MGB

Human
Human
Human
Human

66
65
82
71

FAM-MGB
FAM-MGB
FAM-MGB
FAM-MGB

The TaqMan assay for each target gene was conducted in a 20.0 µL qPCR reaction by following the
manufacturer’s instructions. All cDNA preparations were diluted at 1:5 in RNase-free water and 8.0
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µL was used as the template in each qPCR reaction. qPCR was run on a CFX Connect TM Real Time
PCR Detection System (Bio-Rad) following the thermal cycling steps outlined in the supplier’s
instruction. Negative controls, both the non-template control (NTC) and the -RT control, were run in
the meantime, where RNase-free water and -RT was used as the template, respectively. The relative
expression of each target gene was obtained using the 2-ΔΔCt method, where ΔCt = Gene Ct –
Reference Gene Ct, and ΔΔCt = sample ΔCt – average control group ΔCt. The Ct values of 2D
cultured HDFs were used as the control for all calculations. Three independent experiments were
performed.

4.2.10 Immunofluorescence (IF) staining
IF staining was conducted to assess the potential of 3D printed cellular structures in producing their
own ECM. The samples following 2 weeks’ in vitro culture were washed with PBS and fixed in 3.7%
(w/v) PFA for ~30 min. After another wash with PBS, the samples were permeabilized in 0.1% (v/v)
Triton X-100 in PBS (PBST) for 30 min, and blocked in 10% (v/v) donkey serum (Merck) diluted in
PBST (blocking buffer) for 1 h at room temperature. The samples were then incubated in each of the
solutions of the primary antibodies diluted in blocking buffer at 1:100 for 16 h at 4 °C: (a) rabbit
polyclonal anti-collagen I antibody (Sigma-Aldrich); (b) rabbit polyclonal anti-collagen III antibody
(Abcam); (c) rabbit polyclonal anti-elastin antibody (Abcam); (d) rabbit polyclonal anti-fibronectin
antibody (Abcam). The samples were incubated with donkey anti-rabbit IgG (H+L) secondary
antibody conjugated with Alexa Fluor 488 (Life technologies) in blocking buffer (1:1000) for 2 h at
room temperature. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, 1 µg mL1

in PBS, Invitrogen) for 5 min at room temperature. Fluorescence images were acquired using CLSM.

Three independent experiments were conducted.
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4.2.11 Developing bilayer skin constructs
Bilayer skin constructs were developed by culturing HaCaT cells on the top of 3D printed HDFsladen structures serving as the dermal compartments. U0 and U2 were selected for printing the dermal
compartments. For this purpose, the printing parameters were slightly modified based on that for 3D
printing dermal-like structures as described in 4.2.8. Specifically, the top layer (4th layer) of the
dermal compartment was dispensed at a line space of 0.2 mm (equal to the needle size) rather than
1.0 mm (Figure 4.1). This produced dermal compartments with a continuous surface, which allowed
for laying HaCaT cells later. Dermal compartments were cultured in cell culture medium for 12 days
to allow maturation. Subsequently, HaCaT cells were seeded on the top of the dermal compartment
at a density of 0.5 × 106 cm-2. After submerged culture for 24 h, the bilayer skin constructs were
transferred to transwell inserts (12 mm dia., 3.0 µm pore, Corning), and cultured at the air-liquid
interface (ALI) to induce epidermal differentiation (Figure 4.1). The differentiation medium was
reconstituted as 3 volumes of DMEM and 1 volume of F-12 (Life Technologies) supplemented with
10% (v/v) FBS, 100 units mL-1 of penicillin, 100 µg mL-1 of streptomycin, 0.4 µg mL-1 hydrocortisone,
180 µM adenine, 5 µg mL-1 insulin human solution, 5 µg mL-1 transferrin human, 2-11 M 3,3′,5Triiodo-L-thyronine sodium salt (T3), 10-10 M Cholera Toxin from Vibrio cholerae, 50 µg mL-1 2Phospho-L-ascorbic acid trisodium salt, 1.8 mM CaCl2·H2O and 2 ng mL-1 transforming growth
factor α (TGF-α). 650 µL differentiation medium was added to the outside of each transwell insert.
Differentiation medium was refreshed every 24 h. The bilayer skin constructs were cultured at the
ALI for up to 28 days. At day 7, 14, 21, and 28 after ALI culture, bilayer skin constructs were fixed
in 3.7% PFA for 15 min, processed in a Tissue processor (ASP200S, Leica) and embedded in paraffin.
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Figure 4. 1 Schematic of skin bioprinting and in vitro culture and maturation at the air-liquid interface.

4.2.12 Histology and immunohistochemistry (IHC) analysis of bilayer skin constructs
Paraffin sections of 5 µm thickness were cut using a Rotary Microtome (RM2255, Leica), and
collected on POLYSINE adhesive slides. Prior to histology and fluorescent IHC analysis, paraffin
sections were deparaffinized and rehydrated to water. After melting at 65-70 °C for 30 min, paraffin
sections were placed in xylene twice (each for 5 min). Then the sections were rehydrated in
descending ethanol solutions (100%, 100%, 95% and 70%) for 3-5 min each, and finally in RO water
for 5 min.

Hematoxylin and eosin Y (H & E) staining was performed following the standard protocol by the
manufacturer. Briefly, the hydrated sections were stained with Mayer’s hematoxylin solution (filtered
through 0.45 µm) for 15 min followed by rinse in tap water for 15 min. After placing in RO water for
30 s then in 95% ethanol for 30 s, the sections were counterstained in eosin Y solution (alcoholic with
phloxine, filtered) for 45-60 s. Then the sections were dehydrated in 95% ethanol (2*) and 100%
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ethanol (2*) for 2 min each. Finally, the sections were cleared in two xylenes, and mounted with
resinous mounting medium. Images were acquired using a light microscope (Leica, Germany).

For fluorescent IHC, the hydrated sections were permeabilized in PBST for 10 min and then incubated
in blocking buffer for 1 h. Then the sections were incubated with each of the following primary
antibodies including (1) rabbit polyclonal anti-collagen I antibody (1:100, Sigma), (2) rabbit
polyclonal anti-Ki67 antibody (1:100, Abcam), (3) rabbit polyclonal anti-cytokeratin 10 antibody
(1:200, Abcam), (4) rabbit polyclonal anti-loricrin antibody (1:150, Abcam) and (5) rabbit polyclonal
anti-involucrin antibody (1:150, Abcam) at 2-8 °C for 16 h. After thorough wash in PBS, the sections
were incubated with the secondary antibody of either Alexa FluorTM 488 donkey anti-rabbit IgG(H+L)
or Alexa FluorTM 594 donkey anti-rabbit IgG(H+L) diluted in blocking buffer (1:1000, v/v) for 1 h at
room temperature. For co-labelling of collagen type I and F-actin, the secondary antibody was
reconstituted in blocking buffer containing Alexa FluorTM 488 phalloidin (1:40, v/v, InvitrogenTM,
Life Technologies).

4.2.13 Statistical analysis
Data were presented as mean ± SD (n ≥ 3). Statistical differences were obtained using one-way or
two-way analysis of variation (ANOVA) followed by Tukey’s or Bonferroni’s multiple comparisons
post hoc test with a confidence interval of 95% (GraphPad Prism 9).

4.3 Results and discussion
4.3.1 Material preparations
PDPT and gelatin are water-soluble polymers. They were conjugated with methacryloyl groups to
render them amenable to photo-crosslinking. Both modifications were confirmed successful by 1H
NMR spectroscopy (Figure 4.2). The DS of PDPT-MA was ~1.1 methacrylate group per disaccharide
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repeating unit, which corresponded to a percentage of ~36.7%, while the DS of GelMA was ~40% of
the amino groups from the lysine residues being substituted.

Figure 4. 2 1H NMR spectra in D2O confirmed the successful methacryloylation of PDPT and gelatin.
(A) The spectra of PDPT before and after methacryloylation recorded at 60 °C. Peak a, b, c and d
denote signals of proton(s) as marked in respective formula of disaccharide repeating unit. (B) The
spectra of gelatin before and after methacryloylation recorded at 40 °C. Peak 1 denotes signal of
methylene protons (2H; ε-CH2) from lysine residues that underwent modification. Peak 2 denotes
signal of phenyl protons (5H) from phenylalanine residues used as an internal standard.
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4.3.2 Cytocompatibility of PDPT-MA hydrogels
Prior to ink formulation, PDPT was evaluated for cytocompatibility against HDFs and HaCaT cells.
PDPT-MA hydrogels were shown to be highly cytocompatible with HDFs as demonstrated by high
cell viability at day 1 and day 7 (Figure 4.3). PDPT-MA hydrogels were also shown to support cell
attachment at day 1, and cell proliferation as evidenced by a much denser cell colony at day 7
compared to day 1. This result verified that the reduction of protein content in Ul84 extracts did not
interfere cell-material interactions.

Figure 4. 3 Live/dead staining revealed good cytocompatibility of PDPT-MA hydrogels for human
dermal fibroblasts (HDFs).
There appeared significant cell growth of seeded HDFs over 7 days. Live cells were stained in green
and dead cells in red. Scale bar: 200 µm.

PDPT-MA hydrogels were also cytocompatible with HaCaT cells as demonstrated by high cell
viability over 11 days’ culture (Figure 4.4). At day 1, HaCaT cells were mainly distributed as single
cells, which grew into patched cells at day 7 and finally grew into a complete cell layer at day 11. A
denser population at day 11 compared to day 1 suggests extensive cell proliferation of HaCaT cells
on PDPT-MA hydrogels. This may indicate active cell-material interactions between HaCaT cells
and PDPT-MA hydrogels, which was possibly mediated through the sugar moieties (e.g., L-rhamnose)
in Ul84 interacting with lectin sites on the cell membrane of HaCaT cells.
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Figure 4. 4 Live/dead staining demonstrated good cyto-compatibility of PDPT-MA hydrogels for
HaCaT cells.
It was clear that there was significant cell proliferation of HaCaT cells over 11 days. Live cells were
stained in green and dead cells in red. Scale bar: 200 µm.

Based on these results, PDPT-MA was deemed suitable for bioink formulation.

4.3.3 Rheological assessment
For extrusion-based 3D printing, a bioink needs to be adequately viscous to permit shape retention
after extrusion. Composite bioinks were formulated by incorporating a thermal-responsive
rheological modifier, gelatin, to compensate for the inherent low viscosity of the PDPT-MA solution.
As shown in Table 4.1, four ink formulations were prepared, all containing 3.6% (w/v) gelatin. The
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total solid content of PDPT-MA and GelMA was maintained at 6% (w/v) to avoid the formation of
densely crosslinked networks that impede cell survival and proliferation.26,27,29 The effects of ink
composition on the rheological properties of bioinks were assessed in terms of the gelation
temperature, shear thinning, self-recovery and yield stress.

The gelation temperature of each bioink was determined by temperature sweep. Gelation occurred
when the storage modulus (G’) exceeded the loss modulus (G’’), and the respective sol-gel transition
temperature was used to guide the temperature setup for 3D printing. The sol-gel transition
temperature of the bioinks decreased with increasing PDPT-MA content and reducing GelMA content,
being ~29.5 °C, ~28.0 °C, ~26.5 °C and ~22.0 °C for U0, U2, U4 and U6, respectively (Figure 4.5A).
Subsequent test undertaken on a 3D Bioplotter, determined if the bioinks could be extruded as a
consistent filament at a temperature near the individual gelation point. This determined the printing
temperatures of ~27 °C, ~25 °C, ~25 °C, and ~22 °C for U0, U2, U4 and U6, respectively. Therefore,
the following rheological characterizations were undertaken at the temperature specified for each
bioink.

All the bioinks exhibited a typical non-Newtonian shear thinning behaviour in the range of shear rate
from 0.1 s-1 to 1000 s-1 (Figure 4.5B). For example, the viscosity of U0 at 27 °C was measured to be
1692.0 ± 321.5 Pa s at a low shear rate of 0.1 s-1, which was reduced dramatically to 0.2 ± 0.02 Pa s
as the shear rate increased to 1000 s-1 (n = 3). According to the power-law model describing viscosity
(𝜂) as a function of shear rate (𝛾̇)26, 𝜂 = 𝐾𝛾̇n-1, the flow consistency index K (viscosity at 1 s-1) and
flow behaviour index n (dimensionless) for U0 at 27 °C were 153.9 ± 24.2 Pa s and 0.043 ± 0.007,
respectively. N serves as an indicator of the shear thinning effect of fluids. The smaller the n value is
(0 < n < 1 for power-law fluids), the higher shear thinning effect the ink exhibits.30 This result
indicated that U0 had a strong shear shinning effect at 27 °C. All bioinks were extruded through a
cylindrical needle. According to the law of wall principle, the fluid near the centre of the extruded
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inks moves faster than the fluid near the walls, and experiences the highest level of stress in the
printing nozzle. The maximum shear rate that a bioink may experience during extrusion can be
estimated using the Rabinowitsch-Mooney equation (Eq. 4.3) as below.[17]

𝛾̇ = (3n+1)Q/(nπr3)

(Eq. 4.3)

where 𝛾̇ is the maximum shear rate at the needle wall, r is the needle radius (mm), n is the flow
behaviour index and Q is the volumetric flow rate (mm3 s-1). In the present studies employing a
cylindrical syringe nozzle of 0.1 mm (r) and a printing speed of 8 mm s-1 (Table 4.2), the maximum
shear rate that U0 may experience was estimated to be 2154.2 ± 338.9 s-1. This corresponded to
viscosity of 0.1 ± 0.01 Pa s, according to the power-law model (Table 4.4). On completion of
extrusion assuming a negligible shear rate of 0.1 s-1, the viscosity of U0 was estimated to be 1397.5
±238.4 Pa s.

As shown in Table 4.4, when measured at each respective printing temperature, the n values increased
with increasing PDPT-MA content. This may suggest reduced shear thinning behaviour of the bioinks
at respective printing temperatures. Nonetheless, all the n values (0.108-0.249) here remained
relatively small, falling into in the lower end of the values previously reported for extruding bioinks
(0.148-0.986),30-33 which suggested strong shear thinning characteristics of the evaluated bioinks.

The Rabinowitsch-Mooney equation was also employed to understand the flow behaviour of PDPTMA-containing bioinks in conditions simulating extrusion printing. The estimated maximum shear
rates that PDPT-MA-containing bioinks may experience during printing at each respective printing
temperature were lower than U0 (Table 4.4). The PDPT-MA-containing bioinks showed a similar
trend as U0, with a much lower viscosity (𝜂e, ~0.4-~0.6 Pa s) upon printing to enable ease of flow of
bioinks, and then a higher viscosity (𝜂0.1, ~415.9-~1356.8 Pa s) following extrusion to help retain the
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shape of extruded filaments. These data evidenced the shear thinning behaviour and supported
suitability of PDPT-MA-containing bioinks for extrusion-based printing.

To understand the effect of PDPT-MA on the viscosity of the composite bioinks, the viscometry
profile of an PDPT-MA-alone ink (U9.6) containing the same total solid content as the composite
inks (9.6%(w/v)) was measured. The result showed a Newtonian-like behaviour of U9.6 at 25 °C
(Figure 4.5B). This may suggest a dominant role of GelMA in governing the shear thinning properties
of the composite inks. At the shear rate of 0.1 s-1, the viscosity (𝜂0.1) of the bioinks decreased markedly
with reducing GelMA content at respective testing temperatures (Table 4.4). This is consistent with
our observations, that addition of PDPT-MA reduced the ink’s ability to retain filament shape,
especially when the concentration of PDPT-MA reached a threshold. However, this was counteracted
and filament shape was improved at lower temperatures with the inclusion of PDPT-MA. In the case
of U6, a reduced cartridge temperature (22 °C) was selected, in combination with a reduced substrate
temperature (15 °C) (as will be discussed in 4.3.4), to counteract the effect of a high PDPT-MA
concentration in order to retain the shape of printed structures.
Table 4. 4 Rheological parameters of PDPT-MA-based bioinks
Testing
Bioink temperature
n
𝛾e (s-1)
𝜂e (Pa s)
𝜂0.1 (Pa s)
(°C)
U0
27
0.043 ±0.007
2154.2 ±338.9
0.1 ±0.01
1397.5 ±238.4
U2
25
0.108 ±0.025
1008.4 ±173.2
0.4 ±0.1
1356.8 ±115.0
U4
25
0.172 ±0.008
706.5 ±22.5
0.5 ±0.1
730.3 ±140.5
U6
22
0.249 ±0.038
567.6 ±52.5
0.6 ±0.2
415.9 ±52.0
Note: 𝛾e represents the estimated maximum shear rate at the needle wall during printing in present work with
the use of a cylindrical printing nozzle (I.D. = 0.2 mm) and a printing speed of 8 mm s-1; 𝜂e represents viscosity
at the estimated maximum shear rate (𝛾e) at the wall during printing. 𝜂0.1 represents the calculated viscosity at
the shear rate of 0.1 s-1 at respective printing temperatures, which is an estimated minimal shear rate before
and on completion of printing.

We also examined the self-recovery capacity of the bioinks in the context of bioprinting, which is a
critical property to achieving high fidelity of the printed structures. During extrusion printing, the
bioink experienced high strains to enable flow, whereas it needs to recover its mechanical property
after printing (low strains) to hold the printed shape. A step strain measurement was conducted to
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simulate this process, where the sample underwent disruption at a high strain (1000%) followed by
restoration to 1% strain. This was repeated three times and G’ response was assessed (Figure 4.5C).
All the bioinks appeared to recover and maintain their G’ in each cycle of the step-strain test. This
demonstrates an ability of the bioinks to rapidly recover respective polymeric networks, allowing for
retention of structural integrity for consistent curing post printing. The difference observed in G’ at
1000% strain for the bioinks following the initial stabilization step was likely due to the influence of
different thermal/rheological history that the bioinks experienced.

A yield stress represents the minimal stress that is required for a fluid to yield and flow.31,34 The yield
stress of each bioink at respective printing temperature was determined by oscillatory stress sweep
(Figure 4.5D). It decreased from ~501 Pa for U0 at 27 °C, to ~398 Pa for U2 at 25 °C, ~316 Pa for
U4 at 25 °C, and ~158 Pa for U6 at 22 °C. At stresses below individual yield stress, the bioink had a
higher G’ than G’’ and behaved more as a solid with a low capability to flow. With the stress reaching
(characterized by the crossover of G’ and G’’) and exceeding individual yield stress, the bioink started
to have a higher G’’ than G’, and behaved more as a liquid with a high capability to flow. To enable
extrudability in a tubing needle, the yield stress of a bioink should not exceed the maximum stress, τ
(Pa), of the printer used, which can be estimated using the below equation (Eq. 4.4):35

τ = ΔP/(2L)*r

(Eq. 4.4)

Where ΔP represents the maximum pressure of the printer (Pa), and L and r represents the length (m)
and radius (m) of the extrusion needle, respectively. In this study, a maximum stress of 1968.5 Pa
was estimated, given the use of 27G needle and a maximum pneumatic pressure of 5.0 bar (500 kPa)
of the 3D Bioplotter. This value was higher than the yield stress (~158-501 Pa) determined for all the
bioinks, verifying their extrudability. The decrease in yield stress with increasing PDPT-MA content
likely reflected the effect of inclusion of a Newtonian-like fluid. To preclude any temperature effects,
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U0 and U6 were re-measured at 25 °C, the same temperature as for U2 and U4. A significant decrease
in yield stress was observed with increasing PDPT-MA content (Figure 4.5E). The proportional
decrease in yield stress with increased PDPT-MA content may be attributed to the less entangled
polymer network of the PDPT-MA dispersion compared to the GelMA solution. PDPT-MA is an
amphiphilic molecule, and forms microaggregates in aqueous solution36, whereas GelMA is
completely soluble in water. Upon gelation, GelMA forms a tight hydrogel network with the
interconnected polymeric chains. Inclusion of PDPT-MA could disrupt the tight network of GelMA.
Considering all the bioinks contained the same total polymer content, this result may suggest that the
inclusion of PDPT-MA reduced yield stress of its-containing bioinks. This is consistent with previous
studies on gelatin/alginate37, where higher gelatin contents required higher extrusion pressure,
whereas inclusion of alginate facilitated the flow of bioinks with reduced extrusion pressure.
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Figure 4. 5 Rheological evaluations of PDPT-MA-based bioinks (n ≥ 3).
(A) Temperature sweeps illustrating different gelation temperatures. The gelation temperature was
shown to shift downward as PDPT-MA content increased (GelMA decreased). (B) Viscometry
measurements demonstrating shear thinning properties of PDPT-MA-based bioinks at respective
printing temperatures and a Newtonian-like behaviour of U9.6 at 25 °C. (C) Step-strain tests showing
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the rapid self-recovery behaviours of PDPT-MA-based bioinks at respective printing temperatures
after the high strain was removed. (D) Yield stress of PDPT-MA-based bioinks measured at
respective printing temperatures. (E) Yield stress of PDPT-MA-based bioinks at 25 °C, showing
decreased yield stress with increasing PDPT-MA content.

4.3.4 Printability
Following an initial extrudability test as discussed in 4.3.3, the printing temperature was established
for each bioink, being ~27 °C for U0, ~25 °C for U2, ~25 °C for U4, and ~22 °C for U6. The substrate
was selected at room temperature for printing U0, U2 and U4 and 15 °C for printing U6 respectively
(Table 4.2). The lower substrate temperature selected for U6 was shown to help retain the printed
structure. The printability of bioinks was evaluated by assessing the geometric fidelity of the 3D
printed lattice structures.28 When optimal gelation is achieved, the extruded lines neither spread on
the substrate nor merge with the adjacent filaments. As a result, the printed lattice should produce
pores of rectangular geometries. The pore geometries of 3D printed structures using each bioink were
analyzed (Figure 4.6). The printability (Pr.) value for each ink at respective printing temperature was
within the range of 0.9-1.1 that has been reported to allow for good-shaped filaments and structural
stability.28

Figure 4. 6 Quantitative evaluation of the pore geometries of 3D lattice structures printed with PDPTMA-based bioinks including U0, U2, U4 and U6.
3D printing outcomes revealed Pr. values close to 1.0 for all bioinks, suggesting good shape fidelity
and suitability for extrusion printing. Scale bar: 1.0 mm.

4.3.5 Mechanical stiffness
The mechanical properties of PDPT-MA-based bioinks in the crosslinked form were characterized.
Cast hydrogels were prepared by UV crosslinking of respective bioinks and analyzed by DMA at
37 °C. The Young’s moduli increased with increasing PDPT-MA content (Figure 4.7). Compared to
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U0, hydrogels based on U2, U4 or U6 displayed a ~ 3.9-, ~9.6- or ~11.4-fold increase in Young’s
modulus. This highlighted the contribution of PDPT-MA to the mechanical properties of the
composite hydrogels. PDPT-MA dominating the mechanical properties can be ascribed to its
disaccharide structure. As a GAG analogue, PDPT-MA has more with structural strength, whereas
GelMA has more structural flexibility. For the target applications in skin tissue engineering and
wound healing, the inclusion of PDPT-MA is advantageous as it provides adjustable mechanical
support to better match that of human skin (4.5-8.0 kPa as measured in vivo by indentation tests).38
In this sense, PDPT-MA can be used to bolster the mechanical strength of native protein components
in skin ECM.39

Figure 4. 7 Mechanical stiffness of cast hydrogels made from PDPT-MA-based bioinks (n ≥ 3).
(A) Young’s modulus. One-way ANOVA with Tukey’s multiple comparisons post hoc test was
performed to statistically evaluate the difference among hydrogels based on different bioinks. ****p
< 0.0001. (B) Stress-strain curves.

4.3.6 In vitro cellular growth and ECM production of 3D printed cell-laden structures
3D cell-laden structures were printed using each set of bioink in combination with HDFs. During the
two weeks’ culture, samples were collected to study cell viability, cell proliferation, ECM deposition
and ECM gene expression. Cell viability at day 1 post printing was shown to be (72.5 ±1.7)%, (81.7
± 2.8)%, (93.4 ± 1.7)%, and (97.3 ± 1.0)% (n = 3-6 fields per sample) for cellular structures printed
with U0, U2, U4 and U6, respectively (Figure 4.8). The lower cell viability in GelMA-dominant
structures might be ascribed to higher shear stress (Table 4.4) present to the cell-containing inks
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during the printing process. High cell viability was demonstrated for all the 3D printed structures at
day 7 and 14, with limited numbers of cell death observed (Figure 4.8), suggesting the bioink
formulations and 3D printed structures were cytocompatible with HDFs. Further, all structures
showed to support cell proliferation as indicated by significant increases in cellular metabolic
activities (Figure 4.9). Compared to day 1, cell-laden structures printed with U2 exhibited the highest
increase in cell number at day 14, followed by the structures printed with U6. At early time points up
to day 7, a monotonic cell growth was noted for the structures printed with U0 or U2. In contrast, the
structures printed with U4 or U6 appeared to have limited cell growth, in particular for those printed
with U6 that saw an initial reduction in cellular metabolic activities at day 4.

The difference observed in cell proliferation of 3D printed structures in the early stages might be
ascribed to the effect of matrix mechanical properties as demonstrated in Figure 4.7. Stiffer
microenvironments presented by the photocrosslinked U4 (9.7 kPa) and U6 (12.0 kPa) may hinder
effective cellular movement, cell-cell interactions, and/or nutrient transport,40 compared to the softer
microenvironments endowed by the photocrosslinked U0 (1.1 kPa) and U2 (4.2 kPa). Compared to
structures printed with PDPT-MA-containing inks, the structures printed with U0 saw a more rapid
cell growth from day 1 to day 7, but limited cell growth from day 7 to day 14. This may be correlated
with severe matrix contraction observed in U0-based structures; a characteristic that has been tuned
elsewhere previously in GelMA based bioinks, but that may not be a desirable trait in wound healing
circumstances.21 U0-based structures experienced more significant matrix contraction (~22%) than
PDPT-MA-containing structures (~10-12% for structures printed with U2 or U4, and negligible
contraction for structures printed with U6). The contraction could reduce the surface area to volume
ratio of U0-based structures, which may account for the compromised cellular growth at later time
points. Collectively, our results demonstrated that the 3D printed U2-based structures had the most
suitably tuned mechanical property in support of better cell proliferation.
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Contraction of skin grafts represents a severe problem in wound management. This is especially
prominent for skin grafts composed of ECM proteins such as collagen. Researchers have resorted to
the use of a structurally supportive material along with collagen for developing composite skin
grafts.41,42 In this regard, PDPT-MA is potentially useful to enhance the mechanical property of the
bioengineered skin substitutes for improved structural stability. In our previous work, collagen-coated
ulvan gel showed enhanced cell proliferation with no noticeable contraction.26 The present work
further demonstrated that incorporation of PDPT-MA favoured improved structural stability against
matrix contraction.
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Figure 4. 8 Live/dead staining showed high cell viability of HDFs printed with respective PDPTMA-based bioinks, i.e., U0, U2, U4 and U6, over 2 weeks.
Live cells were stained with calcein AM (green) and dead cells stained with propidium iodide (red).
Scale bar: 200 µm.
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Figure 4. 9 3D cellular structures printed with PDPT-MA-based bioinks were shown to support cell
proliferation of HDFs with increased metabolic activities over 2 weeks (n = 3-4).
Two-way ANOVA with Tukey’s multiple comparisons post hoc test was performed for the statistical
analysis. *p < 0.05; **p < 0.01; ****p< 0.0001.

Subsequently, the gene expression levels of key dermal ECM genes including COL1A1, COL3A1,
ELN and FN1 in the 3D printed cellular structures were examined following two weeks’ culture by
real time qPCR (Figure 4.10). Inclusion of PDPT-MA and replacing GelMA with PDPT-MA did not
induce significant changes in the expression of COL1A1, ELN and FN1 genes (Figure 4.10A, C, D).
This interesting finding provides important implications of the role of ulvan, a seaweed-derived
sulfated polysaccharide, in the regulation of key ECM genes of human skin fibroblasts. On the other
hand, a significant down-regulation effect on COL3A1 gene was noted for the structures printed with
U2, U4 or U6, in comparison with those with U0, at the one point in time used in this assay (Figure
4.10B). This suggests that inclusion of PDPT-MA may inhibit expression of COL3A1 by HDFs
during the healing process, but it is not understood if this regulation was consistent over time. The
reason why this occurs remains to be elucidated. This indicates that dosing of diverse bioink
ingredients with biologically functional traits could be potentially useful in regulating gene
expression in the wound healing environment. During granulation tissue formation and collagen
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remodeling, ECM components undergo dynamic synthesis and catabolism.43 Continuous synthesis of
collagen I without concomitant breakdown often leads to fibrosis.44 In this regard, PDPT-MA may
have therapeutic significance in its treatment. To further study this potential, in vivo assessment will
need to be performed in the future. Future work is also required to investigate a wider range of ECM
genes including proteoglycan genes (such as versican and decorin etc.) and GAGs synthase genes
(such as chondroitin sulfate synthase and hyaluronan synthase genes of HAS1, HAS2 and HAS3 etc.),
and also matrix-degrading metalloproteinases (MMPs, e.g., MMP1) gene expression to better
understand the role of PDPT-MA and ulvan on remodeling and production of skin matrix.
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Figure 4. 10 Gene expression analysis of 3D printed cell-laden structures at day 14 by real-time
qPCR.
The relative expression levels of target genes including (A) COL1A1, (B) COL3A1, (C) ELN, and (D)
FN1 were determined by the TaqMan® assays, with all normalized to that of the reference gene
GAPDH. Relative gene expression was calculated using the 2-ΔΔCt method, and was expressed as fold
changes of corresponding gene expression levels of 2D monolayer cultures. Data were obtained from
three independent experiments and presented as mean ± SD. Statistical significances among 3D
cellular structures printed with respective PDPT-MA-based bioinks (U0, U2, U4 and U6) were
obtained by one-way ANOVA with Tukey’s multiple comparisons post hoc test (*p < 0.05; **p <
0.01).
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The 3D printed structures were also examined for production of major ECM proteins, including
collagen I, collagen III, elastin and fibronectin. Our results by immunostaining confirmed that all 3D
printed cellular structures were able to deposit key ECM proteins found in dermal matrix in vivo
(Figure 4.11). For the predominant interstitial collagens, type I collagen was shown to form thick
fibres while type III collagen formed thin ones (Figure 4.11). The thick collagen I fibres are known
to provide mechanical strength whereas the thin collagen III fibres are responsible for structural
flexibility.45 These fibre characteristics are in line with those found in native skin,46 indicating the
potential of our 3D printed cell-laden structures to develop and establish mechanical and tensile
strength through de novo production of matrix collagens.

Elastin and fibronectin fibres were also detected in all 3D printed structures (Figure 4.11). These
proteins play important roles in skin ECM structuring or the wound healing process. Elastin is a major
fibrous ECM protein, forming the core of elastic fibres in skin tissue.47,48 While it accounts for merely
2% of the total dermal proteins, elastin endows human skin with resilience.49 Fibronectin is a fibrous
ECM glycoprotein responsible for cell adhesion. It is critical for mediating fibroblast migration over
the provisional matrix in the early stage of wound healing.50 Our elastin- and fibronectin-producing
cellular structures are promising for progression towards the development of functional dermal-like
structures.
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Figure 4. 11 Confocal images showing the deposition of ECM components including collagen I (Col
I), collagen III (Col III), elastin (ELN) and fibronectin (FN) (green) in 3D cellular structures printed
with U0, U2, U4 and U6, respectively and cultured for 2 weeks by immunofluorescence staining.
Nuclei was counterstained with DAPI (blue). Scale bar: 50 µm.

4.3.7 In vitro degradation of cellular structures
To understand the degradation behaviour of the artificial matrices produced by GelMA and PDPTMA in the course of in vitro culture, fluorescently labelled GelMA-R and PDPTMA-F were
introduced to respective bioinks to monitor the changes of synthetic matrices. The 3D printed cellladen constructs were collected at day 1 and 14 and cryosectioned for confocal microscopy. The 3D
printed structures using U0 (GelMA) showed fairly uniform morphology at day 1 (Figure 4.12A)
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that became microporous at day 14 (Figure 4.12B). This morphological change likely resulted from
enzymatic degradation by the encapsulated HDFs upon sensing the microenvironments. HDFs may
secret matrix enzymes (e.g., gelatinases) to restructure the surrounding matrix to facilitate cellular
movements and to create space for new ECM synthesis. The 3D printed structures using U6 (PDPTMA) showed particulate fluorescence signals (Figure 4.12A), which might reveal that the polymers
existed in an aggregated form. Previous studies reported aggregation behaviour of ulvan owing to its
amphiphilic nature.36 This is supported by our observation of turbidity in PDPT-MA aqueous
solutions and PDPT-MA-containing composite bioinks. At day 14, there appeared some slight
increase in the porosity of 3D printed cell-laden structures using U6 (Figure 4.12B). Since human
body does not have specific enzymes (ulvan lyases) to break the glycosidic bonds in ulvan, the
degradation of U6-based dermal-like structures was probably a result of some enzymatic activities
(e.g., esterase) that worked on the ester linkages between the polymer backbone and methacryloyl
side chains. Further detailed studies are required to elucidate how the crosslinked ulvan matrix
behaves in vivo.

Both the 3D printed structures using U2 and U4 showed overlay images of both crosslinked forms of
GelMA and PDPT-MA at day 1 and day 14. This suggested uniform mixing and distribution of
GelMA and PDPT-MA within the detection limit of confocal laser scanning microscopy. With
increasing PDPT-MA concentration, the role of PDPT-MA became more dominant in controlling the
morphology of 3D printed structures, as is the case with U4. The cellular structures printed with U0,
U2, U4 and U6 showed a decreasing porosity of (37.2 ±1.3)%, (15.7 ±3.5)%, (7.6 ±1.8)% and (7.6
±1.6)%, respectively at day 14. The reduced porosity with increasing the PDPT-MA content observed
at day 14 reflects an increased ulvan content mitigates against enzymatic degradation initiated by the
encapsulated cells (Figure 4.12B). It is also worth noting that the level of degradation of GelMA
crosslinked form decreased with increasing the PDPT-MA content. This is likely due to two factors,
increased matrix stiffness and increased contribution of PDPT-MA that may protect the crosslinked
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GelMA from degradation by matrix enzymes. Previously, the presence of conjugated ulvan was
shown to protect collagen matrices from degradation by collagenase.51 Our results further support the
view that GAGs are capable of modulating protein matrix degradability.
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Figure 4. 12 Representative confocal images of cross sections of 3D printed cell-laden structures at day 1 (A) and day 14 (B) demonstrated in vitro
degradation of the artificial matrices.
Two fluorescently labelled components constituting the composite bioinks of U2 and U4 were shown to overlap with each other (A), indicating uniform
mixing between GelMA and PDPT-MA. The particulate fluorescence signal may indicate the formation of PDPT-MA aggregates. Scale bar: 50 µm.
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4.3.8 Structures of bilayer skin constructs
Bilayer skin constructs were developed by seeding HaCaT cells on top of the 3D printed HDFs-laden
structures based on U0 and U2, respectively. The HaCaT cells were submerged in cell culture medium
for 1 day. Then the co-cultures were lifted to the ALI to induce differentiation of HaCaT cells for 7,
14, 21 and 28 days, respectively. The structures of bilayer skin constructs were characterized by H &
E staining (Figure 4.13). Both bilayer skin constructs showed two distinctive cellular layers in the
vertical direction, i.e., the dermal and epidermal layer, mimicking the anatomical structure of human
skin. The epidermal layers of both skin constructs were composed of compactly arranged cells in an
organization of multiple cell layers of different orientations. Basically, there were 2-3 microscopically
distinguishable cell layers in the epidermal structures. The inner, middle and outer cell layers were
featured by columnar, spinous and flattened cells, respectively (Figure 4.13). These characteristic
cell layers may correspond to the sublayers (Figure 4.14) of native human epidermis52, i.e., stratum
basale, stratum spinosum and stratum granulosum or stratum corneum, respectively. The outermost
layers of HaCaT cells in U2-based skin constructs started to slough off at day 28 at the ALI. This may
indicate the development of terminally differentiated epidermis. By contrast, U0-based skin
constructs at day 28 at the ALI showed more intact epidermal structures without sloughing off.

The epidermal thickness of both bilayer skin constructs was shown to increase as a function of ALI
culture time (Figure 4.13; Figure 4.15A). For instance, the epidermal thickness of U0-based skin
constructs after 7, 14, 21 and 28 days, respectively of ALI culture was 62.8 ± 17.3 µm, 139.6 ± 13.9
µm, 215.5 ± 16.7 µm, and 277.5 ± 21.6 µm (Figure 4.15A). These values were significantly higher
than the corresponding epidermal thickness of U2-based skin constructs after 14 (100.5 ± 21.2 µm),
21 (105.8 ± 10.9 µm) and 28 days (141.3 ± 22.1 µm) of ALI culture (p < 0.0001) (Figure 4.15B).
ALI cultures at day 7 showed the other way around, with U2-based skin constructs displaying a
significantly thicker epidermal structure of 88.1 ±11.3 µm (p < 0.0001) (Figure 4.15B). The thicker
epidermal structures (> 200 µm) of U0-based skin constructs may suggest that HaCaT cells underwent
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more active cell proliferation at the ALI, compared to those of U2-based skin constructs. The
thickness of > 200 µm was thicker than that of regenerated epidermis using HaCaT cells cultured on
acellular GelMA hydrogels for 6 weeks at the ALI.53 The difference in thickness may be ascribed to
the use of an underlying cellular dermal compartment in this study. Nevertheless, these data were
within the thickness range of human epidermis (75-150 µm on average, with palm and sole up to 600
µm).52

Figure 4. 13 Hematoxylin and eosin Y staining of bilayer skin constructs based on U0 and U2,
respectively.
The bilayer skin constructs were cultured at the air-liquid interface for 7, 14, 21 and 28 days,
respectively. HaCaT cells of different shapes and orientations including columnar cells, spinous cells
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and flattened cells were pointed out by arrows. Nuclei were stained in blue and cytoplasm was stained
in pink. Scale bar = 50 µm.

Figure 4. 14 Structure of human epidermis showing four sublayers including, from bottom to surface,
stratum basale (SB), stratum spinosum (SS), stratum granulosum (SG) and stratum corneum (SC). D:
dermis.52
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Figure 4. 15 Epidermal thickness of bilayer skin constructs based on U0 or U2.
(A) Epidermal thickness increased as a function of air-liquid interface culture time. Statistical
significance was evaluated using two-way ANOVA with Tukey’s multiple comparisons post hoc test
at a confidence interval of 95%. ** Denotes p < 0.01; **** denotes p < 0.0001. (B) Comparisons of
epidermal thickness between two skin constructs at each time point. Statistical significance was
evaluated using two-way ANOVA with Bonferroni’s multiple comparisons post hoc test. ****
Denotes p < 0.0001.

Here, both bilayer skin constructs showed a low hydration state after culture at the ALI for 21 and 28
days (Figure 4.16). This indicated that our differentiation procedure was properly set with regard to
providing an air-exposed environment to induce differentiation of HaCaT cells. The hydration state
(water content) of skin surface, i.e., stratum corneum, is a critical indicator of barrier formation in
bioengineered skin substitutes.54 Future work will need quantitative studies to evaluate the hydration
levels of bioengineered skin constructs. This can be done by assessing the electrical properties
(impedance)
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Figure 4. 16 Physical appearance of bilayer skin constructs showing low hydration states at the airliquid interface for 21 and 28 days, respectively.

Following histology analysis revealing a skin-like double-layer structure, the epidermal layers of both
bilayer skin constructs at day 28 of ALI culture were characterized by fluorescent IHC to visualize
characteristic proliferation- or differentiation-indicating protein markers as found in different
sublayers of native human epidermis (Figure 4.17A).55-57 During epidermal morphogenesis,
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keratinocytes undergo keratinization by expressing certain keratins and move upwards to the skin
surface. Typical keratins include keratin 5 and 14 exclusively expressed in the basal layer, keratin 1
and 10 in the suprabasal layers, and loricrin and involucrin in the granular/cornified layers.58 Ki67 is
a nuclear protein only expressed in actively mitotic cells, and often used as a marker of proliferative
cells.59 Successful stratification is critical for the barrier functions of human epidermis in preventing
body desiccation and microbial invasion.

The bilayer skin constructs at day 28 of ALI culture were confirmed to express Ki67 in the basal
layers (Figure 4.17B). This suggests that the employed differentiation procedure was effective to
produce living constructs that remained proliferative in vitro for up to 41 days. Cytokeratin 10 (K10),
a marker of early stage epidermal differentiation60, was shown to express in the middle cell layers of
both epidermal structures overlying the basal layers (Figure 4.17B), indicating development of
suprabasal layers of stratum spinosum and/or stratum granulosum. This was supported by H & E
staining results showing spinous cells in the middle cell layers. Loricrin and involucrin are two cell
envelope proteins expressed in stratum granulosum/corneum.55 They were examined here to assess
the terminal differentiation of epidermal structures in both skin constructs. Loricrin was shown to
express in different layers in the evaluated skin constructs (Figure 4.17B). In skin constructs based
on U2, loricrin was expressed in the area seemingly being the granular layer. Whereas, in skin
constructs based on U0, expression of loricrin was confined in a thin layer overlying the basal layer,
which was considered disorganized as normally loricrin expresses in the granular layer.55 This result
may suggests that the inclusion of PDPT-MA could facilitate the normal expression of loricrin during
epidermal differentiation. Similar to the disorganized loricrin expression in skin constructs based on
U0, expression of involucrin in both skin constructs was also shown to be disorganized, being located
at the bottom of the epidermal structures spanning likely stratum basale and stratum spinosum
(Figure 4.17B). The disorganized expression of terminal differentiation protein markers might be
correlated with the use of an immortalized HaCaT cell line or the differentiation-induction conditions
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used in present study.53 HaCaT cells are a naturally transformed keratinocyte cell line in adult
epidermis that carries genetic alterations, which might potentially influence the differentiation
potential.61,62 These results necessitate further studies in the future to either optimize the
differentiation protocol or use a primary human epidermal keratinocytes for bioengineering bilayer
skin constructs.

Figure 4. 17 (A) Epidermal differentiation and characteristic protein markers.63 (B)
Immunofluorescence labelling of Ki67 (red, B-a, e), cytokeratin 10 (K10, green, B-b, f), loricrin (red,
B-c, g) and involucrin (green, B-d, h) in bilayer skin constructs based on U0 or U2 cultured at the airliquid interface for 28 days. Nuclei were counterstained with DAPI (blue).
The distribution of cells and newly deposited collagen I in the bilayer skin constructs was studied by
fluorescent IHC on 7 days’ and 28 days’ old ALI cultures (Figure 4.18). For skin constructs cultured
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at the ALI for 7 days, HaCaT cells were shown to be in a tight organization, forming the top epidermal
layer in both skin constructs. The varied epidermal thickness at different positions reflected uneven
surfaces of the underlying 3D printed HDFs-laden structures. For the distribution of HDFs, there were
disparities between areas in the pores and within the hydrogel matrices for both dermal compartments
(Figure 4.18). In pore areas, HDFs were much denser in the form of cell clusters, whereas within
hydrogel matrices HDFs were sparse (Figure 4.18). This was likely ascribed to the biochemical 3D
microenvironments restricting cellular movement and migration and consequently cell proliferation.
Similarly, collagen I was less produced within the hydrogel matrices in both dermal compartments,
whereas more abundant collagen I was produced in the pores and on the surfaces (Figure 4.18). Skin
constructs cultured at the ALI for 28 days showed similar cell distribution in epidermal and dermal
compartment, respectively. It is noted that more collagen I fibres were deposited at the interface of
epidermal-dermal compartments. This may imply continuous production and accumulation of
collagen I during ALI culture by HDFs. Collectively, these results revealed that HDFs and the newly
deposited collagen I were located mainly in the surface and in the pores of the dermal compartments.
The hydrogel networks presented by the photo-crosslinked U0 or U2 may limit cellular activities of,
for example, migration, proliferation and producing ECM components. Therefore, these results
highlighted the importance of introducing macro/micro-scale pores by 3D printing to augment
cellular activities toward tissue development.
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Figure 4. 18 Fluorescent labelling of cytoskeleton (F-actin, green) and collagen I (red) in the cross
sections of bilayer skin constructs based on (A, C) U0 and (B, D) U2 after (A, B) 7 and (C, D) 28
days of air-liquid interface culture.
Two distinct cell layers were evident in both skin constructs, representing the epidermal (E) and
dermal (D) structures as separated by white dash lines. Nuclei were counterstained with DAPI (blue).
Asterisk(s) mark areas with corresponding magnified images presented in the bottom panels.

Taken together, bilayer skin constructs were developed using HDFs and HaCaT cells based on PDPTMA. H & E staining showed that the skin constructs had two distinct cellular layers, resembling the
anatomical structure of human skin. The bilayer skin constructs recapitulate some key features
regarding epidermal regeneration. For future studies, it is recommended to use a suitable epidermal
cell model (i.e., primary epidermal keratinocytes), as well as to further optimize the ALI culture
conditions to realize successful epidermal stratification and barrier formation. Furthermore, in vivo
studies need to be implemented in order to assess the functionality of the final skin constructs in skin
regeneration and wound repair.

4.4 Conclusions
In this study, composite bioinks were developed based on PDPT-MA and GelMA for 3D bioprinting
dermal-like structures. The bioinks exhibited diversity, and therefore tunability, across shear-thinning
properties, yield stress, mechanical strength and self-recovery properties. The 3D printed cellular
structures supported cell proliferation which was also tunable and increased with time, upon
increasing PDPT-MA inclusion. The expression of key dermal ECM genes and de novo production
of key dermal ECM components was influenced by the bioink composition, and the progression of
gene expression stages during tissue matrix formation should be considered in future studies. Finally,
the resilience of the printed scaffold to both shrinkage and enzymatic degradation was also tunable
with the addition of PDPT-MA, and led to more resistant scaffolds. These are properties that can be
beneficial towards the development of improved wound healing and functional native skin traits in a
clinical setting. In vivo studies will be of paramount importance to assess the material’s responses in
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a close-to-application environment involving a plethora of growth factors, proteinases, various cell
types and surrounding tissues.

Bilayer skin constructs were created by culturing HaCaT keratinocytes on top of the matured dermallike structures, and the co-culture was allowed to further mature by exposure to air for up to 28 days.
Histological studies revealed that bilayer skin constructs had two distinct cellular layers, mimicking
the anatomical structure of human skin. Immunohistochemistry showed certain levels of stratification
of the epidermal layer. Collectively, this work provides insights into the utilization of PDPT-MA and
Ul84 for developing printable and biologically functional inks for skin bioengineering. The focuses
of future work will be constructing bilayer skin equivalents using primary epidermal keratinocytes to
closely mimic normal human skin, conducting more in-depth in vitro studies and evaluating the
bilayer skin constructs in vivo.
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Chapter 5 In vivo assessment of PDPT-MA scaffolds for cutaneous wound
healing: A pilot study

5.1 Introduction
In losses of a large portion of or whole dermis, skin is unable to regenerate.1 Skin substitutes,
especially dermal substitutes, are an indispensable component for treating full-thickness wounds.
Compared to cellularized dermal substitutes, acellular dermal substitutes (dermal matrix mimic) are
cheaper and more convenient to provide immediate wound coverage because of the off-the-shelf
nature and easy access.2 For large full-thickness wounds, such as deep burns affecting a significant
proportion of total body surface, immediate wound coverage with an off-the-shelf acellular dermal
substitute (matrix) could be highly beneficial in order to minimize infection, prevent body fluid loss
and facilitate re-epithelialization to achieve permanent wound closure.3

Cell-instructive dermal matrices that support fibroblast function toward skin regeneration have been
pursued in skin tissue engineering for wound healing applications. Such matrices are important in
assisting the migration and proliferation of skin cells (mainly fibroblasts and keratinocytes) in the
wound area. Owing to the innate biocompatibility, biological dermal matrices are highly promising
candidates. Miscellaneous biomaterials have been assessed in this respect, and some of them have
been successfully commercialized and used clinically for promoting wound healing.4-8 For example,
Alloderm® regenerative tissue matrix, a commercially available decellularized dermis (dECM)
derived from cadaveric skin, has been used to treat deep partial thickness facial burns9 and full
thickness burns4,5. Biobrane® (Smith & Nephew, UK) is another widely used acellular dermal matrix
composed of a superficial layer of semi-permeable silicone rubber (6 µm) and a layer of flexible
trifilament nylon mesh (360 µm) covalently conjugated with porcine collagen.2,6,10,11 Biobrane® has
mainly been used as a temporary wound dressing to treat burns and donor sites of partial thickness.2,11172
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Since most of the commercial dermal substitutes are collagen- or dECM-based, they are

manufactured at a relatively high cost and production quantity is limited.14 Meanwhile, challenges
are emerging with the growingly unmet needs of effective and affordable dermal matrices by the
expanding aging population with chronic wounds.15

To bridge the gap between the growing needs and low availability, significant efforts have been made
in searching for optimal materials/formulations to manufacture cell-instructive dermal matrices. To
allow a scalable manufacturing process and to reduce costs, non-animal-originated biomaterials have
been utilized.16,17 Marine-based biomaterials such as alginate and chitosan are highly promising
candidates due to their massive abundance and advantageous structural and biological properties.18
Alginates from brown seaweed are cytocompatible and gel-forming polysaccharides.19 Alginates
have been frequently used in wound dressing products for clinical uses to absorb wound fluids and to
maintain a moist wound environment.20 Alginates can be fabricated either as a pure alginate film/sheet,
a membrane loaded with active agents, or a composite film in combination with chitosan. 20,21
Chitosan deriving from shellfish represents an economic biomaterial and exhibits many wound
healing-promoting properties.22 However, alginates and chitosan are known to be biologically
inactive with respect to mediating cell-material interactions.19,23 In this sense, they are not ideal
materials for dermal matrix regeneration.

Compared to alginate and chitosan, green algae-originated ulvan type polysaccharides with chemical
structures resembling connective tissue glycosaminoglycans are relatively underexploited in this field.
With a unique source located in Australia, Ul84 used in this project is a novel ulvan extract rich in Lrhamnose moieties. In Chapter 3 and Chapter 4, in vitro studies have demonstrated good
cytocompatibility of Ul84 hydrogels in supporting cell attachment, spreading and proliferation of
human dermal fibroblasts and HaCaT keratinocytes. It provided strong evidences that Ul84 extract
might be superior to alginates or chitosan in terms of mediating cell-material interactions. In this
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chapter, we brought Ul84 hydrogels to in vivo studies in animals to unveil potentials in wound healing.
PhycoDerm® PhycoTrix (PDPT) was chosen for the animal work. Due to the time limit of my PhD
study, this chapter only included the pioneer work outlined for the long term animal study. The
objective of this chapter was to perform a pilot study using a mouse excisional wound model to assess
the materials’ cytotoxicity and to identify possible issues that may need attention in the following
large-scale study. The pilot study included a no-treatment control group and three experimental
groups. 3D printed PDPT-MA (i.e., PDPT methacrylate) scaffolds and injectable in situ-forming
PDPT-MA hydrogels were both included in order to highlight possible roles of scaffold morphology
in promoting wound healing. 3D printed PDPT-MA scaffolds with introduced macroscale pores
should be advantageous in facilitating cell infiltration, whereas injectable hydrogel is non-invasive
and should minimise irritation and facilitate full coverage of irregular wounds. A comparable control
group was further included using 3D printed alginate scaffolds. The pilot study is scheduled to last
for 7 days to obtain preliminary data.

5.2 Materials and methods
5.2.1 Bioink preparation
Bioinks were prepared for both PDPT-MA and sodium alginate. Specifically, PDPT-MA-based
bioink comprised 10% (w/v) PDPT-MA, 5% (w/v) gelatin from porcine skin (gel strength 300, Type
A) and 0.06% (w/v) lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP). Alginate based bioink
contained 4% sodium alginate (low viscosity, Sigma) and 5% gelatin from porcine skin (gel strength
300, Type A). Both bioinks were formulated in PBS supplemented with 1% (v/v)
penicillin/streptomycin.

5.2.2 3D printing macroporous scaffolds
Polysaccharidic scaffolds were prepared by extrusion-based 3D printing using each bioink on a 3DBioplotter (EnvisionTEC, Germany). A cube-shaped box (20 mm × 20 mm × 20 mm) was created
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(https://www.tinkercad.com/). The box was then sliced with a 65% needle (I.D. = 200 µm) offset
using the software Perfactory RP 3.2.2945 and imported to the Virtual Machines software
(EnvisionTEC, Germany). Prior to printing, each bioink was thoroughly mixed at 37 °C, followed by
incubation in ice for 5 min to induce fast gelation. The printing temperature (cartridge) was set at
23 °C for PDPT-MA-based bioink and at 25 °C for alginate-based bioink; whereas the substrate for
printing both bioinks was set at 15 °C. The printing pressure and speed for PDPT-MA-based bioink
was 3.0-3.3 bar and 8-10 mm s-1, respectively. These parameters for alginate based bioink were 4.55.0 bar and 6-10 mm s-1, respectively. For each scaffold, four layers of bioink were dispensed with a
printing height of 130 µm, a line space of 0.8 mm and a line-crossing angle of 90 °. 27G precision
stainless steel tips (length = 12.7 mm; I.D. = 0.20 mm, Nordson, USA) were used for all the printing.
After printing, PDPT-MA-based scaffolds were immediately exposed to visible light (400 nm) for 60
s (corresponding to a light energy of 792 mJ, Lumen Dynamics OmniCure LX400+) for permanent
crosslinking. PDPT-MA scaffolds were washed in PBS supplemented with 1% (v/v)
penicillin/streptomycin at 37 °C for 2 days. For alginate scaffolds, the gelation of alginate was
realized by 24 h incubation/wash in 2% (w/v) calcium chloride dihydrate at 37 °C with a few changes.
After the wash, both types of scaffolds were freeze dried, UV-sterilized and stored on the shelf.

5.2.3 Excisional full thickness wound model
Both 3D printed PDPT-MA scaffolds and in situ-forming PDPT-MA hydrogels were assessed in vivo
using a mouse excisional full thickness wound model for potentials in promoting wound healing. The
animal work was carried out at the Burn Injury Research Unit at the University of Western Australia
(UWA), and was ethically approved by the Animal Ethic Committee of UWA. Female mice of Mus
musculus (C57BL/6Jwildtype), 9 weeks’ old with each weighing approx. 19 g, were used. Mice were
acclimatized for 1 week before excision. The pilot study used a total of 12 mice, which were divided
into 4 groups with 3 mice per group. After anesthetization, shaving the dorsal hair and sterilizing the
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dorsal skin, a full-thickness excisional wound was created using a biopsy punch (I.D. = 12 mm).
Immediately after excision, photos of the wounds were taken. Subsequently, the wound was covered
with either a 3D printed PDPT-MA scaffold or a 3D printed alginate scaffold. Both scaffolds
overlapped with the surrounding mouse skin. For the in situ-forming PDPT-MA hydrogel, ~60-100
µL PDPT-MA-based bioink was injected to the wound, and allowed to spread before exposure to
visible light (400 nm, 13.2 mW) for 60 s at a distance of approx. 5 cm. The wounds of the no-treatment
control group were left open by adding sterile PBS instead. Photos were also taken after the scaffolds
were applied. Each group of mice were housed in one cage and fed with soft food. The weights of
mice were recorded before excision, and monitored at day 1, 2, 3 and 7 post excision. The wounded
mice were monitored for 7 days and photos of wounds were taken at day 1, 2, 3 and 7. The areas of
wounds at different time points were measured using ImageJ for calculating the healing rates.

All mice were sacrificed at day 7 post the surgery. Skin biopsies of wound tissues and normal skin
tissues were collected, fixed, and embedded in paraffin. 5 µm thick sections were cut using a
Microtome and collected on adhesive slides. The sections were deparaffinized and rehydrated to
reverse osmosis (RO) water by following the procedure as described in detail in the section of 4.2.12
in Chapter 4.

Hematoxylin and eosin Y (H & E) staining and Masson’s trichrome staining were performed by
following the manufacturer’s standard protocols. For H & E staining, the procedure is referred to the
section of 4.2.12 in Chapter 4 where a brief description is provided. Masson’s trichrome staining
was conducted using a Trichrome Stain (Masson) Kit. Briefly, the hydrated sections were mordanted
in Bouin’s solution overnight. The yellow stain in the sections was cleaned under running tap water.
Subsequently, the sections were stained in Weigert’s iron hematoxylin working solution for 5 min,
washed in running tap water for 5 min, and rinsed with RO water. Then the sections were stained
with Biebrich scarlet-acid fuchsin for 5 min and rinsed with RO water. Further, the sections were
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sequentially placed in working Phosphotungstic/Phosphomolybdic acid solution, Aniline blue
solution and 1% acetic acid for 5 min, 5 min, and 2 min, respectively. Ultimately, the sections were
dehydrated, cleared and mounted with resinous mounting media in the same way as for H & E-stained
sections. Images of both stained sections were acquired using a light microscope (Leica, Germany)
equipped with Leica Application Suite V4 (LAS V4.3). For H & E staining, nuclei, cytoplasm and
red blood cells were stained in blue, pink to pink-orange and red, respectively. For Masson’s
trichrome staining, nuclei, cytoplasm and muscle fibres, and collagen were stained in black, red and
blue, respectively.

5.2.4 Statistical analysis
Data were shown as mean ± SD, where n ≥ 3. Two-way analysis of variation (ANOVA) with Tukey’s
multiple comparisons post hoc test was used to calculate the statistical significance levels with a
confidence interval of 95% (GraphPad Prism 9).

5.3 Results and discussion
The aim of the pilot study was to evaluate the cytotoxicity of PDPT-MA scaffolds/hydrogels as
potential wound dressings and to identify issues that may need particular attention for a larger scale
study. No lethal effects post the surgery were revealed during the period of 7 days for all mice in the
study, demonstrating the non-toxic nature of PDPT-MA. The major problems identified during the
pilot study included (1) loss of materials due to low adhesion of 3D printed scaffolds to the wound
beds without proper wound wrapping-up and (2) the mice being very active, not helping maintain
scaffolds/in situ-forming hydrogels in the wound beds. Due to possible scratching by the mice upon
wrapping the wounds up, the suggested solution to these problems is to use docile rats instead in the
future and wrap up wounds if necessary.
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5.3.1 Wound closure
As shown in Figure 5.1, all mice progressed toward wound closure over the one-week period. The
wound sizes and edge morphologies were macroscopically different among four groups. Specifically,
mice in the alginate scaffold group, especially mouse 2, showed more jagged wound edges. In contrast,
mice treated with 3D printed PDPT-MA scaffolds showed much smoother wound edges compared to
other groups. The jagged wound edges may indicate irritation from the materials, acute wound healing,
and likely scar tissue development. The smoother wound edges observed in mice of the PDPT-MA
scaffold group indicated that PDPT-MA scaffolds might be less irritating than alginate scaffolds. It
was also noted that wound sizes of the PDPT-MA scaffold group appeared to be much larger than the
rest at each time point till day 7. These observations reflected that the wounds receiving different
treatments may undergo different healing paths. This might be evidences supporting that, even though
material loss was evident, there remained some material debris in the wounds, and the material debris
may exert differential impacts on the wound healing process.
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Figure 5. 1 Wound appearances of 12 mice at day 0 before (A) and after (B) scaffolds were applied,
and at (C) day 1, (D) day 2, (E) day 3 and (F) day 7 post the surgery.
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Mouse 1, 2 and 3 in each row were from one treatment group. From top to bottom row, the wounds
were treated with in situ-formed PDPT-MA gel, 3D printed alginate scaffolds, 3D printed PDPT-MA
scaffolds and PBS (no-treatment control), respectively. Macroscopic differences in terms of wound
areas, wound edges and the degrees of wound closure were evident.
Wound areas were then quantified using ImageJ, and the results supported the above observations
(Figure 5.2; Figure 5.3). The absolute wound areas were firstly compared within each group as a
function of time post the surgery (Figure 5.2A). At day 1 post excision, all groups showed significant
increases in wound areas compared to the original areas (Day 0) (p < 0.001 for alginate; p < 0.0001
for the rest). This was likely due to the stretch of flexible mouse skin. After this period of wound
enlargement and stabilization, all groups underwent reductions in wound areas to different degrees
(Figure 5.2A). However, wound areas at day 7 were not significantly reduced in all groups when
compared to respective wound areas at day 0. At day 2, significant daily reductions in wound area
were observed in all groups (p < 0.05 for injectable, alginate scaffolds and ulvan scaffolds; p < 0.001
for the no-treatment control group). Day 3 saw no significant daily decreases in wound area while
day 7 only saw significant reductions in both the injectable PDPT-MA hydrogel group and the 3D
printed PDPT-MA scaffold group (p < 0.05 for injectable PDPT-MA hydrogel; p < 0.01 for 3D
printed PDPT-MA scaffolds). This could indicate that there may be heightened benefits from treating
the wounds with ulvan-based structures compared to the other groups.

Absolute wound areas were also compared among different groups at each time point for the oneweek period (Figure 5.2B). At day 1, 2 and 3, mice in the PDPT-MA scaffold group were shown to
have significant greater wound areas (up to ~229.9 ± 22.2 mm2 at day 1) compared to the rest. The
wound areas of the alginate scaffold group showed a bigger variation. This was likely because mouse
2 in this group may experience an abnormally dramatic wound contraction with wavy wound edges
(Figure 5.1C-F, row 2). Even though wound areas of the PDPT-MA scaffold group were
significantly higher in several cases (p < 0.01 vs the injectable PDPT-MA group and p < 0.001 vs the
alginate scaffold group at day 1; p < 0.01 vs the injectable PDPT-MA group and the no-treatment
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group, and p < 0.001 vs the alginate scaffold group at day 2; p < 0.05 vs the no-treatment group at
day 3; Figure 5.2B), no significant differences were noted in wound areas at day 7 among the four
groups (Figure 5.2B).

Figure 5. 2 Wound area compared (A) within each group as a function of time and (B) among
different groups at each time point for the one-week period.
Two-way ANOVA with Tukey’s multiple comparisons post hoc test was performed for the statistical
analysis. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Injectable: injectable in situ-forming
PDPT-MA hydrogel; Alginate: 3D printed alginate scaffold; Ulvan: 3D printed PDPT-MA scaffolds;
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BC: the no-treatment group.

In terms of wound closure rates, wound areas as percentages of each respective original wound area
were calculated (Figure 5.3). It was clear that, at day 1, the wound areas (%) in both the PDPT-MA
scaffold group and the no-treatment group were significantly higher than those in the injectable
PDPT-MA group (p < 0.05) and the alginate scaffold group (p < 0.05 and p < 0.01). At day 2, wound
areas (%) of the PDPT-MA scaffold group were significantly higher than those of the injectable
PDPT-MA group and the alginate scaffold group (p < 0.05). Nevertheless, wound areas (%) of the
PDPT-MA scaffold group were not significantly different from the other three groups at either day 3
or day 7 (Figure 5.3).

Figure 5. 3 Wound closure rates shown as percentages of the initial wound areas at day 0.
Two-way ANOVA with Tukey’s multiple comparisons post hoc test was used to calculate the
statistical significance levels. *p < 0.05 (injectable ulvan at day 1 vs BC at day 1; alginate scaffolds
at day 1 vs ulvan scaffolds at day 1; injectable ulvan at day 2 vs ulvan scaffolds at day 2; alginate
scaffolds at day 2 vs ulvan scaffolds at day 2); **p < 0.01 (alginate scaffolds at day 1 vs BC at day
1). Injectable ulvan: injectable in situ-forming PDPT-MA hydrogel; Alginate scaffolds: 3D printed
alginate scaffold; Ulvan scaffolds: 3D printed PDPT-MA scaffolds; BC: the no-treatment group.

During the pilot study, we repeatedly had problems in maintaining scaffolds on the wounds. Some
scaffolds fell off from the wounds within 4 h, and a new scaffold was re-applied. For the secondary
application, a larger scaffold was used because the wound size increased to ~16-17 mm in diameter
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due to stretch of flexible mouse skin. No scaffolds remained intact in the wounds at day 1 post the
surgery. Even though a small fragment of PDPT-MA scaffold remained in the wound bed in mouse
1 at day 1, this fragment became smaller after four hours. As implied by the adhesion difficulties
during surgery, the invisibility of scaffolds/hydrogels was probably a reflection of material loss, rather
than completely absorbed by the wounds. Nevertheless, some material debris remained as we
experienced difficulties in removing debris from a previous scaffold from the wound when trying to
re-apply a new scaffold. Considering there was no lethal effects on the mice, we could deduce from
the pilot study that PDPT-MA was not toxic to the mice. However, due to the absence of an intact
matrix material, the healing outcomes presented here were probably deprived of possible effects of
scaffold matrices on the wound healing process. However, they might be still useful regarding wound
healing in these circumstances, and may serve as controls for subsequent studies in the future.

The low adhesion of printed scaffolds to the wound beds may be ascribed to the following factors.
Firstly, there was an inadequate amount of wound fluids produced upon excision. Wound fluids
containing electrolytes and various endogenous proteinases24 were viscous, and were supposed to
facilitate the adhesion of scaffolds to the wound beds. The insufficiently wetted scaffolds were unable
to drape and attach to the wound beds. The dry scaffolds also caused irritation to the soft skin tissue.
To reduce irritation, PBS was added in order to hydrate the scaffolds, which however was not
beneficial to scaffold adhesion. Secondly, the scaffolds did not possess adhesive properties. This is a
practical drawback typical for most of wound dressings.25 To overcome this problem, surgical
practices often use a secondary dressing such as gauze and tape to keep the primary wound dressing
in place. Considering the mice may scratch the wounds upon wrapping-up with gauze and tape, the
pilot study did not wrap the wounds up, and this is an issue that needs to be addressed in a larger scale
study in the future. Lastly, mouse activity partly accounted for the constant failure of scaffolds and
in situ-forming hydrogels to stick to the wound beds. This was because mice frequently rubbed their
back (including wound areas) against cage walls. This may also reflect irritations of the introduced
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materials.

Together, the pilot study verified that PDPT-MA was not toxic for in vivo applications in mice. The
major issues identified by the pilot study include that the scaffolds lacked proper adhesive properties
and that the mouse wound model may be not suitable for this study. Wound closure results suggested
that the remnant materials of PDPT-MA scaffolds may cause significant increases in wound areas at
early time points (< 7 days). Nevertheless, the wound closure rates at day 7 were not adversely
affected. Further, the injectable PDPT-MA gel (remnant) was shown to significantly reduce wound
areas at day 7 compared to day 0. This may highlight the potential of PDPT-MA in promoting
cutaneous wound healing.

5.3.2 Histology
Wound tissues at day 7 were collected and analyzed by H & E staining and Masson’s trichrome
staining to visualize the anatomic structures of and collagen fibres in wound tissues. Normal mouse
skin from a different site were also processed and analysed. As shown in Figure 5.4, H & E staining
of normal mouse skin showed two distinctive cellular layers including the top epidermis and the
beneath dermis. Hair follicles and sebaceous glands were evident.

Figure 5. 4 Hematoxylin and eosin Y staining of normal mouse skin at (A) 20 ×magnification (scale
bar = 100 μm) and (B) 40 × magnification (scale bar = 50 μm).
Nuclei: blue; cytoplasm: pink to pink-orange. Hair follicles and shafts (blue arrows) and sebaceous
glands (black arrows) were evident.
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H & E staining results of wound tissues were shown in Figure 5.5 for all mice receiving different
treatments. Basically, no wound tissues (Figure 5.5B) showed the typical bilayer structure as seen in
the normal skin (Figure 5.4) or in the surrounding normal skin of wound tissues (Figure 5.5A). The
absence of an epidermal layer on the top of wound tissues indicated the failure of wound reepithelialization at day 7 post surgery. This may suggest that all the wounds were at the early stage
of the healing timeline (i.e., inflammation). It is noteworthy that the epidermis adjacent to the wound
was much thicker than other parts of the normal mouse skin epidermis (Figure 5.6). Further, there
seemed no traces of materials in the wound tissues. This might further reflect the loss of scaffolds/in
situ-formed materials from the wound beds.
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Figure 5. 5 Hematoxylin and eosin Y staining results of mouse wound tissues at day 7 post the surgery.
(A) Normal skin surrounding wound tissues. (B) Wound tissues. Nuclei: blue; cytoplasm: pink. Scale
bar = 50 μm.
The wound tissues were basically characterized by pink-coloured cytoplasm with interspersed bluestained nuclei (Figure 5.5B). These nuclei appeared to have smaller sizes than those in the
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surrounding normal mouse skin (Figure 5.5A). It is likely that these nuclei belonged to blood cells
or immune cells (e.g., neutrophils and monocytes/macrophages etc.) other than skin fibroblasts. It is
less likely that they were bacterial nuclei, considering such a dense bacterial colonization would
otherwise cause death to the mice, and no mice were deadly affected during the course of study. The
pink-coloured cytoplasm contained two distinguished areas in the light of nuclei density. The minor
areas, mainly in the upper part of wound tissues, had sparsely distributed or no nuclei at all. The rest
major areas, mainly located at the bottom, were characterized by significant accumulation of nuclei.
These features did not resemble that of either a normal scar or a keloid scar.26 It therefore suggested
that no scar tissue formed in all mice at this point. Normally acute wounds take about 2-3 weeks to
heal and form scar tissue.27 Moreover, no sebaceous glands or hair follicles were visible in the wound
tissues in any of the mice. Red blood cells (anucleate) were found to be present in the surrounding
normal skin adjacent to wound tissues, but were absent in the pink-coloured cytoplasm. This possibly
indicated the absence of blood vessel formation in the wound tissues at this stage.

Figure 5. 6 Hematoxylin and eosin Y staining results showing wound edges at (A) 4 × and (B) 10 ×
magnification (scale bar = 200 µm).
Epidermis adjacent to the wound was thicker than that of peripheral skin tissue.

No notable differences were observed among the three experimental groups, or between three
experimental groups and the no-treatment control group. This may be a reflection of losses of the
scaffolds/materials so that the healing of full thickness wounds was deprived of possible effects of
scaffolds/in situ-formed hydrogel. Some interesting phenomena were observed in the H & E staining
results. Specifically, in mouse 1 of the injectable PDPT-MA hydrogel group, an unstained part of
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tightly stacked cells (lack of nucleus) was observed in the surface of the wound tissue (Figure 5.5B).
Mouse 2 of the no-treatment group showed a similar but different unstained part with no sign of cells.
It is known that stratum lucidum, a hyaline sublayer of dead, flattened cells in human epidermis of
palm and sole, remains unstained in H & E staining.28 However, the observations in the mouse here
did not fit into the scenario. These observations remained unexplainable under present circumstances.

Masson’s trichrome staining was conducted to visualize collagen fibres in normal mouse skin and
wound tissues. As shown in Figure 5.7, collagen fibres were evident in normal mouse skin tissue. By
contrast, no collagen fibres were present in wound tissues in all mice (Figure 5.8). The skin tissue
section of mouse 3 of the PDPT-MA scaffold group was shown to include only half of the wound
tissue, and at the wound edge a small-scaled normal skin tissue was present with dermis, epidermis,
hair follicles, sebaceous glands, and collagen fibres (Figure 5.8). This was unusual compared to
others, and require further studies to confirm and understand what it was.

Figure 5. 7 Masson’s trichrome staining results of normal mouse skin at (A) 20 × magnification
(scale bar = 100 μm) and (B) 40 × magnification (scale bar = 50 μm).

The absence of collagen fibres in wound tissues indicated that these wounds did not progress to the
stage of mature granulation tissue formation yet. This made sense considering wound healing of the
full-thickness wounds in this study only lasted for 7 days. As the advanced stage of typical wound
healing process, proliferation or granulation tissue formation normally occurs at day 2-10 after injury
and is characterized by active fibroblast proliferation and ECM (mainly collagen) deposition.29 These
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results suggested that all wounds at day 7 may be in a transitional stage from inflammation to
proliferation. Considering these stages overlap chronologically, proliferation may have started but far
from finishing since no collagen fibres were present. Collectively, Masson’s trichrome staining
revealed that no collagen fibres were detected in any of the wounds at day 7 post the surgery,
indicating the wounds were probably in a transitional stage from inflammation to granulation tissue
formation.
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Figure 5. 8 Masson’s trichrome staining results of mouse wound tissues at day 7 post the surgery.
(A) Normal skin surrounding wound tissues. (B) Wound tissues. Collagen fibres: blue; Nuclei: black;
cytoplasm: red. Scale bar = 50 μm.

5.4 Conclusions
In this study, a pilot animal study was conducted to evaluate the wound healing potential of PDPTMA macroporous scaffolds fabricated by extrusion-based 3D printing. The mouse excisional full
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thickness wound model demonstrated nontoxicity of PDPT-MA in vivo in mice. Strong evidences
indicated low adhesion of the 3D printed PDPT-MA scaffold to the wounds. H & E staining revealed
that wound tissues at day 7 did not exhibit bilayer skin structure nor realize re-epithelialization. No
blood vessels or skin appendages were present in wound tissues at this time point. Masson’s trichrome
staining revealed that no collagen fibres were detectable in wound tissues at day 7 post the surgery.
To address the major issues of low adhesion of the 3D printed scaffolds, actions such as wrapping of
wounds after applying the scaffolds need to be implemented.

5.5 References
1
2
3

4
5

6
7

8

9
10
11
12

13
14

Schulz III J T, Tompkins R G and Burke J F, Artificial skin, Annual Review of Medicine 2000,
51, 231-244.
Supp D M and Boyce S T, Engineered skin substitutes: practices and potentials, Clinics in
Dermatology 2005, 23, 403-412.
Burke J F, Yannas I V, Quinby Jr W C, Bondoc C C and Jung W K, Successful use of a
physiologically acceptable artificial skin in the treatment of extensive burn injury, Annals of
Surgery 1981, 194, 413-427.
Wainwright D J, Use of an acellular allograft dermal matrix (AlloDerm) in the management
of full-thickness burns, Burns 1995, 21, 243-248.
Wainwright D, Madden M, Luterman A, Hunt J, Monafo W, Heimbach D, Kagan R, Sittig K,
Dimick A and Herndon D, Clinical evaluation of an acellular allograft dermal matrix in fullthickness burns, Journal of Burn Care & Rehabilitation 1996, 17, 124-136.
Whitaker I S, Worthington S, Jivan S and Phipps A, The use of Biobrane® by burn units in
the United Kingdom: A national study, Burns 2007, 33, 1015-1020.
Heimbach D M, et al., Multicenter postapproval clinical trial of Integra® Dermal
Regeneration Template for burn treatment, Journal of Burn Care & Rehabilitation 2003, 24,
42-48.
Min J H, Yun I S, Lew D H, Roh T S and Lee W J, The use of Matriderm and autologous skin
graft in the treatment of full thickness skin defects, Archives of Plastic Surgery 2014, 41, 330336.
Horch R E, Jeschke M G, Spilker G, Herndon D N and Kopp J, Treatment of second degree
facial burns with allografts—preliminary results, Burns 2005, 31, 597-602.
Purdue G F, et al., Biosynthetic skin substitute versus frozen human cadaver allograft for
temporary coverage of excised burn wounds, The Journal of Trauma 1987, 27, 155-157.
Whitaker I S, Prowse S and Potokar T S, A critical evaluation of the use of Biobrane as a
biologic skin substitute, Annals of Plastic Surgery 2008, 60, 333-337.
Barret J P, Dziewulski P, Ramzy P I, Wolf S E, Desai M H and Herndon D N, Biobrane versus
1% silver sulfadiazine in second-degree pediatric burns, Plastic Reconstructive Surgery 2000,
105, 62-65.
Alrubaiy L and Al-Rubaiy K K, Skin substitutes: a brief review of types and clinical
applications, Oman Medical Journal 2009, 24, 4-6.
Jones I, Currie L and Martin R, A guide to biological skin substitutes, British Journal of
Plastic Surgery 2002, 55, 185-193.
191

15

16

17

18

19
20
21

22
23
24
25
26

27
28
29

Sen C K, Gordillo G M, Roy S, Kirsner R, Lambert L, Hunt T K, Gottrup F, Gurtner G C and
Longaker M T, Human skin wounds: a major and snowballing threat to public health and the
economy, Wound Repair and Regeneration 2009, 17, 763-771.
Bhatnagar M and Bhatnagar A, Wound dressings from algal polymers, in Marine Algae
Extracts: Processes, Products, and Applications, 2015, Wiley-VCH Verlag GmbH & Co.
KGaA: Germany, p. 523-555.
Jayakumar R, Prabaharan M, Kumar P T S, Nair S V and Tamura H, Biomaterials based on
chitin and chitosan in wound dressing applications, Biotechnology Advances 2011, 29, 322337.
Colliec-Jouault S, Skin tissue engineering using functional marine biomaterials, in Functional
Marine Biomaterials: Properties and Applications, 2015, Woodhead Publishing: England, p.
69-90.
Lee K Y and Mooney D J, Alginate: properties and biomedical applications, Progress in
Polymer Science 2012, 37, 106-126.
Mogoşanu G D and Grumezescu A M, Natural and synthetic polymers for wounds and burns
dressing, International Journal of Pharmaceutics 2014, 463, 127-136.
Boateng J S, Matthews K H, Stevens H N E and Eccleston G M, Wound healing dressings
and drug delivery systems: A review, Journal of Pharmaceutical Sciences 2008, 97, 28922923.
Dodane V and Vilivalam V D, Pharmaceutical applications of chitosan, Pharmaceutical
Science & Technology Today 1998, 1, 246-253.
Kim I-Y, Seo S-J, Moon H-S, Yoo M-K, Park I-Y, Kim B-C and Cho C-S, Chitosan and its
derivatives for tissue engineering applications, Biotechnology Advances 2008, 26, 1-21.
Cutting K F, Wound exudate: composition and functions, British Journal of Community
Nursing 2003, 8, S4-S9.
Pereira R F, Barrias C C, Granja P L and Bartolo P J, Advanced biofabrication strategies for
skin regeneration and repair, Nanomedicine 2013, 8, 603-621.
Tan K T, McGrouther D A, Day A J, Milner C M and Bayat A, Characterization of hyaluronan
and TSG‐6 in skin scarring: differential distribution in keloid scars, normal scars and
unscarred skin, Journal of the European Academy of Dermatology and Venereology 2011, 25,
317-327.
Stojadinovic A, Carlson J W, Schultz G S, Davis T A and Elster E A, Topical advances in
wound care, Gynecologic Oncology 2008, 111, S70-S80.
Montagna W and Parakkal P F, The structure and function of skin, 1974, Academic Press:
New York, 433.
Gurtner G C, Werner S, Barrandon Y and Longaker M T, Wound repair and regeneration,
Nature 2008, 453, 314-321.

192

Chapter 6 Conclusions and future perspectives

6.1 Conclusions
This project aims to investigate the potential of a species-specific ulvan extract (Ul84) in the field of
wound healing and skin tissue engineering. Three Ul84 extracts of different purities have been
involved, with studies being performed in four separated but closely-related aspects.

Firstly, chemical and physical characterizations revealed that these Ul84 extracts had decreasing
protein contents for PhycoTrix (~21.1%), PhycoDerm (~13.2%) and PhycoDerm® PhycoTrix
(~3.1%), as per the time they were received. Monosaccharide analysis by GC/MS revealed that Ul84
was mainly composed of L-rhamnose, D-xylose, D-glucuronic acid, L-iduronic acid, D-galactose and
D-glucose. Among these sugars were ~50% neutral sugars, ~16% acid sugars, ~17% sulfate and ~13%
ash. PhycoTrix had a higher MW of ~1,244 kDa than ~1,002 kDa for PhycoDerm as equivalent
dextran. For both PhycoTrix and PhycoDerm, the MW distribution was broad with a PDI of ~1.6.
Physical characterizations by 1H NMR and FT-IR showed some characteristic peaks that confirmed
ulvan-related groups and structures. All three Ul84 extracts were verified to aggregate in aqueous
solutions. These studies reveal that Ul84 is a rhamnose-rich heteropolysaccharide with a moderate
sulfation. The continuously improved purity in terms of protein contamination in the extracts is
decisive for which one to be used for fabrication and cell-related studies.

Secondly, PhycoDerm with ~13% protein has been chosen for fabricating scaffolds as substrates for
culturing HDFs. PhycoDerm was modified by methacrylation to introduce photocrosslinkable
functional groups. PDMA hydrogels were prepared via photo-crosslinking, and showed stiff and
tuneable mechanical properties, high water contents (> 96%) and porous microstructures in the cross
section upon freeze drying. HDFs seeded onto the freeze-dried PDMA hydrogels showed high cell
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viability, significant cell proliferation and flattened and elongated cell morphologies. Our results
therefore demonstrate that Ul84 extract is highly cytocompatible with HDFs, and supports cell
attachment, cell spreading and cell proliferation. This indicates active cell-material interactions
between HDFs and PDMA hydrogels. PDMA-based bioinks were formulated with gelatin, and the
feasibility of 3D printing PDMA with and without HDFs was verified with high cell viability.
However, due to a stiff mechanical 3D environment, the PDMA-based bioink formulation used for
cell encapsulation did not necessarily promote cell proliferation.

Thirdly, PhycoDerm® PhycoTrix with ~3% protein has been chosen for further bioink formulation
and optimisation for 3D bioprinting dermal-like structures and establishing bilayer skin constructs.
PDPT-MA was shown to be highly cytocompatible with HDFs and HaCaT cells. Printable bioinks
were formulated comprising PDPT-MA, GelMA and gelatin. The inclusion of PDPT-MA to GelMA
resulted in reduced shearing thinning effects and yield stress but increased mechanical properties. All
printed cell-laden structures with encapsulated HDFs showed high cell viability and support of
cellular growth post printing, with U2-based structures outperforming the rest. In addition to cell
growth, all 3D printed cellular structures showed dermal-like properties with HDFs being functional
to deposit their own ECM proteins, including collagen I, collagen III, elastin and fibronectin. The
presence of PDPT-MA in the artificial matrices was shown to inhibit the gene expression (mRNA
levels) of collagen III, whereas it did not induce significant impacts on the gene expression of collagen
I, elastin and fibronectin. Bilayer skin equivalents were constructed by seeding HaCaT cells onto
matured, cellular and dermal-like structures printed using U2 serving as the dermal compartments.
Submerged and air-exposed culture for up to 28 days led to the formation of bilayer structures,
resembling that of native human skin. The top-located epidermal-like structures were composed of
densely packed multiple cell layers. Some protein markers regarding epidermal proliferation and
differentiation were confirmed, including Ki67, a marker of proliferative cells, and cytokeratin 10, a
marker of early stage epidermal differentiation. The visualization of terminal differentiation protein
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markers of loricrin and involucrin was however not successful. This may be correlated to the use of
an immortalized HaCaT cell line that has some chromosomal mutations. These findings may imply
potentials of Ul84 as a dermal matrix component for developing full thickness skin equivalents.

Lastly, PhycoDerm® PhycoTrix with ~3% protein has been chosen for assessing whether it promotes
wound healing in vivo or not considering its cell-instructive properties as demonstrated in previous
chapters. A pilot animal study has been performed for a period of 7 days using a mouse excisional
full thickness wound model. The pilot animal work identified a major issue about the 3D printed
scaffolds based on PDPT-MA or alginate. These preformed scaffolds have issues to adhere to the
wound bed, and ultimately the full thickness wounds underwent healing without proper material
covering as per the plan of the study. Nevertheless, the pilot study demonstrated non-toxicity of
PDPT-MA either as preformed scaffolds or in-situ crosslinked hydrogels, with their remnants likely
staying in the wounds and no mice being detrimentally affected. More importantly, the adhesion
issues identified here point out that efforts need to be made to keep the materials in the wound bed.
These may require further material design, or putting a secondary dressing in place, or even use a
more docile animal model.

In summary, this project achieved several goals as to understand better the novel seaweed
polysaccharide Ul84 towards biomedical applications. Three Ul84 extracts have different chemical
compositions, in particular the protein content. Ul84 has been modified, and Ul84-based hydrogels
have been demonstrated to be cytocompatible and support cell attachment and proliferation of human
dermal fibroblasts. Ul84-based bioinks have been formulated and optimized for extrusion-based 3D
printing. HDFs encapsulated in these bioinks have been 3D bioprinted to obtain dermal-like structures.
The printed cell-laden structures showed cell growth and cell functions in depositing several ECM
proteins. Bilayer skin constructs have been further established by co-culturing 3D printed dermal-like
structures with HaCaT keratinocytes at the air-liquid interface. Histology and immunohistochemistry
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studies confirmed successful development of bilayer skin constructs with anatomical structures
resembling that of human skin and some levels of epidermal differentiation.

6.2 Future Perspectives
As left behind in this project, some work needs to be continued in order to keep progressing Ul84
towards real world applications. First of all, the hypothesis that PDPT-MA preformed scaffolds and/or
in-situ formed hydrogels promote in vivo wound healing will need to be investigated using a proper
experimental design or animal model. Biological characterizations will be important to understand
whether host skin fibroblasts are recruited to the wound sites, inflammatory responses are mitigated,
cell penetration and proliferation is enabled, or cell functions in terms of ECM deposition and wound
tissue remodeling is instructed/maintained. The key information here will lay a profound foundation
for possible development of Ul84 based products/devices for clinical uses.

Second of all, skin bioprinting will need to be further investigated using maybe primary human
epidermal keratinocytes instead. The bilayer skin constructs using HaCaT cells barely achieved
terminal differentiation. Apart from realizing epidermal terminal differentiation, the demonstration
of basement membrane (BM) formation is of critical importance. BM is a pericellular matrix that is
in close contact with overlying cells and underlying dermal ECM so as to compartmentalize dermis
and epidermis and form an organizational continuum of skin. The demonstration can be linked to the
expression of several BM proteins such as the glycoprotein laminin-332, collagen IV, and anchoring
collagen VII. Furthermore, functions of the bilayer skin equivalents will need to be investigated in
terms of the epidermal barrier functions including macromolecular diffusion1, water vapour
transmission rate2, and hydration state of stratum corneum by measuring surface electrical
capacitance (SEC)3. Lastly, in vivo assessment in animals will be necessary to examine the
constructed skin equivalents in promoting wound healing.
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There are tremendously wide options in exploiting this naturally sulfated polysaccharide in the
biomedical field. This thesis has done pioneering work by demonstrating and taking advantages of
the innate biocompatibility and mechanical attributes of Ul84 in supporting cellular attachment,
spreading and proliferation of HDFs. More than this, Ul84 can be further studied by applying different
strategies in material design and/or combination, and potentially for other biomedical applications.
Below are some aspects as to the possible research directions of this ulvan extract in the future to
maximize its value.

Being a sulfated polysaccharide with negative charges, Ul84 can be investigated for its potential in
sequestering growth factor for sustainable release and for drug delivery application. It is known that
GAGs, such as heparin and heparan sulfate, are able to bind to proteins of growth factors and
cytokines in a non-specific way.4 As a GAG analogue, Ul84 thus holds promises in the fabrication of
structures that can synchronously serve as growth factor reservoirs for tissue engineering and
regenerative medicine. For example, heparin was functionalized with different sulfation patterns, and
heparin-based gels with different sulfation patterns were demonstrated to have different affinities to
platelet-derived growth factor B. These gels were found to be able to dictate the fate of encapsulated
MSCs in 3D structures. The work suggested that the sulfation pattern could play important roles in
modulating cellular activities by creating signalling gradients in hydrogel matrices.5 Alginate was
also sulfated to mimic the structures of proteoglycans for cartilage regeneration. Alginate gels with a
higher sulfation degree has shown to promote the proliferation of chondrocytes via fibroblast growth
factor signalling.6

Ul84 can also be functionalized through the conjugation of enzyme-sensitive groups to study the
design’s effects on cellular growth and behaviour, as well as both in vitro and in vivo degradation of
its based matrices. For example, MMP-sensitive groups can be conjugated to Ul84 for the fabrication
of cellularized structures with cell-invasive properties in the matrix. Cellular activities can be
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investigated in terms of cell proliferation, new matrix deposition, matrix degradation and the MMP
expression levels of the 3D printed cell-laden structures. The proteolytical microenvironments may
facilitate the embedded cells to reform the provisional matrices, and may resultantly help the process
of new matrix production and collagen remodeling by fibroblasts. This could further unlock the
potential of Ul84 in wound healing applications. Lutolf et al. conducted an exemplary study where
PEG gels were functionalized with both MMP groups that enabled matrix breakdown for cell invasion
and cell binding integrin domains for cell adhesion. Human foreskin fibroblasts were able to attach
and proteolytically infiltrate the synthetic gels due to cell-derived MMP activities. The degradable
PEG gels loaded with human bone morphogenetic protein-2 were also demonstrated to facilitate in
vivo bone regeneration in a rat model, which depended on the gel’s proteolytic sensitivity.7

To address the issue of brittleness of Ul84-based matrices as demonstrated previously, Ul84 can be
molecularly engineered to improve the metrices’ bioadhesiveness. Specifically, Ul84 can be coupled
with, for example, the bio-inspired catechol groups to render it adhesive, and ultimately to heighten
the toughness of Ul84-based matrices. For instance, HA was successfully functionalized with
catechol moieties to produce adhesive gels that adhered well to wet substrates. The HA-catechol
hydrogels were shown to support the proliferation of human umbilical vein endothelial cells which
lined and formed capillary-like structures, suggesting its potential for tissue adhesive and
angiogenesis.8

Importantly, advanced technologies such as, for example, the microsphere technique9, can be
employed to broaden the applicability of Ul84. Microsphere technique can be harnessed in
combination with 3D bioprinting to fabricate porous structures at both the macro- and micro- levels.
For example, to address the nonporous structures and often passive release of active agents faced by
injectable hydrogel matrices that are important for non-invasive interventions, an adaptable
microporous hydrogel has been developed where microspheres produced by a microfluidic chip were
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used to introduce interconnected micropores and to carry the bioactive molecules. Such injectable
hydrogels allow in situ formation of complex shapes. The nerve growth factor of a high dose and
gradient concentrations loaded into the hydrogels effectively induced Schwann cells migration,
promoted significant axon outgrowth and elevated axon fibre intensity.9 This strategy is promising to
produce hydrogels with controllable micropores. In combination with 3D bioprinting technique, it
would be especially beneficial when the target hydrogel is stiff (e.g., Ul84-based hydrogels) and cell
movement is hampered.

Apart from above-mentioned research directions, Ul84 can also be investigated in terms of other
important aspects such as amongst others thermoresponsiveness10, in situ enzymatic gelation11 and
electrostatic interactions with positively charged polymers (e.g., chitosan)12. These research activities
can largely enrich the fundamental knowledge of Ul84, and therefore are able to provide applicationdriven information about Ul84 to better uncover its potentials in biomedical applications. With the
encouraging findings presented in this thesis, it is envisaged that a more useful platform can be
established with this naturally sulfated polysaccharide that holds promises to ultimately benefit our
community.
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